<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><style scope="figure-callout">figure-callout:not([filenames=""]) a.figure-callout {
  cursor: zoom-in;
  text-decoration: underline;
  text-decoration-color: #ddd;
}</style><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><style scope="image-carousel">image-carousel {
  display: block;
}

.thumbnails.image-carousel {
  display: block;
        background-color: transparent;
        padding: 7px;
        white-space: nowrap;
        overflow: auto;
        font-size: 0;
}

.thumbnails.image-carousel img.image-carousel {
  margin-right: 7px;
        cursor: zoom-in;
}

.thumbnails.image-carousel img[selected].image-carousel {
  outline: solid 3px #4285f4;
}

.thumbnails.image-carousel img.image-carousel:last-of-type {
  margin-right: 0;
}</style><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>US8715951B2 - Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US8715951B2/en">
    <meta name="description" content="
     Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
       ">
    <meta name="DC.date" content="2012-07-18" scheme="dateSubmitted">
    <meta name="DC.description" content="
     Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia. 
   
   ">
    <meta name="citation_patent_application_number" content="US:13/552,246">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/cb/fd/a3/acb007d73a3169/US8715951.pdf">
    <meta name="citation_patent_number" content="US:8715951">
    <meta name="DC.date" content="2014-05-06" scheme="issue">
    <meta name="DC.contributor" content="Behnaz Parhami-Seren" scheme="inventor">
    <meta name="DC.contributor" content="Kenneth G. Mann" scheme="inventor">
    <meta name="DC.contributor" content="David N. Fass" scheme="inventor">
    <meta name="DC.contributor" content="University of Vermont and State Agricultural College" scheme="assignee">
    <meta name="DC.relation" content="US:4795806" scheme="references">
    <meta name="DC.relation" content="US:20030170613:A1" scheme="references">
    <meta name="DC.relation" content="US:20030224477:A1" scheme="references">
    <meta name="DC.relation" content="US:7855274" scheme="references">
    <meta name="DC.relation" content="US:8236518" scheme="references">
    <meta name="citation_reference" content="International Search Report for PCT/US06/27409 issued Jan. 15, 2007 and mailed Apr. 23, 2007." scheme="references">
    <meta name="citation_reference" content="Precup et al. A Monoclonal Antibody to Factor VIII Inhibits von Willebrand Factor Binding and Thrombin Cleavage, Blood (1991), 77 (9): pp. 1929-1936." scheme="references">
    <meta name="citation_reference" content="Precup, et al., &quot;A Monoclonal Antibody to Factor VIII Inhibits von Willebrand Factor Binding and Thrombin Cleavage,&quot; Blood. 1991, 77(9): pp. 1929-1936." scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA133356387" lang="EN" load-source="patent-office" class="style-scope patent-text">
    <div num="p-0001" class="abstract style-scope patent-text">Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.</div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              
                <section id="thumbnails" class="style-scope patent-result">
                  <h3 class="style-scope patent-result">Images (<span class="style-scope patent-result">35</span>)</h3>
                  <image-carousel id="figures" class="style-scope patent-result">
    
    
      <div class="thumbnails style-scope image-carousel">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/09/73/75/09f80c90830648/US08715951-20140506-D00000.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/b6/f4/aa/1f51dee3c3d2f0/US08715951-20140506-D00001.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/03/7c/92/e0382ad1f422a2/US08715951-20140506-D00002.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/0e/36/2d/294193d44ce051/US08715951-20140506-D00003.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/bf/77/fb/db5192d40391fa/US08715951-20140506-D00004.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/8c/aa/3e/5e0c2311c5bc8a/US08715951-20140506-D00005.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/6d/ea/dd/06f70a8e76dc77/US08715951-20140506-D00006.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/b0/0f/18/e01c716c1d2175/US08715951-20140506-D00007.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/65/03/81/7da4bcfd17e57f/US08715951-20140506-D00008.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/8f/26/02/9dac7b280c48b6/US08715951-20140506-D00009.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/9e/30/9c/d036905c036dfa/US08715951-20140506-D00010.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/78/82/d0/5588d02d0b0902/US08715951-20140506-D00011.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/4c/71/ef/c4dda827dacbf0/US08715951-20140506-D00012.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/ee/c5/0e/fda1de7b4d8f5a/US08715951-20140506-D00013.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/1d/1f/24/d8a0bce2a666dd/US08715951-20140506-D00014.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/8b/b4/c5/2a14feb4a12c3c/US08715951-20140506-D00015.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/53/00/bc/c50a7a997bdffc/US08715951-20140506-D00016.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/00/c5/a3/e99b25b3aad7be/US08715951-20140506-D00017.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/6b/7f/dc/79338eb25838fb/US08715951-20140506-D00018.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/fa/56/22/bed58a81a4ce7f/US08715951-20140506-D00019.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/68/67/4a/3fa0c0d5369f4b/US08715951-20140506-D00020.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/7a/63/b4/669027e907ecaf/US08715951-20140506-D00021.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/90/ce/e0/bd094759e6bb06/US08715951-20140506-D00022.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/f9/de/e1/0ed079c3b42fa7/US08715951-20140506-D00023.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/57/56/63/07ab2abe398824/US08715951-20140506-D00024.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/fe/94/b7/e995d39dc71b6e/US08715951-20140506-D00025.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/81/93/d3/9ec86135c13c2b/US08715951-20140506-D00026.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/a1/d2/3e/b0155b1e6a6821/US08715951-20140506-D00027.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/f5/67/10/d13dd92ba5b6b2/US08715951-20140506-D00028.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/53/b5/11/724d461049e503/US08715951-20140506-D00029.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/2d/a9/1a/ddb8f173f5c22b/US08715951-20140506-D00030.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/97/67/c2/398fef43fce93a/US08715951-20140506-D00031.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/f5/db/95/4ea2eb6a636296/US08715951-20140506-D00032.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/75/95/5b/6ad39ff506db1d/US08715951-20140506-D00033.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/cd/a9/7b/2ac76d05844d4f/US08715951-20140506-D00034.png">
        <template is="dom-repeat" as="img" class="style-scope image-carousel"></template>
      </div>
    <template is="dom-if" class="style-scope image-carousel"></template>
  </image-carousel>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/00"><a id="link" href="#" class="style-scope state-modifier">G01N33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/48"><a id="link" href="#" class="style-scope state-modifier">G01N33/48</a></state-modifier>
                  <span class="description style-scope classification-tree">Biological material, e.g. blood, urine; Haemocytometers</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N33/50"><a id="link" href="#" class="style-scope state-modifier">G01N33/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="G01N33/86"><a id="link" href="#" class="style-scope state-modifier">G01N33/86</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/36"><a id="link" href="#" class="style-scope state-modifier">C07K16/36</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/40"><a id="link" href="#" class="style-scope state-modifier">C07K16/40</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G"><a id="link" href="#" class="style-scope state-modifier">G</a></state-modifier>
                  <span class="description style-scope classification-tree">PHYSICS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01"><a id="link" href="#" class="style-scope state-modifier">G01</a></state-modifier>
                  <span class="description style-scope classification-tree">MEASURING; TESTING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N"><a id="link" href="#" class="style-scope state-modifier">G01N</a></state-modifier>
                  <span class="description style-scope classification-tree">INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/00"><a id="link" href="#" class="style-scope state-modifier">G01N2333/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/435"><a id="link" href="#" class="style-scope state-modifier">G01N2333/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving biological materials from specific organisms or of a specific nature from animals; from humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="G01N2333/745"><a id="link" href="#" class="style-scope state-modifier">G01N2333/745</a></state-modifier>
                  <span class="description style-scope classification-tree">Assays involving non-enzymic blood coagulation factors</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="G01N2333/755"><a id="link" href="#" class="style-scope state-modifier">G01N2333/755</a></state-modifier>
                  <span class="description style-scope classification-tree">Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y"><a id="link" href="#" class="style-scope state-modifier">Y</a></state-modifier>
                  <span class="description style-scope classification-tree">GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10"><a id="link" href="#" class="style-scope state-modifier">Y10</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNICAL SUBJECTS COVERED BY FORMER USPC</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10S"><a id="link" href="#" class="style-scope state-modifier">Y10S</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10S435/00"><a id="link" href="#" class="style-scope state-modifier">Y10S435/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemistry: molecular biology and microbiology</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="Y10S435/962"><a id="link" href="#" class="style-scope state-modifier">Y10S435/962</a></state-modifier>
                  <span class="description style-scope classification-tree">Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y"><a id="link" href="#" class="style-scope state-modifier">Y</a></state-modifier>
                  <span class="description style-scope classification-tree">GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10"><a id="link" href="#" class="style-scope state-modifier">Y10</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNICAL SUBJECTS COVERED BY FORMER USPC</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10T"><a id="link" href="#" class="style-scope state-modifier">Y10T</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10T436/00"><a id="link" href="#" class="style-scope state-modifier">Y10T436/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemistry: analytical and immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10T436/25"><a id="link" href="#" class="style-scope state-modifier">Y10T436/25</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemistry: analytical and immunological testing including sample preparation</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="Y10T436/25125"><a id="link" href="#" class="style-scope state-modifier">Y10T436/25125</a></state-modifier>
                  <span class="description style-scope classification-tree">Digestion or removing interfering materials</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y"><a id="link" href="#" class="style-scope state-modifier">Y</a></state-modifier>
                  <span class="description style-scope classification-tree">GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10"><a id="link" href="#" class="style-scope state-modifier">Y10</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNICAL SUBJECTS COVERED BY FORMER USPC</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10T"><a id="link" href="#" class="style-scope state-modifier">Y10T</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10T436/00"><a id="link" href="#" class="style-scope state-modifier">Y10T436/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemistry: analytical and immunological testing</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y10T436/25"><a id="link" href="#" class="style-scope state-modifier">Y10T436/25</a></state-modifier>
                  <span class="description style-scope classification-tree">Chemistry: analytical and immunological testing including sample preparation</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="Y10T436/25375"><a id="link" href="#" class="style-scope state-modifier">Y10T436/25375</a></state-modifier>
                  <span class="description style-scope classification-tree">Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 6 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Chemical &amp; Material Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Chemical &amp; Material Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">US8715951B2</h2>
                  <p class="tagline style-scope patent-result">United States</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Patent ( having previously published pre-grant publication)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/cb/fd/a3/acb007d73a3169/US8715951.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;fviii&quot;,&quot;antibody&quot;,&quot;plasma&quot;,&quot;mab&quot;,&quot;concentration&quot;]" data-before="20050715"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/US8715951B2"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Behnaz Parhami-Seren"><a id="link" href="#" class="style-scope state-modifier">Behnaz Parhami-Seren</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Kenneth G. Mann"><a id="link" href="#" class="style-scope state-modifier">Kenneth G. Mann</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="David N. Fass"><a id="link" href="#" class="style-scope state-modifier">David N. Fass</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    University of Vermont and State Agricultural College
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2006</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2007011746A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/US2006/027409</div>
                <div class="style-scope application-timeline">Filing date: 2006-07-13</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8236518B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/988,518</div>
                <div class="style-scope application-timeline">Filing date: 2006-07-13</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2615328A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA002615328A</div>
                <div class="style-scope application-timeline">Filing date: 2006-07-13</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2006270168B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2006270168A</div>
                <div class="style-scope application-timeline">Filing date: 2006-07-13</div>
                <div class="style-scope application-timeline">Legal status: Ceased</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP1915176A4/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP06787333A</div>
                <div class="style-scope application-timeline">Filing date: 2006-07-13</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2012</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8715951B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/552,246</div>
                <div class="style-scope application-timeline">Filing date: 2012-07-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application US13/552,246 events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2012-07-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="University of Vermont and State Agricultural College"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by University of Vermont and State Agricultural College</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="priority style-scope application-timeline">2012-07-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8715951B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority to US13/552,246</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2013-05-09</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20130115621A1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US20130115621A1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2014-05-06</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2014-05-06</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US8715951B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of US8715951B2</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2026-07-13</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (6)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#nplCitations" class="style-scope patent-result">Non-patent citations (3)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (13)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;p=1&amp;u=/netahtml/PTO/srchnum.html&amp;r=1&amp;f=G&amp;l=50&amp;d=PALL&amp;s1=8715951.PN.">USPTO</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patentcenter.uspto.gov/applications/13552246">USPTO PatentCenter</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=8715951">USPTO Assignment</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=8715951B2&amp;KC=B2&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/patent/US/8715951/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/US8715951">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PDES69085705" lang="EN" load-source="patent-office" class="description style-scope patent-text">
    
    <heading class="style-scope patent-text">CROSS-REFERENCE TO RELATED APPLICATIONS</heading>
    <div num="p-0002" class="description-paragraph style-scope patent-text">The present application is a continuation of U.S. national phase application Ser. No. 11/988,518, filed Apr. 21, 2009, now U.S. Pat. No. 8,236,517, pursuant to 35 U.S.C. 371, of PCT international application Ser. No. PCT/US2006/027409, filed Jul. 13, 2006, designating the United States and published in English, which claims the benefit of the following U.S. Provisional Patent Application Ser. No. 60/699,584 entitled Highly Sensitive Immunoassays and Antibodies for Detection of Blood Factor VIII, filed Jul. 15, 2005, and U.S. Provisional Patent Application Ser. No. 60/715,978 of the same title, filed Sep. 9, 2005, the disclosures of which are hereby incorporated by reference in their entireties.</div>
    
    
    <heading class="style-scope patent-text">STATEMENT OF U.S. GOVERNMENT INTEREST</heading>
    <div num="p-0003" class="description-paragraph style-scope patent-text">This invention was made with government support under Grant Nos. HL-46703 and RO3 A1057727 awarded by the National Institutes of Health. The Government has certain rights in the invention.</div>
    
    
    <heading class="style-scope patent-text">FIELD OF THE INVENTION</heading>
    <div num="p-0004" class="description-paragraph style-scope patent-text">The invention generally relates to compositions and methods for detecting and quantifying levels of proteins present in bodily fluids such as blood, plasma or serum. More particularly, it relates to antibodies that selectively bind to blood coagulation factors such as FVIII, and immunological methods of using these antibodies in assays to detect these factors in body fluids of patients, including those with blood coagulation disorders such as hemophilia.</div>
    <heading class="style-scope patent-text">BACKGROUND</heading>
    <div num="p-0005" class="description-paragraph style-scope patent-text">Blood clotting begins when platelets adhere at a lesion site in the cut wall of an injured blood vessel. In a cascade of enzymatically regulated reactions, soluble fibrinogen molecules are converted by the enzyme thrombin to insoluble strands of fibrin that hold the platelets together in a thrombus. At each step in the cascade, a protein precursor is converted to a protease that cleaves the next protein precursor in the series. Co-factors are required at most of the steps.</div>
    <div num="p-0006" class="description-paragraph style-scope patent-text">The human factor VIII (FVIII) is a plasma glycoprotein that acts as a cofactor for the serine protease factor FIXa to activate FX in the intrinsic cascade of blood coagulation. Factor VIII circulates as an inactive precursor at a very low concentration in blood, bound tightly and non-covalently to von Willebrand factor. Factor VIII is proteolytically activated by thrombin or factor Xa, which dissociates it from von Willebrand factor and activates its procoagulant function in the cascade (Hoyer, 1981; Kane and Davie, 1988). In its active form, the protein FVIIIa is a cofactor that increases the catalytic efficiency of factor IXa toward factor X activation by several orders of magnitude.</div>
    <div num="p-0007" class="description-paragraph style-scope patent-text">Quantitative or qualitative deficiency in FVIII results in a bleeding disorder called hemophilia A (Scandella et al., 1998; Rick et al., 2003). Severe hemophiliacs number about 17,000 in the United States. These patients can suffer uncontrolled internal bleeding that may result in serious symptoms ranging from inflammatory reactions in joints to early death. These patients can be treated with human FVIII, which will restore the blood's normal clotting ability if administered with sufficient frequency and concentration. Hemophiliacs require daily replacement of factor VIII to prevent bleeding and the resulting deforming hemophilic arthropathy.</div>
    <div num="p-0008" class="description-paragraph style-scope patent-text">Several commercial preparations of human plasma-derived FVIII of varying degrees of purity are available for the treatment of hemophilia A. These products are derived from blood plasma of human donors treated to remove viruses, or prepared by recombinant means from cultures of cells that carry genetically engineered recombinant (r) full-length or truncated FVIII (Brackmann et al., 1993; Lusher et al., 1993); Bihoreau et al., 1991; Pipe and Kaufman, 1997; Sandberg et al., 2001).</div>
    <div num="p-0009" class="description-paragraph style-scope patent-text">Unfortunately, human factor VIII is unstable at physiologic concentrations and pH, and is present in blood at an extremely low concentration. Problems in therapeutic use occur due to difficulty in isolation and purification, immunogenicity, and the necessity of removing the AIDS and hepatitis infectivity risk.</div>
    <div num="p-0010" class="description-paragraph style-scope patent-text">Accurate assessment of the quantity and quality of FVIII is critical to successful outcome in hemophilia patients undergoing FVIII replacement therapy. Current assays of quantification of FVIII products and concentrates involve bioassays including clotting assays and generation of FXa (Langdell et al., 1953; Niemetz and Nossel, 1969; Over, 1986; Kemball-Cook et al., 1993). Thus currently available assays measure FVIII concentration only indirectly (Hoyer, 1981; Kane and Davie, 1988; Chavin and Fay, 1989; Foster and Zimmerman, 1989; Fay, 1993; Lenting et al., 1998). Unfortunately such indirect assays exhibit problems of poor reproducibility and lack of precision due to complex reaction kinetics.</div>
    <div num="p-0011" class="description-paragraph style-scope patent-text">A particular problem associated with FVIII preparations is the presence of FVIII degradation product. This is undesirable for several reasons. First, much more FVIII is required to achieve a desired therapeutic goal. Also, degradation products can interfere with FVIII function by interacting with substrate proteins, reducing the efficiency of FVIII activation by the substrates. Use of excess FVIII in patients is also undesirable as it can enhance production of neutralizing FVIII-specific antibodies (Scandella et al., 1998; El Alfy et al., 2000; Klinge et al., 2001; Lindgren et al., 2002). Available bioassays for FVIII reflect only the concentration of fully functional FVIII. Thus, if FVIII preparations contain degraded or inactive FVIII, such products are not detectable by bioassays.</div>
    <div num="p-0012" class="description-paragraph style-scope patent-text">To enhance ability to precisely assess the quality of FVIII preparations in a timely and cost effective manner, there exists a clear need for sensitive assays that can determine both the concentration and the biological activity of FVIII in FVIII preparations.</div>
    <div num="p-0013" class="description-paragraph style-scope patent-text">As discussed, FVIII is present in the blood of normal subjects at a very low concentration (about 100-700 pM). In severe hemophilia patients, FVIII concentrations are below 1% physiological concentration. Such low FVIII concentrations are below the level of detection of existing assay methods. A great improvement in the diagnosis and management of hemophilia patients would be achieved if it were possible to accurately measure FVIII levels in the plasma of these patients. Thus both for monitoring FVIII levels in patients suspected of having a blood clotting disorder, and in severe, moderate, and mild hemophilia patients undergoing FVIII replacement therapy, there is an unmet need for highly specific and sensitive assays that can detect FVIII at physiological concentrations and significantly below.</div>
    <heading class="style-scope patent-text">SUMMARY OF THE INVENTION</heading>
    <div num="p-0014" class="description-paragraph style-scope patent-text">The invention provides highly sensitive immunoassays and antibodies capable of accurate detection of FVIII concentration in the plasma of normal human subjects and those with hemophilia. Levels of detection exhibited by particular embodiments greatly exceed those of previously described assays, for example by at least 3400-fold. The enhanced sensitivity of the assays is contributed in part by using a combination of two antibodies that can bind human FVIII protein in plasma with high affinity and selectivity following treatment with an agent that causes the FVIII to dissociate from FVIII-binding molecules to which it is bound, such as Von Willebrand factor (vWF).</div>
    <div num="p-0015" class="description-paragraph style-scope patent-text">Preferred antibodies of the invention are monoclonal and specifically bind an epitope on the Heavy-chain, B-domain or Light-chain of native human FVIII protein. Binding affinities (IC<sub class="style-scope patent-text">50</sub>) of preferred antibodies are in the range of 50-160 nM FVIII. Antibodies of the invention are particularly useful in in vitro assays to detect and quantitate free FVIII or FVIII fragments and FVIII in complex with vWF in a laboratory or biological sample including a body fluid. These factors can be detected in the picomolar range in human plasma and in sub-picomolar concentrations in commercial products containing these factors.</div>
    <div num="p-0016" class="description-paragraph style-scope patent-text">Antibodies of the invention can be used to prepare substantially pure native FVIII, particularly native human FVIII from a biological sample.</div>
    <div num="p-0017" class="description-paragraph style-scope patent-text">Antibodies of the invention can also be employed as a component of a diagnostic kit, e.g., for detecting and preferably quantifying native FVIII in a biological sample, such as plasma from normal individuals or a human subject with a bleeding disorder.</div>
    <div num="p-0018" class="description-paragraph style-scope patent-text">Further provided are novel immunoassays that in some embodiments are at least 3400-fold more sensitive than existing assays and can measure FVIII concentrations as less than 1 pM in a biological sample such as human plasma.</div>
    <div num="p-0019" class="description-paragraph style-scope patent-text">A method for detecting a FVIII protein or a fragment thereof in a sample in accordance with the invention includes: (a) contacting a sample comprising FVIII protein with a reducing agent that releases FVIII from a FVIII-binding molecule; (b) contacting the sample of step (a) with a first (capture) antibody directed to a FVIII antigen such that the FVIII protein or fragment binds to the antibody and forms a complex therewith; (c) contacting the complex formed in step (b) with a second (probe) antibody directed to a FVIII antigen, the probe antibody being labeled with a detectable marker, to form a complex which includes the antibody of step (b), the FVIII protein or fragment, and the second antibody; and (d) detecting the second antibody in the complex formed in step (c), thereby detecting the FVIII protein or fragment in the sample. The method can be used to determine FVIII concentration in biological samples and commercial products comprising plasma.</div>
    <div num="p-0020" class="description-paragraph style-scope patent-text">In some embodiments of the assay, the reducing agent is selected from the group consisting of -mercaptoethanol, sodium borohydride, dithiothreitol, erytritol, and ethane thiol.</div>
    <div num="p-0021" class="description-paragraph style-scope patent-text">A highly sensitive immunoassay in accordance with the invention, in which capture anti-FVIII antibodies are conjugated to fluorescent beads and probe antibodies are detected by flow analysis (e.g., using lasers, optics, micro-fluidics and advance signal processing) is sufficiently sensitive to be useful for determining FVIII levels in a human subject having or at risk of developing a blood clotting disorder such as hemophilia. Sensitivity of the assay is contributed in part by the very high binding affinity of a preferred capture antibody, and by ability of the anti-FVIII antibodies used in the assay to bind to FVIII protein under conditions in which the protein is dissociated from FVIII-binding molecules such as von Willebrand factor after treatment with a reducing agent. In a preferred embodiment of the method, the concentration of FVIII protein detectable in the sample is less than 1 pM.</div>
    <div num="p-0022" class="description-paragraph style-scope patent-text">Other aspects and advantages of the invention are discussed below.</div>
    
    
    <description-of-drawings class="style-scope patent-text">
      <heading class="style-scope patent-text">BRIEF DESCRIPTION OF THE DRAWINGS</heading>
      <div num="p-0023" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A-C</figref> is three graphs showing detection and quantification of blood factor VIII (FVIII) in a double sandwich enzymatic immunoassay (ELISA) according to an embodiment of the invention. Human FVIII protein is captured by a first anti-FVIII monoclonal antibody (mAb) (Fab)<sub class="style-scope patent-text">2 </sub>fragment, anti-FVIII-24. Binding of FVIII is detected by a second anti-FVIII mAb (as specified) and a horse peroxidase (HRP)-labeled anti-mouse FC fragment. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A</figref> shows detection by mAbs anti-FVIII-1, -20, and -21 and <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1B</figref> shows detection by mAbs anti-FVIII-23, -25, and -68. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1C</figref> shows specificity of the immunoassay for human FVIII protein.</div>
      <div num="p-0024" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2A-B</figref> is two photographs of immunoblots showing reactivity of mAbs anti-FVIII-1 (<b class="style-scope patent-text">2</b>A) and anti-FVIII-68 (<b class="style-scope patent-text">2</b>B) against preparations containing FVIII protein, according to an embodiment of the invention.</div>
      <div num="p-0025" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3A-B</figref> is two graphs showing the binding specificity of certain anti-FVIII mAbs for recombinant FVIII protein (rFVIII) or activated FVIII (rFVIIIa) in a double sandwich immunoassay according to an embodiment of the invention. Binding was detected with anti-FVIII-23 mAb (<b class="style-scope patent-text">3</b>A) or anti-FVIII-68 mAb (<b class="style-scope patent-text">3</b>B).</div>
      <div num="p-0026" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4</figref> is a graph illustrating the binding specificity of anti-FVIII-24 mAb according to an embodiment of the invention. FVIII-vWF complex was immobilized on anti-FVIII-24 mAb (Fab)<sub class="style-scope patent-text">2 </sub>fragment. Binding was probed with anti-vWF mAb and HRP-anti-mouse FC.</div>
      <div num="p-0027" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5A-B</figref> is two graphs illustrating the binding specificity of anti-FVIII-25 mAb in the presence of CaCl<sub class="style-scope patent-text">2 </sub>containing HBS (<b class="style-scope patent-text">5</b>A) or PBS (<b class="style-scope patent-text">5</b>B), according to an embodiment of the invention. The detecting mAb is anti-FVIII-68.</div>
      <div num="p-0028" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref> is a graph showing results of a typical titration curve in which the concentration of FVIII in commercial products containing FVIII-vWF complex was determined by double mAb sandwich immunoassay, according to an embodiment of the invention.</div>
      <div num="p-0029" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7A-B</figref> is two graphs illustrating a double sandwich immunoassay for quantifying von Willebrand factor (vWF) in products containing FVIII, according to an embodiment of the invention. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7A</figref> shows a standard curve generated by immobilizing purified vWF on an anti-vWF mAb and detecting binding with a labeled second antibody. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7B</figref> shows quantification of vWF in commercial products containing FVIII using the immunoassay.</div>
      <div num="p-0030" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref> is a schematic diagram illustrating a highly sensitive fluorescence-based immunoassay (FLI) for detection of FVIII, according to an embodiment of the invention.</div>
      <div num="p-0031" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9</figref> is a graph showing detection of recombinant FVIII (rFVIII) in FVIII-depleted plasma spiked with using a fluorescence-based immunoassay (FLI) according to an embodiment of the invention. FVIII is not detected in control plasma without addition of rFVIII.</div>
      <div num="p-0032" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref> is a graph showing quantification of FVIII in two different FVIII-immunodepleted plasmas in the picomolar range in a concentration-dependent manner, using a FLI according to an embodiment of the invention.</div>
      <div num="p-0033" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 11A-B</figref> is two graphs showing quantification of FVIII in human plasma treated with a reducing agent (mercaptoethanol) at 1 mM (<b class="style-scope patent-text">11</b>A) or 10 mM (<b class="style-scope patent-text">11</b>B) concentration, and subjected to FLI according to an embodiment of the invention.</div>
      <div num="p-0034" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 12</figref> is a graph showing the effect of dialysis of human plasma on the sensitivity of detection of FVIII in the plasma, using a FLI according to an embodiment of the invention.</div>
      <div num="p-0035" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 13</figref> is a graph showing that treatment of human plasma with a reducing agent improves the binding of anti-FVIII mAbs in a FLI of FVIII according to an embodiment of the invention.</div>
      <div num="p-0036" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 14</figref> is a graph showing the detection of FVIII in FVIII-depleted plasma spiked with recombinant FVIII (rFVIII) or with a commercial FVIII product enriched in vWF (Immunate) using a FLI according to an embodiment of the invention.</div>
      <div num="p-0037" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 15</figref> is a graph showing detection sensitivity of the FVIII FLI. Plasma of healthy individuals can be diluted several thousand fold and picomolar concentrations of FVIII can be quantified in plasma of human subjects by a FLI according to an embodiment of the invention.</div>
      <div num="p-0038" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 16</figref> is a graph showing a comparison of FVIII antigen levels as determined by ELISA and FLI, according to an embodiment of the invention, in plasma of a healthy human population.</div>
      <div num="p-0039" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 17</figref> is a graph showing highly sensitive detection of FVIII in a FLI according to an embodiment of the invention. Recombinant FVIII is detectable in the range of 1 pM and below.</div>
      <div num="p-0040" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 18A-B</figref> is two photographs showing SDS-gel electrophoresis (<b class="style-scope patent-text">18</b>A) and immunoblot (<b class="style-scope patent-text">18</b>B) analysis of rFVIII used as calibrator in FLI and ELISA.</div>
      <div num="p-0041" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 19</figref> is a graph showing comparison of binding patterns of equimolar concentrations of rFVIII and Immunate, according to an embodiment of the invention.</div>
      <div num="p-0042" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 20</figref> is a graph demonstrating the ability to detect different molar concentrations of rFVIII that have been added to plasma from normal human donors, according to an embodiment of the invention.</div>
      <div num="p-0043" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 21</figref> is a plot showing FVIII concentration and ranges in a healthy human population, determined in accordance with an embodiment of the invention.</div>
      <div num="p-0044" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 22</figref> is a plot showing the concentration and ranges of plasma FVIII as determined by prior art APTT and chromogenic assays.</div>
      <div num="p-0045" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 23A-D</figref> is four graphs showing correlations of FVIII antigen concentration as determined by immunoassay in accordance with the invention and as determined by APTT and chromogenic assays.</div>
      <div num="p-0046" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24A-B</figref> is two graphs showing high (<b class="style-scope patent-text">24</b>A) and low (<b class="style-scope patent-text">24</b>B) calibration curves of recombinant FVIII, according to an embodiment of the invention.</div>
      <div num="p-0047" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 25A</figref> is a graph showing the pattern of binding of pooled plasma from healthy donors as determined by a fluorescent immunoassay (FLI) in accordance with an embodiment of the invention.</div>
      <div num="p-0048" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 25B</figref> is a plot showing plasma FVIII concentrations and ranges in a healthy donor population, measured by FLI.</div>
      <div num="p-0049" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 26A</figref> is a bar graph showing a comparison of plasma FVIII concentrations in patients with hemophilia, as measured by FLI and APTT assay. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 26B</figref> is a graph showing the relationship between FVIII antigen concentration in hemophilia patients as measured by FL and APTT.</div>
      <div num="p-0050" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 27</figref> is a bar graph showing correlation between FVIII antigen concentration in severe hemophilia patients (n=8) as measured by FLI and APTT assays.</div>
      <div num="p-0051" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 28A</figref> is two plots showing FVIII concentrations and ranges in patients (n=100) with diseases including autoimmune disorders and FVIII deficiency, as determined by FLI and APTT assays.</div>
      <div num="p-0052" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 28B</figref> is a graph showing correlation between measurements of plasma FVIII concentration as determined by FLI and APTT assays.</div>
      <div num="p-0053" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 29A</figref> is two plots showing a comparison of plasma FVIII concentrations calculated from rFVIII and Immunate calibrators.</div>
      <div num="p-0054" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 29B</figref> is a graph showing a comparison of FVIII concentrations as determined using the two calibrators.</div>
    </description-of-drawings>
    
    
    <heading class="style-scope patent-text">DETAILED DESCRIPTION OF THE INVENTION</heading>
    <div num="p-0055" class="description-paragraph style-scope patent-text">Human factor VIII (FVIII) is a plasma glycoprotein that acts as a cofactor of FIXa to activate FX in the intrinsic cascade of blood coagulation. As discussed, under normal circumstances FVIII circulates as an inactive precursor at a very low concentration in the blood, as a minor component tightly bound to a very large protein, the von Willebrand factor (vWF) (Hoyer, 1981; Kane and Davie, 1988). Detection of FVIII in human plasma by immunological methods is significantly complicated both by its very low concentration in biological fluids and particularly by its association with vWF. In one aspect, the invention newly addresses this problem by providing highly sensitive methods of detecting FVIII in a sample such as human plasma that in some embodiments exceed the sensitivity of existing immunoassays by a factor of 3400-fold or more. The methods derive their extreme sensitivity for FVIII from two interrelated discoveries. The first is that despite the noncovalent binding of FVIII to FVIII-binding molecules such as vWF, unexpectedly, reducing agents such as mercaptoethanol can be successfully used at low concentration (about 1-10 mM) to separate FVIII from these molecules. Importantly, this separation is effected without destruction of epitopes necessary for antibody recognition of FVIII. The second discovery is that anti-FVIII antibodies can be isolated and purified having the ability to bind FVIII with high specificity and affinity in the presence of such reducing agents. Accordingly, these antibodies can recognize and bind to epitopes in FVIII in its most accessible form, free from its natural binding partner, the much larger vWF. This feature greatly enhances the level of detection of FVIII achievable in fluid samples in which this protein is normally present at very low concentration, such as in plasma of healthy human subjects, and more particularly in that of patients with blood clotting disorders such as hemophilia, in which FVIII levels are extremely reduced.</div>
    <heading class="style-scope patent-text">Immunoassays for Detecting FVIII</heading>
    <div num="p-0056" class="description-paragraph style-scope patent-text">In one important aspect, the invention provides a highly sensitive method for detecting a FVIII protein or a fragment thereof in a sample. The method includes the step of contacting a sample comprising FVIII protein with a reducing agent that irreversibly releases FVIII from a factor VIII-binding molecule. As discussed, the presence of such molecules that can bind to FVIII can interfere with FVIII detection in immunoassays. An example of a factor VIII-binding molecule is von Willebrand factor (vWF), with which FVIII is normally associated in the circulating blood of a subject. Any reducing agent can be employed in the method that can cause the separation of FVIII from vWF without destruction of antigenic sites on the FVIII molecule that are specifically recognized by antibodies used to detect FVIII in an immunoassay. Many reducing agents are known (e.g., -mercaptoethanol, sodium borohydride, dithiothreitol, erytritol, ethane thiol) and those suitable for use in the invention can be determined empirically by testing for this quality in an immunoassay using particular anti-FVIII antibodies under consideration.</div>
    <div num="p-0057" class="description-paragraph style-scope patent-text">A preferred reducing agent for this purpose is -mercaptoethanol. As shown below, pretreatment of both human plasma and samples containing recombinant FVIII (rFVIII) prior to immunoassay with this reducing agent at 1-10 mM concentration enables detection of FVIII at levels as low as 1 pM. See, for instance, Examples 8 and 9, infra.</div>
    <div num="p-0058" class="description-paragraph style-scope patent-text">As is apparent from the foregoing, a key aspect of the method for detecting a FVIII protein or fragment is the step of contacting the sample with an antibody directed to a FVIII antigen. In general, the method can be practiced with a wide variety of anti-FVIII antibodies. As described in more detail below, many forms of antibodies and fragments thereof are known. All of these can be used as anti-FVIII antibodies in the method. As also described below, in another aspect the invention provides monoclonal antibodies that possess unique qualities that render them particularly suitable for detection of FVIII in human plasma and in various FVIII-containing commercial products.</div>
    <div num="p-0059" class="description-paragraph style-scope patent-text">In a method of detecting FVIII, a first antibody of the subject invention is used as a capture antibody. The capture antibody is directed to an epitope on the FVIII protein or fragment thereof such that upon contact, the FVIII protein or fragment specifically binds to the antibody and forms a complex with it. In this manner the antibody captures the FVIII protein or fragment, removing it from the sample. As discussed, the capture antibody may be a monoclonal antibody or a polyclonal antibody.</div>
    <div num="p-0060" class="description-paragraph style-scope patent-text">The method further includes the use of a second (probe) antibody, also directed to a FVIII antigen. The epitope recognized by the probe antibody is different from the epitope recognized by the first (capture) antibody. Thus, upon binding to its recognition site on the captured FVIII protein molecule, the probe antibody contributes to a complex that includes the capture antibody and the probe antibody, with the FVIII protein or fragment sandwiched between the two anti-FVIII antibodies.</div>
    <div num="p-0061" class="description-paragraph style-scope patent-text">The probe antibody is generally labeled with a detectable marker. Detection of the FVIII protein in the complex is achieved by detecting the marker on the probe antibody. A wide variety of labels may be suitably employed to detectably-label the probe antibody, such as radionuclides, fluors, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands such as, e.g., haptens, and the like. Detectable labels also include, but are not limited to, luminescent probes, radioisotopes, chromophores, fluorophores, or heavy metals. Anti-FVIII immunoglobulin linked to N-hydroxysuccinimidobiotin (i.e., biotin) can also be an effective probe for FVIII antigen when reacted with a detector (e.g., avidin, streptavidin or horseradish peroxidase). The peroxidase substrates identified above can be used to generate the color endpoint. The color detectors are most convenient but the invention is not so limited. Other detection systems including radioisotopic, luminescent, or electrochemical labels can also be employed. See also Examples below illustrating use of several detectable markers conjugated to anti-FVIII probe antibodies.</div>
    <div num="p-0062" class="description-paragraph style-scope patent-text">In some embodiments, the capture agents (antibodies) are immobilized, permanently or reversibly, on a solid support such as a bead, chip, or slide. In one embodiment, the capture agents are conjugated with a reporter molecule such as a fluorescent molecule or an enzyme, and used to detect the presence of bound FVIII on a substrate, for example, a sandwich type assay in which one capture agent is immobilized on a support to capture a FVIII antigen while a second, labeled antibody also specific for the captured FVIII may be added to detect/quantitate the captured FVIII. In some methods disclosed above, the detectable marker is preferably an enzyme. Preferred enzymes are horseradish peroxidase and alkaline phosphatase, although other enzymes known to those skilled in the art can also be used in the subject invention.</div>
    <div num="p-0063" class="description-paragraph style-scope patent-text">Numerous types of assays can be used in the subject invention as long as the configuration of the assay allows the antibodies to recognize the FVIII epitopes. Those skilled in the art to which the subject invention pertains would readily understand that any conventional immunoassay which would allow the recognition of the FVIII epitopes can be used in the subject invention to both quantitatively and qualitatively detect FVIII antigen. Such assays include regular sandwich assays, wherein an antigen is sandwiched between the bound antibody on a solid carrier and a labeled antibody; reverse sandwich assays, in which a labeled antibody is reacted with the antigen prior to contact with the bound antibody; and a simultaneous sandwich assay, in which the antibodies and the antigen are reacted simultaneously. These and other immunoassay methods can be used with the antibodies of the subject invention if they allow recognition by the antibodies of the FVIII epitopes.</div>
    <div num="p-0064" class="description-paragraph style-scope patent-text">The capture antibody, which is initially contacted with the FVIII-containing sample, may be attached to an immunological reaction surface. An immunological reaction surface is a surface that is insoluble in the reacting medium and on which immunological reactions take place, for example reactions involved in the enzyme-linked immunosorbent (ELISA) procedure. Typically the surfaces are glass, paper, or plastic, such as polystyrene or polyacrylate. The surface may be the interior surface of a test tube, the well of a microtiter plate or some other container suitable for an immunological reaction. Those skilled in the art will know of other appropriate surfaces on which an immunological reaction can take place and which can be used in the subject invention, such as glass or plastic beads or rods, or paper strips. For purposes of the subject invention, such an immunological reaction surface will be one to which the antibodies of the subject invention will adhere.</div>
    <div num="p-0065" class="description-paragraph style-scope patent-text">A particularly preferred surface is a bead or microsphere having physical characteristics and fluorescent properties suitable for use in applications such as flow cytometry. Beads suitable for use as a starting material in accordance with the invention are generally known in the art and may be obtained from manufacturers such as Spherotech (Libertyville, Ill.), Molecular Probes (Eugene, Oreg.) and Luminex (Austin Tex.). Once a homogeneous subset of beads is obtained, the beads are conjugated with a first anti-FVIII antibody of the invention. Preferably the bead comprises at least one appropriate fluorescing compound.</div>
    <div num="p-0066" class="description-paragraph style-scope patent-text">Flow analysis operates in a conventional manner. That is, the beads are processed by illuminating them, essentially one at a time, with a laser beam. Measurements of the scattered laser light are obtained for each illuminated bead by a plurality of optical detectors. In addition if a bead contains at least one appropriate fluorescing compound, it will fluoresce when illuminated. A plurality of optical detectors within the flow analyzer measure fluorescence at a plurality of wavelengths. Typical measured bead characteristics include, but are not limited to, forward light scatter, side light scatter, red fluorescence, green fluorescence, and orange fluorescence. An exemplary flow cytometric system for simultaneous assay of multiple analytes in a sample, including antigens bound to antibodies conjugated to fluorescent beads is marketed by Luminex (Austin, Tex.) and is described, for example, in U.S. Pat. No. 5,981,180, the disclosure of which is herein incorporated by reference in its entirety.</div>
    <div num="p-0067" class="description-paragraph style-scope patent-text">As illustrated in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref>, a particularly preferred highly sensitive method for detecting a FVIII protein or fragment comprises contacting a sample with an anti-FVIII capture antibody attached to a first (test) bead having at least one detectable characteristic, such as a first identifiable spectral property. As a control, the sample is contacted with an irrelevant antibody (i.e., an antibody of the same class having no binding affinity to FVIII) that is attached to a second (control) bead having at least one characteristic distinguishable from that of the first bead, such as a fluorescent bead having a second spectral property distinguishable by detectors in a flow analyzer from that of a first fluorescent bead to which a FVIII capture antibody is attached. Upon contact with the sample, FVIII in the sample complexes with the anti-FVIII capture antibody. In the case of the control beads, some proteins in the sample may form non-specific complexes with the control antibody. The complexes formed on the beads comprising capture anti-FVIII antibodies and on the beads comprising control antibodies (if such complexes form) are detected by contacting the respective beads with a second (probe) antibody directed to a FVIII antigen labeled with a detectable marker. Complexes which include the capture and control antibodies are then detected, and the amount of FVIII protein in the sample is determined by subtracting the non-specific binding detected by the probe antibody on the control beads from that of the specific binding detected by the probe antibody on the capture beads. Incorporation of this control ensures that spurious, non-specific binding can be screened for and subtracted from the determination of FVIII concentration.</div>
    <div num="p-0068" class="description-paragraph style-scope patent-text">Although immunoassays using antibodies attached to surfaces such as beads have been previously described, the inventors have discovered that particular conditions tailored to the specific anti-FVIII antibodies are necessary to achieve the very high levels of detection of FVIII protein in bead-based fluorescent immunoassays of the invention. Detailed exemplary protocols for attachment of FVIII antibodies to microspheres are provided infra, for instance in Examples 8 and 9. In general, several factors were found to be important to obtain a high yield of beads with appropriately conjugated antibodies, and to achieve the observed high level sensitivity of the bead-based FVIII immunofluorescent assay.</div>
    <div num="p-0069" class="description-paragraph style-scope patent-text">One important aspect is avoidance of methods such as vortexing and sonication throughout the procedures involving coupling of antibodies to beads. Use of these methods significantly reduces yields by causing the microspheres to disintegrate. Time and speed of centrifugation of beads is also important for recovery. A preferred centrifugation protocol is about 3 minutes at 11,000-12,000 rpm. It is also preferable to considerably increase the pH of the coupling buffer above that recommended by a commercial supplier (Luminex), to approximately pH 6.0. In addition, it is important that the concentration of the capture antibody incubated with the beads during the attachment step not be too high. For example, the inventors have determined that for anti-FVIII mAb-68 described herein, a preferred concentration is 5 g/ml, which is significantly lower than the concentration (25 g/ml) recommended, for example, by Luminex.</div>
    <div num="p-0070" class="description-paragraph style-scope patent-text">Immunological reaction conditions for the disclosed methods are conditions with respect to temperature, concentration, solvent, pH, etc., under which the immunological reaction such as the formation of an antibody/antigen complex will take place. Those skilled in the art are familiar with the parameters under which such complexes will form. They will know that the temperature cannot be so high or the pH so extreme as to inactivate the reactant. The solvent is typically a selected buffer or other carrier for the reactants. It may be plasma, serum or some fraction of these materials. The reaction products, including the intermediate reaction products of this invention, are soluble in the reaction solvent. Any suitable immunological reaction conditions which allow the recognition of the epitopes by the antibodies of the subject invention may be used in the methods of the invention. Further details of suitable immunological reaction conditions for specific immunoassays including ELISA, sandwich assays and bead-based fluorescent assays are described in Examples below.</div>
    <div num="p-0071" class="description-paragraph style-scope patent-text">The samples which can be analyzed using the methods of the subject invention can be obtained from any vertebrate species in which one is interested in determining the FVIII content of the sample. Preferably, the vertebrate species is a warm-blooded vertebrate species. Such warm-blooded vertebrate species include, but are not limited to, human, canine, porcine, bovine, guinea pig, horse, cat, monkey, sheep, rat, mouse, goat, rabbit, manatee, llama, chicken and camel. A particularly preferred subject is a human having or at risk of developing a bleeding disorder.</div>
    <div num="p-0072" class="description-paragraph style-scope patent-text">The sample which is analyzed using the subject invention is preferably a biological fluid. Suitable biological fluids include serum, plasma, cell lysates, urine, or products from a tissue culture cell. A person skilled in the art to which the subject invention pertains would readily understand that numerous other biological fluids from the vertebrate species can be used as samples in the subject assay. In preferred embodiments of the subject invention, however, the biological fluid comprises serum or plasma, with the most preferred biological fluid comprising blood plasma.</div>
    <div num="p-0073" class="description-paragraph style-scope patent-text">In addition to their uses for detection of FVIII in biological samples, the immunoassays of the invention are especially suitable for analysis of the concentration of FVIII in commercial products containing FVIII or recombinant FVIII (see, for instance, Examples 5-7 and Table III). A bead-based fluorescent immunoassay embodiment is particularly useful, due to its very high level of sensitivity in the picomolar range, for detection of FVIII in human plasma from normal subjects and those with blood clotting and autoimmune disorders, as described, for instance, in the Examples below.</div>
    <heading class="style-scope patent-text">Antibodies Directed to FVIII</heading>
    <div num="p-0074" class="description-paragraph style-scope patent-text">In one aspect, the invention provides antibodies directed against FVIII protein or peptide antigens (anti-FVIII antibodies). As used herein, a FVIII antigen or factor VIII antigen means any portion of a FVIII protein or peptide that elicits an immune response. A preferred FVIII antigen is a sequence contained in a human FVIII protein.</div>
    <div num="p-0075" class="description-paragraph style-scope patent-text">Several preferred anti-FVIII antibodies useful, for example, as capture or probe agents in immunoassays for detection of VIII in fluids such as plasma include mouse monoclonal antibodies (mAb) directed against human FVIII protein. Preferred mouse monoclonal antibodies identified herein as <figure-callout id="1" label="anti-FVIII mAb clones" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="24" label="anti-FVIII mAb clones" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="20" label="anti-FVIII mAb clones" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="23" label="anti-FVIII mAb clones" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="68" label="anti-FVIII mAb clones" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">anti-FVIII mAb clones</a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> </a></figure-callout> 1, 24, 20, 21, 23, 25, and 68 have been extensively characterized, as further described below in Examples 2-4. A particularly preferred antibody is anti-FVIII mAb-24. A hybridoma cell line designated FVIII-24 producing mAb-24 was deposited on Jul. 28, 2005, under Accession Number PTA-6890, with the American Type Culture Collection (ATCC), at 10801 University Boulevard, Manassas, Va. 20110-2209 USA, which is an International Depository Authority (IDA) listed in MPEP 2405 as being recognized under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made under the provisions of the Budapest Treaty and the regulations thereunder. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. 1.808(b), and the term of the deposit will comply with 37 C.F.R. 1.806.</div>
    <div num="p-0076" class="description-paragraph style-scope patent-text">In some embodiments the capture agents are referred to as first antibodies. An antibody useful as capture or probe antibody for FVIII may be a full length antibody or a fragment thereof, which includes an antigen-binding portion of an antibody. The term antigen-binding portion, as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term antigen-binding portion of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V<sub class="style-scope patent-text">L</sub>, V<sub class="style-scope patent-text">H</sub>, C<sub class="style-scope patent-text">L </sub>and C<sub class="style-scope patent-text">H1 </sub>domains; (ii) a F(ab)<sub class="style-scope patent-text">2 </sub>fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V<sub class="style-scope patent-text">H </sub>and C<sub class="style-scope patent-text">H1 </sub>domains; (iv) a Fv fragment consisting of the V<sub class="style-scope patent-text">L </sub>and V<sub class="style-scope patent-text">H </sub>domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a V<sub class="style-scope patent-text">H </sub>domain; and (vi) an isolated complementarity determining region (CDR).</div>
    <div num="p-0077" class="description-paragraph style-scope patent-text">Furthermore, although the two domains of the Fv fragment, V<sub class="style-scope patent-text">L </sub>and V<sub class="style-scope patent-text">H</sub>, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V<sub class="style-scope patent-text">L </sub>and V<sub class="style-scope patent-text">H </sub>regions pair to form monovalent molecules (known as single chain Fv, scFv); see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; and Osbourn et al. 1998, Nature Biotechnology 16: 778). Such single chain antibodies are also intended to be encompassed within the term antigen-binding portion of an antibody. Any V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>sequences of specific scFv can be linked to human immunoglobulin constant region cDNA or genomic sequences, in order to generate expression vectors encoding complete IgG molecules or other isotypes. V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>can also be used in the generation of Fab, Fv or other fragments of immunoglobulins using either protein chemistry or recombinant DNA technology.</div>
    <div num="p-0078" class="description-paragraph style-scope patent-text">Other forms of single chain antibodies, such as diabodies are also encompassed. Diabodies are bivalent, bispecific antibodies in which V<sub class="style-scope patent-text">H </sub>and V<sub class="style-scope patent-text">L </sub>domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see, e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123).</div>
    <div num="p-0079" class="description-paragraph style-scope patent-text">Antibody portions, such as Fab and F(ab)<sub class="style-scope patent-text">2 </sub>fragments, can be prepared from whole antibodies using conventional techniques, such as papain or pepsin digestion, respectively, of whole antibodies. Moreover, antibodies, antibody portions and immunoadhesion molecules can be obtained using standard recombinant DNA techniques.</div>
    <div num="p-0080" class="description-paragraph style-scope patent-text">As discussed, anti-FVIII antibodies may be polyclonal or monoclonal. The terms monoclonal antibodies and monoclonal antibody composition, as used herein, refer to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of an antigen, whereas the term polyclonal antibodies and polyclonal antibody composition refer to a population of antibody molecules that contain multiple species of antigen binding sites capable of interacting with a particular antigen. A monoclonal antibody composition typically displays a single binding affinity for a particular antigen with which it immunoreacts.</div>
    <div num="p-0081" class="description-paragraph style-scope patent-text">Any art-recognized methods can be used to generate a FVIII directed antibody. For example, a FVIII protein or peptide (alone, or linked to a hapten or protein carrier) can be used to immunize a suitable subject, (e.g., rabbit, goat, mouse or other mammal or vertebrate). For example, the methods described in U.S. Pat. Nos. 5,422,110; 5,837,268; 5,708,155; 5,723,129; and 5,849,531 (the contents of each of which are incorporated herein by reference) can be used. The immunogenic preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with a FVIII protein or fragment thereof induces a polyclonal anti-FVIII antibody response. The anti-FVIII antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized FVIII protein or peptide. The antibody molecules directed against a FVIII antigen can be isolated from the immunized mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction.</div>
    <div num="p-0082" class="description-paragraph style-scope patent-text">At an appropriate time after immunization, e.g., when the anti-FVIII antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare, e.g., monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497 (see also, Brown et al. (1981) J. Immunol. 127:539-46; Brown et al. (1980) J. Biol. Chem. 255:4980-83; Yeh et al. (1976) Proc. Natl. Acad. Sci. USA 76:2927-31; and Yeh et al. (1982) Int. J. Cancer 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al. (1983) Immunol Today 4:72), or the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). The technology for producing monoclonal antibody hybridomas is well known (see generally, R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, N.Y. (1980); E. A. Lerner (1981) Yale J. Biol. Med., 54:387-402; M. L. Gefter et al. (1977) Somatic Cell Genet. 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a FVIII immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a FVIII antigen.</div>
    <div num="p-0083" class="description-paragraph style-scope patent-text">Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-FVIII monoclonal antibody (see, e.g., G. Galfre et al. (1977) Nature 266:55052; Gefter et al. Somatic Cell Genet.; Lerner, Yale J. Biol. Med.; Kenneth, Monoclonal Antibodies, cited supra). Moreover, one of ordinary skill will appreciate that there are many variations of such methods which also would be useful.</div>
    <div num="p-0084" class="description-paragraph style-scope patent-text">Typically, an immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine-(HAT medium). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from American Type Culture Collection (ATCC). Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol (PEG). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells. (Unfused splenocytes die after several days because they are not transformed.) Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind a FVIII antigen, e.g., using a standard ELISA assay.</div>
    <div num="p-0085" class="description-paragraph style-scope patent-text">Anti-FVIII antibodies in accordance with the invention can be characterized by one or more distinguishing features, which provide utility in different types of assays. As shown in Tables I and II, infra, useful monoclonal antibodies in accord with the invention can exhibit varying affinities for FVIII protein and can be directed to binding regions in the B-domain, H-chain, or L-chain of a FVIII protein.</div>
    <div num="p-0086" class="description-paragraph style-scope patent-text">Some embodiments of the antibodies of the subject invention are characterized by particularly strong binding affinity for FVIII protein. Useful binding affinities (IC<sub class="style-scope patent-text">50</sub>) are in the range of about 50-160 nM FVIII. Some embodiments of antibodies in accordance with the invention are directed to an epitope in the H-chain or L-chain of FVIII (designated H/L) and exhibit a relative binding affinity (IC<sub class="style-scope patent-text">50</sub>) in the range of about 50-103 nM. (See, e.g., Table 1, infra.) Other distinguishing features of antibodies of the subject invention are described in the Examples below.</div>
    <div num="p-0087" class="description-paragraph style-scope patent-text">In some embodiments, antibodies of the subject invention can be conjugated to a variety of pharmaceutical agents such as, e.g., drugs, enzymes, hormones, chelating agents capable of binding a radionuclide, as well as other proteins and polypeptides useful for diagnosis or treatment of disease. For diagnostic and other purposes, as discussed, the antibodies of the present invention can be used either detectably-labeled or unlabeled. For example, a wide variety of labels may be suitably employed to detectably-label the antibody, such as radionuclides, fluors, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands such as, e.g., haptens, and the like.</div>
    <div num="p-0088" class="description-paragraph style-scope patent-text">Diagnostic methods are also contemplated including in vivo diagnostic imaging (see, e.g., A. K. Abbas, Cellular and Molecular Immunology, pg. 328 (W.B. Saunders Co. 1991)). For most in vivo imaging applications, an antibody of the invention can be detectably-labeled with, e.g., <sup class="style-scope patent-text">125</sup>I, <sup class="style-scope patent-text">32</sup>P, <sup class="style-scope patent-text">99</sup>Tc, or other detectable tag, and subsequently administered to a mammal, particularly a human, for a pre-determined amount of time sufficient to allow the antibody to contact a desired target. The subject is then scanned by known procedures such as scintigraphic camera analysis to detect binding of the antibody. The analysis could aid in the diagnosis and treatment of a number of bleeding disorders such as those specifically disclosed herein.</div>
    <div num="p-0089" class="description-paragraph style-scope patent-text">Antibodies of the invention also can be used to prepare substantially pure (e.g., at least about 90% pure, preferably at least about 96 or 97% pure) native FVIII, particularly native human FVIII from a biological sample such as human plasma. For example, native FVIII can be obtained and purified by admixing the solution with a solid support comprising the antibody to form a coupling reaction admixture. Exemplary solid supports include a wall of a plate such as a microtiter plate, as well as supports including or consisting of polystyrene, polyvinylchloride, a cross-linked dextran such as Sephadex. (Pharmacia Fine Chemicals), agarose, polystyrene beads, polyvinyl chloride, polystyrene, polyacrylamide in cross-linked form, nitrocellulose or nylon and the like. The FVIII can then be isolated from the solid support in substantially pure form in accordance with standard immunological techniques. See generally, Ausubel et al., Current Protocols in Molecular Biology, John Wiley &amp; Sons, New York, (1989); Harlow and Lane in Antibodies: A Laboratory Manual, CSH Publications, NY (1988).</div>
    <div num="p-0090" class="description-paragraph style-scope patent-text">As also discussed above, antibodies of the invention can be employed to detect native human FVIII in a biological sample. Exemplary biological samples include blood plasma, serum, saliva, urine, stool, vaginal secretions, bile, lymph, ocular humors, and cerebrospinal fluid. Samples may be suitably obtained from a mammal suffering from or suspected of suffering from a bleeding disorder</div>
    <div num="p-0091" class="description-paragraph style-scope patent-text">For such assays, as discussed above, an antibody of the invention can be detectably-labeled with a suitable atom or molecule e.g., radioactive iodine, tritium, biotin, or reagent capable of generating a detectable product such as an anti-iodiotypic antibody attached to an enzyme such as -galactosidase or horseradish peroxidase, or a fluorescent tag (e.g., fluorescein or rhodamine) in accordance with known methods. After contacting the biological sample with the detectably-labeled antibody, any unreacted antibody can be separated from the biological sample, the label (or product) is detected by conventional immunological methods including antibody capture assay, antibody sandwich assay, RIA, ELISA, immunoprecipitation, immunoabsorption, immunoblotting and the like. Any label (or product) in excess of that detected in a suitable control sample is indicative of the presence of native FVIII in the biological sample. For example, antibodies of the invention can be detectably-labeled to detect, and preferably quantitate, native FVIII in accordance with immunological techniques as discussed above such as antibody capture assay, ELISA, antibody sandwich assay, RIA, immunoprecipitation, immunoabsorption, bead-based fluorescent assay and the like). See generally, Harlow and Lane and Ausubel et al., supra).</div>
    <heading class="style-scope patent-text">EXAMPLES</heading>
    <div num="p-0092" class="description-paragraph style-scope patent-text">The invention is further illustrated by reference to the following non-limiting examples.</div>
    <heading class="style-scope patent-text">Example 1</heading>
    <heading class="style-scope patent-text">Materials and Methods</heading>
    <div num="p-0093" class="description-paragraph style-scope patent-text">The following materials and methods were used as needed to conduct studies outlined in Examples 1-10. Additional methodological details are included in Examples 11 and 12.</div>
    <div num="p-0094" class="description-paragraph style-scope patent-text">1. Proteins</div>
    <div num="p-0095" class="description-paragraph style-scope patent-text">Albumin-free rFVIII was used as our gold standard in all immunoassays and activity assays), Recombinate (albumin-stabilized rFVIII), Hemofile-M (plasma-derived, immunoaffinity purified vWF-containing FVIII), Immunate (plasma-derived FVIII containing excess molar concentration of vWF), Refacto (B-domain-deleted FVIII) and Kogenate (sucrose-stabilized rFVIII, Bayer Corporation, Elkhart, Ind.) were obtained from Baxter Healthcare Corporation, Westlake Village, Calif.). VWF (purified, MW of 250,000) was a generous gift from Dr. Rick Jenny, Haematologic Technologies Inc., Essex Junction, Vt.).</div>
    <div num="p-0096" class="description-paragraph style-scope patent-text">2. Production of FVIII- and vWF-Specific Monoclonal Antibodies (mAbs)</div>
    <div num="p-0097" class="description-paragraph style-scope patent-text">Balb/C mice were used for immunization with plasma purified FVIII and vWF. Immunization protocols and mAb production methods were similar to those reported previously (Foster et al., 1982; Foster et al., Blood). FVIII light-chain specific mAb clone 68 (designated as F68) was a generous gift from Dr. David Fass (Mayo Clinic, Rochester, Min.).</div>
    <div num="p-0098" class="description-paragraph style-scope patent-text">3. Immunoassays</div>
    <div num="p-0099" class="description-paragraph style-scope patent-text">3a. Direct binding ELISA was used to determine the binding specificity of mAbs for FVIII. In such assays, wells of polyvinyl chloride (PVC) microtiter plate (Falcon, Becton Dikinson Labware, Franklin Lakes, N.J.) were coated over night with 50 l of a solution of 5 g/ml PBS (phosphate buffered saline (0.15 M NaCl, 0.1 M sodium phosphate, pH 7.2) of full-length rFVIII. Excess FVIII was removed by washing the wells with 1% bovine serum albumin fraction V (BSA, Sigma, St. Louis, Mo.) in PBS. Fifty l of various dilutions of culture supernatants or increasing concentrations of purified mAbs were added to the pre-coated wells and incubated for 1 hr at room temperature using an orbital shaker. Following 3 washes to remove excess Ab, binding of mAb was detected using horse radish peroxidase (HRP) labeled goat anti-mouse Ig (Sigma) and a chromogenic substrate (KPL, Gaithersburg, Md.). The end point of reaction was determined after addition of 25 l of 2 M phosphoric acid in a plate reader (Bio-Tek Instruments, Inc., Winooski, Vt.) at 450 nm.</div>
    <div num="p-0100" class="description-paragraph style-scope patent-text">3b. Competition ELISA was used to determine the relative apparent affinity of each mAb for FVIII. Wells of PVC microtiter plate were coated with 50 l of 5 g/ml PBS of rFVIII. First we determined mAb-containing culture supernatant dilution or mAb concentration that was not in excess of the immobilized antigen. Using the direct binding assay described above, the culture supernatant dilution or mAb concentration at which 50% binding was achieved was ascertained. Inhibition of binding of mAbs to FVIII was determined by adding 25 l of mAb-containing culture supernatant or purified mAb (at 50% binding) and 25 l of free rFVIII (0.6-400 nM, 2-fold dilutions). The percent inhibition is the ratio of (OD<sub class="style-scope patent-text">450 </sub>in the presence of BSA-OD<sup class="style-scope patent-text">450 </sup>in the presence of FVIII)/(OD<sub class="style-scope patent-text">450 </sub>in the presence of BSA)100. The relative affinity (IC<sub class="style-scope patent-text">50</sub>) is the FVIII concentration (nM) that inhibits 50% of the binding of mAb to immobilized FVIII.</div>
    <div num="p-0101" class="description-paragraph style-scope patent-text">3c. Double sandwich mAb immunoassay was utilized for quantification of various FVIII products, FVIII-vWF preparations and determination of FVIII specific activity. In such assays, one FVIII-specific monoclonal (Fab)<sub class="style-scope patent-text">2 </sub>fragment was immobilized in the wells of microtiter plate. Various dilutions or concentrations (10-0.04 nM, 3-fold dilutions) of FVIII or FVIII-vWF complex were added to the pre-coated wells. FVIII binding was probed with a different FVIII-specific mAb or anti-vWF mAb. Binding of this second mAb was detected using HRP-anti-mouse FC (Sigma) and a chromogenic substrate as described above. Unless it is specified all FVIII immunoassays were carried out in the presence PBS.</div>
    <div num="p-0102" class="description-paragraph style-scope patent-text">3d. A double Ab sandwich assay was utilized to determine concentration of vWF in FVIII concentrates. In such assay purified vWF or FVIII concentrates containing vWF were immobilized in the wells of microtiter plate pre-coated with anti-vWF mAb. Protein binding was probed using goat anti-human vWF (also a gift from Dr. Rick Jenny) and HRP-rabbit anti-goat Ig (Southern Biotechnology Associates, Inc., Birmingham, Ala.).</div>
    <div num="p-0103" class="description-paragraph style-scope patent-text">4. FVIII Activation Using Thrombin</div>
    <div num="p-0104" class="description-paragraph style-scope patent-text">Activated FVIII (FVIIIa) was used in experiments involving epitope mapping and for dissociation of FVIII-vWF complex. Forty g rFVIII (6.5 l of 0.62 mg/ml FVIII) was added to 12.2 l of HBS buffer (HEPES buffered saline, 0.15 M NaCl, 0.02 M HEPES, pH 7.4) containing 0.1% polyethylene glycol (PEG, MW 8000, Sigma) and 2 mM CaCl<sub class="style-scope patent-text">2</sub>. Alpha thrombin (generous gift from Hematologic Technologies Inc.) at final concentration of 20 nM (2.8 NIH units) was added and was incubated for 5 minutes at room temperature. The reaction was terminated by addition to final concentration of 20 mM EDTA and 10 M PPACK (Phe-Pro-Arg-chloromethyl Ketone, Sigma). Activation of FVIII was confirmed by coagulation assay using Automated APTT (activated partial thromboplastin time) according to the manufacturer's protocol (bioMrieux, Inc., Durham, N.C.) and by immunoblotting as described below.</div>
    <div num="p-0105" class="description-paragraph style-scope patent-text">5. Preparation of FVIII-vWF Complex</div>
    <div num="p-0106" class="description-paragraph style-scope patent-text">Twenty nM FVIII was mixed with 40 nM vWF in HBS buffer containing 2 mM Cl<sub class="style-scope patent-text">2</sub>Ca. The mixture was incubated for 5 minutes at 37 C. in a water bath. Various concentrations (0.082-20 nM) were used for immunoassays.</div>
    <div num="p-0107" class="description-paragraph style-scope patent-text">6. Immunoblotting</div>
    <div num="p-0108" class="description-paragraph style-scope patent-text">Immunoblotting was utilized as a complementary approach to assess the blotting capabilities and epitope specificity of each mAb shown in Table I. Immunoblotting was also used determine FVIII concentration in commercial preparations, and to confirm FVIII activation. Various concentrations of FVIII were electrophoresed on a gradient SDS-PAGE (5-15%) and subsequently transferred onto nitrocellulose membranes. Membranes were first blocked in 10% non-fat dry milk in PBS-0.05<figure-callout id="20" label="% Tween" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 20 and then reacted with FVIII heavy chain (H), light chain (L) and B-domain specific mAbs. Binding was probed with HRP-sheep anti-mouse Ig (Amersham Life Science, Arlington Heights, Ill.). Proteins were detected with enhanced chemiluminescence (ELC) Western blotting detection reagents (Amersham Life Sciences, Piscataway, N.J.).</div>
    <heading class="style-scope patent-text">Example 2</heading>
    <heading class="style-scope patent-text">Immunological Characterization of FVIII-Specific mAbs</heading>
    <div num="p-0109" class="description-paragraph style-scope patent-text">Monoclonal antibodies against Factor VIII were prepared as described in Methods. From eighteen stable clones produced, six clones (designated M1 and M20-M25) were selected for further characterization. Immunological characteristics of these clones are shown in Table I. Immunological properties of anti-FVIII mAb clone 68 (F68, see Methods) is also included in the Table I. A hybridoma cell line designated FVIII-68 producing mAb-68 was deposited on Jul. 28, 2005, under Accession Number PTA-6891, with the American Type Culture Collection (ATCC).</div>
    <div num="p-0110" class="description-paragraph style-scope patent-text">As shown in Table I, all FVIII clones exhibited apparent affinities in the range of 49-160 nM. Two clones (M1 and F68) could be used in immunoblotting for structural analysis of full-length FVIII and FVIII fragments, and for epitope mapping. Clone F68 binds to protein A; thus binding of this mAb to FVIII could be probed by both HRP-anti-mouse Ig and HRP-protein A.</div>
    <div num="p-0111" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00001" num="00001" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE I</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Immunological characteristics of FVIII-specific clones</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Relative</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Affinity,</td>
                <td class="description-td style-scope patent-text">Protein A</td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Binding</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Clone</td>
                <td class="description-td style-scope patent-text">IC50(nM)<sup class="style-scope patent-text">a</sup> </td>
                <td class="description-td style-scope patent-text">binding<sup class="style-scope patent-text">b</sup> </td>
                <td class="description-td style-scope patent-text">Immunoblot<sup class="style-scope patent-text">c</sup> </td>
                <td class="description-td style-scope patent-text">Isotype<sup class="style-scope patent-text">d</sup> </td>
                <td class="description-td style-scope patent-text">region<sup class="style-scope patent-text">e</sup> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <figure-callout id="50" label="light chain M21" filenames="US08715951-20140506-D00004.png,US08715951-20140506-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
              </a></figure-callout><figure-callout id="50" label="light chain M21" filenames="US08715951-20140506-D00004.png,US08715951-20140506-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
              </a></figure-callout><figure-callout id="100" label="light chain M23" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
              </a></figure-callout><figure-callout id="100" label="light chain M23" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
              </a></figure-callout><figure-callout id="103" label="light chain M24" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00010.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
              </a></figure-callout><figure-callout id="103" label="light chain M24" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00010.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
              </a></figure-callout><figure-callout id="60" label="light chain F68" filenames="US08715951-20140506-D00004.png,US08715951-20140506-D00024.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
              </a></figure-callout><figure-callout id="60" label="light chain F68" filenames="US08715951-20140506-D00004.png,US08715951-20140506-D00024.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
              </a></figure-callout><table align="left" colsep="0" rowsep="0" cols="6" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M1</td>
                <td class="description-td style-scope patent-text">160</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">IgG1, </td>
                <td class="description-td style-scope patent-text">B-domain</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M20</td>
                <td class="description-td style-scope patent-text">90</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">IgG1, </td>
                <td class="description-td style-scope patent-text">Heavy or</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="50" label="light chain M21" filenames="US08715951-20140506-D00004.png,US08715951-20140506-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">light chain</a></figure-callout> </td>  </tr> <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M21</td> </tr>  <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">IgG1, </td>
                <td class="description-td style-scope patent-text">Heavy or</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="100" label="light chain M23" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">light chain</a></figure-callout> </td>  </tr> <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M23</td> </tr>  <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">100</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">IgG1, </td>
                <td class="description-td style-scope patent-text">Heavy or</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="103" label="light chain M24" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00010.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">light chain</a></figure-callout> </td>  </tr> <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M24</td> </tr>  <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">103</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">IgG1, </td>
                <td class="description-td style-scope patent-text">Heavy or</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">light chain</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">M25</td>
                <td class="description-td style-scope patent-text">49</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">IgG1, </td>
                <td class="description-td style-scope patent-text">Heavy or</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="60" label="light chain F68" filenames="US08715951-20140506-D00004.png,US08715951-20140506-D00024.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">light chain</a></figure-callout> </td>  </tr> <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">F68</td> </tr>  <tr class="description-tr style-scope patent-text"> <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">60</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">IgG<sub class="style-scope patent-text">2</sub>b, </td>
                <td class="description-td style-scope patent-text">Light chain</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="6"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="left" id="FOO-00001" class="description-td style-scope patent-text" colspan="6"> <sup class="style-scope patent-text">a</sup>Relative affinity was determined using competition solid-phase ELISA. Binding of murine anti-FVIII mAbs (mAb concentration which was not in excess of immobilized antigen i.e., equivalent to 30-50% binding to rFVIII) to immobilized rFVIII was determined in the absence or presence of various concentrations (1-200 nM) of free soluble rFVIII. Binding was determined using HRP-anti-mouse Ig. IC<sub class="style-scope patent-text">50 </sub>is FVIII concentration that inhibits 50% of the binding of mAb to immobilized FVIII.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="left" id="FOO-00002" class="description-td style-scope patent-text" colspan="6"> <sup class="style-scope patent-text">b</sup>Protein A (PA) binding was determined using solid-phase ELISA. Wells of the microtiter plate were coated with FVIII. Binding of mAbs to immobilized FVIII was determined using HRP-PA.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="left" id="FOO-00003" class="description-td style-scope patent-text" colspan="6"> <sup class="style-scope patent-text">c</sup>FVIII was subjected to SDS-gel electrophoresis under non-reducing conditions and transferred onto nitrocellulose paper. Binding of mAbs to FVIII was probed using HRP-anti-mouse Ig and chemiluminescence detection reagents.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="left" id="FOO-00004" class="description-td style-scope patent-text" colspan="6"> <sup class="style-scope patent-text">d</sup>Isotype of each mAb was determined using solid-phase ELISA in which binding of mAbs to immobilized FVIII was determined using rabbit-anti-mouse isotype specific Abs and HRP-anti-rabbit Ig.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <heading class="style-scope patent-text">Example 3</heading>
    <heading class="style-scope patent-text">Double Sandwich Immunoassays Comprising FVIII-Specific mAbs</heading>
    <div num="p-0112" class="description-paragraph style-scope patent-text">In an exemplary double sandwich mAb assay, F(ab)<sub class="style-scope patent-text">2 </sub>fragment from <figure-callout id="24" label="clone" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">clone</a></figure-callout> 24 was immobilized in the wells of microtiter plates. Binding of FVIII to mAb 24 was detected using different anti-FVIII-specific mAbs as shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 1A and 1B</figref>. More particularly, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 1A and 1B</figref> show immunoassays in which recombinant Factor VIII (rFVIII) was captured using anti-FVIII-24 mAb(Fab)2 fragment. Binding of rFVIII was detected with one of the anti-Factor VIII mAbs as indicated, i.e., anti-FVIII-1, -20 and -21 mAbs (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1A</figref>) or anti-Factor VIII-23, 25, or -68 mAbs (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1B</figref>).</div>
    <div num="p-0113" class="description-paragraph style-scope patent-text">Binding specificity of anti-FVIII mAbs was confirmed using porcine FVIII as compared with human FVIII. A representative curve is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1C</figref> in which binding of FVIII to immobilized anti-FVIII-24 (Fab)<sub class="style-scope patent-text">2 </sub>was probed with anti-FVIII-20 mAb. Human or porcine FVIII bound to anti-FVIII-24 mAb (Fab)<sub class="style-scope patent-text">2 </sub>fragment was probed with anti-FVIII-20 mAb and HRP-anti-mouse FC fragment. The results show that the immunoassay detects human, but not porcine, FVIII.</div>
    <heading class="style-scope patent-text">Example 4</heading>
    <heading class="style-scope patent-text">Epitope Mapping of Anti-FVIII mAbs</heading>
    <div num="p-0114" class="description-paragraph style-scope patent-text">Using immunoassays and various forms of FVIII, epitope mapping was performed to localize the binding specificity of anti-FVIII mAbs. Table II summarizes the binding specificity of mAbs for full-length FVIII, FVIIIa, B-domain less FVIII and FVIII-vWF complex. Details of the epitope mapping for individual monoclonal antibodies are described infra.</div>
    <div num="p-0115" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00002" num="00002" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE II</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Epitope specificity of anti-FVIII mAbs<sup class="style-scope patent-text">a</sup> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">ReFacto</td>
                <td class="description-td style-scope patent-text">FVIII-</td>
                <td class="description-td style-scope patent-text">Binding</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Clone<sup class="style-scope patent-text">b</sup> </td>
                <td class="description-td style-scope patent-text">rFVIII</td>
                <td class="description-td style-scope patent-text">rFVIIIa</td>
                <td class="description-td style-scope patent-text">(B-domain less)</td>
                <td class="description-td style-scope patent-text">vWF<sup class="style-scope patent-text">c</sup> </td>
                <td class="description-td style-scope patent-text">region<sup class="style-scope patent-text">d</sup> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="6"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">1</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">B-<figure-callout id="24" label="domain" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">domain</a></figure-callout> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">24</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">H/L-<figure-callout id="23" label="chain" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">chain</a></figure-callout> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">23</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">H/L-<figure-callout id="20" label="chain" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">chain</a></figure-callout> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">20, 21, 25</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">H/L-<figure-callout id="68" label="chain" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">chain</a></figure-callout> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">68</td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">+</td>
                <td class="description-td style-scope patent-text"></td>
                <td class="description-td style-scope patent-text">L-chain</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="6"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="left" id="FOO-00005" class="description-td style-scope patent-text" colspan="6"> <sup class="style-scope patent-text">a</sup>Binding specificity of anti-FVIII mAbs was determined using double mAb sandwich assay as described in FIG. 1. In all assays, <figure-callout id="24" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 24 was used for capture of FVIII products.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="left" id="FOO-00006" class="description-td style-scope patent-text" colspan="6"> <sup class="style-scope patent-text">b</sup>Immunological characteristics of FVIII-specific mAbs are described in Table I.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="left" id="FOO-00007" class="description-td style-scope patent-text" colspan="6"> <sup class="style-scope patent-text">c</sup>FVIII-vWF complex was prepared by mixing 20 nM FVIII with 40 nM vWF as described in Methods.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="6" align="left" id="FOO-00008" class="description-td style-scope patent-text" colspan="6"> <sup class="style-scope patent-text">d</sup>Binding region was deduced from the results of immunoassay and immunoblotting. H/L designates heavy or light chain.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div num="p-0116" class="description-paragraph style-scope patent-text">Anti-FVIII-1 mAb. Following capture of the FVIII proteins by <figure-callout id="24" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 24, anti-FVIII-1 mAb bound to full-length FVIII but it did not react with FVIIIa or ReFacto. This result indicates that the binding region of <figure-callout id="1" label="mAb" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 1 is located in the B-domain. As shown in Table II, <figure-callout id="1" label="Clone" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Clone</a></figure-callout> 1 epitope is sterically hindered when FVIII is in complex with vWF.</div>
    <div num="p-0117" class="description-paragraph style-scope patent-text">The epitope specificity of anti-FVIII-1 mAb was confirmed by immunoblotting (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2</figref>). More specifically, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2</figref> shows immunoblots of reactivity using anti-FVIII-1 (<b class="style-scope patent-text">2</b>A) and anti-FVIII-68 (B) as probes. Proteins (0.2 g in 50 l) were subjected to electrophoresis (7.5% SDS-PAGE, under non-reducing conditions) and immunoblotting. Binding of FVIII-specific mAbs was visualized with sheep anti-mouse Ig and ELC western blotting detection reagents. As seen in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2A</figref>, <figure-callout id="1" label="mAb" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 1 does not bind to ReFacto whereas it reacts with full-length rFVIII. In contrast, ReFacto could be detected using a different mAb, i.e., anti-FVIII-68 (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2B</figref>). <figure-callout id="68" label="Monoclonal Ab" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Monoclonal Ab</a></figure-callout> 68 bound to an approximately 80 kDa fragment consistent with binding specificity for FVIII light chain. This mAb bound both the full-length FVIII and ReFacto (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 2B</figref>). Though anti-FVIII-68 bound ReFacto, it did not exhibit significant binding to activated FVIII and it did not bind to FVIII in complex with vWF (Table II). This indicates that the binding region of <figure-callout id="68" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 68 is sterically hindered when FVIII is in complex with vWF.</div>
    <div num="p-0118" class="description-paragraph style-scope patent-text">Anti-FVIII-23 mAb. The epitope recognized by the <figure-callout id="23" label="clone" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">clone</a></figure-callout> 23 antibody was mapped to FVIII heavy (H/L)-chain. Nevertheless, its epitope was not found to overlap with that of <figure-callout id="24" label="clone" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">clone</a></figure-callout> 24, as evidenced by the fact that binding of FVIII to mAb 24 could be probed with anti-FVIII-23, as shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 1B</figref>.</div>
    <div num="p-0119" class="description-paragraph style-scope patent-text">Interestingly, <figure-callout id="23" label="mAb" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 23 exhibited preferential binding to activated-FVIII, as illustrated in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3</figref>. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3</figref> shows the binding specificity of mAb-23 compared with mAb-68. More specifically, a sandwich immunoassay was performed in which FVIII or FVIIIa was immobilized on anti-FVIII-24 (Fab)<sub class="style-scope patent-text">2 </sub>fragment. FVIII binding was probed using anti-FVIII-23 mAb (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3A</figref>) or anti-FVIII-68 mAb (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3B</figref>) and HRP-anti-mouse FC. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3A</figref> shows that once captured by anti-FVIII-24 (Fab)<sub class="style-scope patent-text">2</sub>, <figure-callout id="23" label="mAb" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 23 binds to FVIIIa significantly better than to FVIII. By contrast, <figure-callout id="68" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 68 binds preferentially to rFVIII (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3B</figref>).</div>
    <div num="p-0120" class="description-paragraph style-scope patent-text">Anti-FVIII-24 mAb. The binding specificity of <figure-callout id="24" label="clone" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">clone</a></figure-callout> 24 was mapped to the FVIII H/L chain. The epitope for this mAb is exposed when FVIII is in complex with vWF. This was demonstrated using an immunoassay in which binding of complexed FVIII-vWF to immobilized anti-FVIII-24 (Fab)<sub class="style-scope patent-text">2 </sub>fragment was probed using vWF-specific mAb and HRP-anti-FC (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4</figref>). More particularly, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4</figref> shows the results of an immunoassay in which FVIII-vWF complex was immobilized on anti-FVIII-24 mAb (Fab)<sub class="style-scope patent-text">2 </sub>fragment and binding was probed with anti-vWF mAb and HRP-anti-mouse FC.</div>
    <div num="p-0121" class="description-paragraph style-scope patent-text">Anti-FVIII-20, -21, and -25 mAbs. As shown in Table II, binding of each of these mAbs to FVIII and FVIIIa protein was indistinguishable. Representative graphs for mAb-25 are shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 5A and 5B</figref>. More specifically, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5</figref> shows results of immunoassays in which rFVIII and rFVIIIa or ReFacto were immobilized on full-length anti-FVIII-25 mAb. Binding was probed with L-chain specific anti-FVIII-68 and HRP-protein A (only <figure-callout id="68" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 68 binds to protein A, see Table I). Binding in the presence of CaCl<sub class="style-scope patent-text">2 </sub>containing HBS is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5A</figref>. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5B</figref> illustrates binding in the presence of PBS.</div>
    <div num="p-0122" class="description-paragraph style-scope patent-text">The binding region of mAbs-20, 21 and 25 is sterically and spatially different from that of <figure-callout id="23" label="mAbs" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="24" label="mAbs" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAbs</a></figure-callout> </a></figure-callout> 23 and 24. Unlike <figure-callout id="23" label="mAb" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 23, these mAbs do not distinguish between FVIII and FVIIIa. Unlike <figure-callout id="24" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 24, the epitope for these mAbs is sterically hindered when FVIII is in complex with vWF.</div>
    <div num="p-0123" class="description-paragraph style-scope patent-text">The binding region of these mAbs was tentatively mapped to FVIII H/L-chain due to the fact that both FVIII and ReFacto can be captured by these mAbs and detected using a light chain-specific mAb (i.e., anti-FVIII-68). A representative experiment is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 5B</figref> in which binding of immobilized rFVIII or ReFacto on anti-FVIII-25 can be detected using <figure-callout id="68" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 68 and HRP-protein A.</div>
    <heading class="style-scope patent-text">Example 5</heading>
    <heading class="style-scope patent-text">Use of Anti-FVIII mAbs in Immunoassays to Determine Concentration of FVIII in Commercial Products Comprising FVIII</heading>
    <div num="p-0124" class="description-paragraph style-scope patent-text">Using immunoassays as described above, several approaches were utilized to determine FVIII concentration as follows:</div>
    <div num="p-0125" class="description-paragraph style-scope patent-text">a. Concentration of free FVIII (for example, as found in Recombinate, ReFacto, or Kogenate) was determined using a double mAb sandwich assay in which FVIII was captured by anti-FVIII-24 (Fab)<sub class="style-scope patent-text">2 </sub>fragment and its binding was probed using a light-chain specific mAb (as shown, for example, in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 4B</figref>).</div>
    <div num="p-0126" class="description-paragraph style-scope patent-text">b. Concentration of FVIII in products that contained vWF (for example, Hemofile M and Immunate) was determined by first using thrombin to activate FVIII (i.e., to release FVIII from vWF) and then using a double mAb sandwich immunoassay in which binding of immobilized FVIII on anti-FVIII-24 (Fab)<sub class="style-scope patent-text">2 </sub>was probed using <figure-callout id="23" label="mAb" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 23 which binds preferentially to the activated form of FVIII (as illustrated above, for example, in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3A</figref>).</div>
    <div num="p-0127" class="description-paragraph style-scope patent-text">Immunoassay data for commercial products containing FVIII are summarized in Table III infra. A representative titration curve for one batch each of Hemofil M and Immunate is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref>. More specifically, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref> shows results of immunoassays used to determine the concentration of FVIII in products which contain FVIII complexed with vWF. In the example shown, Immunate or Hemofile M were treated with thrombin as described in Materials and Methods. FVIII proteins were immobilized on anti-FVIII-24 (Fab)<sub class="style-scope patent-text">2 </sub>fragment and binding was detected using anti-FVIII-23 mAb and HRP-anti-mouse FC as probes.</div>
    <div num="p-0128" class="description-paragraph style-scope patent-text">Titration curves similar to that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref> were generated for each batch of FVIII concentrate shown in Table III. The concentration of FVIII was determined using a standard curve generated for rFVIII, similar to that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3</figref>.</div>
    <div num="p-0129" class="description-paragraph style-scope patent-text">
      <tables id="TABLE-US-00003" num="00003" class="style-scope patent-text">
        <patent-tables frame="none" colsep="0" rowsep="0" class="style-scope patent-text">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table style-scope patent-text" width="100%">
            <thead class="style-scope patent-text">
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" rowsep="1" class="description-td style-scope patent-text" colspan="1">TABLE III</td>
              </tr>
            </thead>
            
              <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="1"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Determination of Specific Activity of FVIII Commercial Products<sup class="style-scope patent-text">a</sup> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">Units/</td>
                <td class="description-td style-scope patent-text">Concentration</td>
                <td class="description-td style-scope patent-text">Specific activity</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Product</td>
                <td class="description-td style-scope patent-text">ID</td>
                <td class="description-td style-scope patent-text">ml</td>
                <td class="description-td style-scope patent-text">(nM)</td>
                <td class="description-td style-scope patent-text">(units/g)<sup class="style-scope patent-text">b</sup> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <figure-callout id="200" label="Recombinate TM RAC" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
                </a></figure-callout><figure-callout id="200" label="ReFacto TM RF9" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
                </a></figure-callout><figure-callout id="100" label="Kogenate TM K9P" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
                </a></figure-callout><figure-callout id="200" label="M TM H54EA" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
                </a></figure-callout><figure-callout id="100" label="Immunate TM IM1I" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">
                </a></figure-callout><table align="left" colsep="0" rowsep="0" cols="5" class="description-table style-scope patent-text" width="100%">
            <tbody class="style-scope patent-text"><tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> <figure-callout id="200" label="Recombinate TM RAC" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Recombinate</a></figure-callout> </td> <td class="description-td style-scope patent-text">RAC</td>  <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">120</td>
                <td class="description-td style-scope patent-text">5.8</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="200" label="RAB" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">RAB</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">126</td>
                <td class="description-td style-scope patent-text">5.6</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="200" label="RAA" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">RAA</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">132</td>
                <td class="description-td style-scope patent-text">5.3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> <figure-callout id="200" label="ReFacto TM RF9" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">ReFacto</a></figure-callout> </td> <td class="description-td style-scope patent-text">RF9</td>  <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">39</td>
                <td class="description-td style-scope patent-text">30.1</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="200" label="RF1" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">RF1</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">23.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="200" label="RF4" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">RF4</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">50</td>
                <td class="description-td style-scope patent-text">23.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> <figure-callout id="100" label="Kogenate TM K9P" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Kogenate</a></figure-callout> </td> <td class="description-td style-scope patent-text">K9P</td>  <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">100</td>
                <td class="description-td style-scope patent-text">77</td>
                <td class="description-td style-scope patent-text">4.5</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">K7G</td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">176</td>
                <td class="description-td style-scope patent-text">4.0</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">KF1</td>
                <td class="description-td style-scope patent-text">400</td>
                <td class="description-td style-scope patent-text">218</td>
                <td class="description-td style-scope patent-text">6.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text">Hemofile <figure-callout id="200" label="M TM H54EA" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">M</a></figure-callout> </td> <td class="description-td style-scope patent-text">H54EA</td>  <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">135</td>
                <td class="description-td style-scope patent-text">5.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text"> <figure-callout id="200" label="H44EA" filenames="US08715951-20140506-D00015.png,US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">H44EA</a></figure-callout> </td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">131</td>
                <td class="description-td style-scope patent-text">5.3</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">H04EB</td>
                <td class="description-td style-scope patent-text">200</td>
                <td class="description-td style-scope patent-text">123</td>
                <td class="description-td style-scope patent-text">5.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> <figure-callout id="100" label="Immunate TM IM1I" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Immunate</a></figure-callout> </td> <td class="description-td style-scope patent-text">IM1I</td>  <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">100</td>
                <td class="description-td style-scope patent-text">129</td>
                <td class="description-td style-scope patent-text">2.7</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">IM2K</td>
                <td class="description-td style-scope patent-text">100</td>
                <td class="description-td style-scope patent-text">143</td>
                <td class="description-td style-scope patent-text">2.4</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td class="description-td style-scope patent-text"> </td>
                <td class="description-td style-scope patent-text">IM1K</td>
                <td class="description-td style-scope patent-text">100</td>
                <td class="description-td style-scope patent-text">160</td>
                <td class="description-td style-scope patent-text">2.2</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td style-scope patent-text" colspan="5"> </td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="left" id="FOO-00009" class="description-td style-scope patent-text" colspan="5"> <sup class="style-scope patent-text">a</sup>FVIII specific activity was determined using two different double mAb sandwich assay. For Recombinate, ReFacto and Kogenate, FVIII bound to <figure-callout id="24" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 24 was probed with an L-chain specific mAb as described. For Hemofile M and Immunate, activated proteins bound to <figure-callout id="24" label="mAb" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAb</a></figure-callout> 24 were probed with anti-FVIII-23 mAb as described. In general, each vial of FVIII was reconstituted with sterile water based on activity (units) reported on the vial to contain 100-400 units/ml.</td>
              </tr>
              <tr class="description-tr style-scope patent-text">
                <td namest="1" nameend="5" align="left" id="FOO-00010" class="description-td style-scope patent-text" colspan="5"> <sup class="style-scope patent-text">b</sup>For determination of specific activity a molecular weight of 170,000 was assumed for ReFacto and 285,000 for all other products specified above.</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    <div num="p-0130" class="description-paragraph style-scope patent-text">In summary, as shown in Table II, the epitope specificity of various mAbs of the invention generally divided into three groups; i.e., H/L-chain specific (for example, <figure-callout id="20" label="mAbs" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="23" label="mAbs" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="24" label="mAbs" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mAbs</a></figure-callout> </a></figure-callout> </a></figure-callout> 20, 23, 24 and 25), L-chain specific (for example, mAb 68) and B-domain specific (for example, mAb 1). The H/L-chain specific mAbs differed in their fine specificity as evidenced by their different reaction with activated FVIII and FVIII-vWF complex (Table II).</div>
    <div num="p-0131" class="description-paragraph style-scope patent-text">As shown above, these differences among the antibodies enabled double sandwich mAb assays to be designed in which FVIII can be quantitated even when complexed with vWF (see, for example, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3A</figref> and <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 6</figref>). Availability of a large panel of FVIII mAbs is also useful for quantifying FVIII fragments such as the B-domain-deleted FVIII, ReFacto. By using a combination of heavy/light- and light-chain specific mAbs, the concentration of ReFacto was determined to be in the range of 50-77 nM in three different preparations (See, for example, Table III).</div>
    <div num="p-0132" class="description-paragraph style-scope patent-text">For FVIII products that contained vWF, a different assay was designed. Two H-chain-specific mAbs were used, one of which preferentially binds to activated FVIII. Thus when FVIII products are activated with thrombin to dissociate FVIII from vWF, activated FVIII can be probed with mAb 23 (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 3A</figref>). Using the above-described assay, the concentration of FVIII in Hemofile M and Immunonate can be assessed (Table III).</div>
    <div num="p-0133" class="description-paragraph style-scope patent-text">From the foregoing, it can be appreciated that the antibodies and immunoassays of the invention can enable precise determination of the concentration of FVIII in various forms of FVIII products, and calculation of the specific activity of these products.</div>
    <heading class="style-scope patent-text">Example 6</heading>
    <heading class="style-scope patent-text">Use of Immunoassays to Determine Concentration of Von Willebrand Factor (vWF) in Commercial Products Comprising FVIII</heading>
    <div num="p-0134" class="description-paragraph style-scope patent-text">The concentration of vWF in Hemofile M and Immunate was determined using a double sandwich assay combining mAb and polyclonal antibody in which vWF was immobilized on anti-vWF mAb. Binding to the mAb was probed using goat anti-vWF polyclonal Ab and HRP-anti-goat Ig. Representative data is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7</figref>. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7A</figref> shows a standard curve for purified vWF. More particularly, the standard curve was generated by immobilizing the indicated concentrations of purified vWF on an anti-vWF mAb. Detection of binding was achieved using a polyclonal goat anti-vWF antibody and HRP-anti-goat Ig.</div>
    <div num="p-0135" class="description-paragraph style-scope patent-text">For determination of the concentration of vWF in commercial products containing FVIII, the FVIII concentrates were diluted 14-fold, with 3-fold dilutions thereafter. Binding was probed as described for the vWF standard curve (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7A</figref>). Representative results are shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7B</figref>.</div>
    <div num="p-0136" class="description-paragraph style-scope patent-text">Referring to <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 7B</figref>, the concentration of vWF in Hemofile M was found to be 207 g/ml, whereas the concentration of vWF in Immunate was 1665 g/ml. These data indicates that Immunate contains approximately 8-fold more vWF than Hemofile M. vWF Results of repeat experiments with three separate batches of these products showed that the concentration of vWF in Hemofile M was in the range of 153-207 g/ml, and in Immunate was in the range of 1665-1713 g/ml.</div>
    <heading class="style-scope patent-text">Example 7</heading>
    <heading class="style-scope patent-text">Combined Immunoassay and Biological Assay Method for Improved Quality Assessment in FVIII Products</heading>
    <div num="p-0137" class="description-paragraph style-scope patent-text">Precise determination of FVIII quality in commercial concentrates is critical in the management of hemophilia A. Currently, two assays are used for the evaluation of FVIII activity in concentrates, i.e., clotting assays (for example, the activated partial thromboplastin time (APTT) assay and chromogenic assays (Kleinveld et al., 1999; Mikaelsson et al., 2001; Barrowcliffe et al., 2002; Mikaelsson and Oswaldsson, 2002). There are significant discrepancies among these activity assays (Lundblad et al., 2000). The discrepant findings in activity assays could arise from the differences in the standards, source of reagents, variations in the protocols or the nature of the FVIII concentrate (Lusher et al., 1998; Mikaelsson et al., 1998; Mikaelsson et al., 2001; Barrowcliffe et al., 2002; Mikaelsson and Oswaldsson, 2002).</div>
    <div num="p-0138" class="description-paragraph style-scope patent-text">Importantly, activity assays describe a complex array of kinetic reactions that could be differ among various plasmas from healthy individuals made immunodeficient for FVIII. For example, it has been shown that the response in healthy individuals is significantly influenced by the overall composite of quantitative levels of other hemostatic factors that typically fall within the range of 50-150% (Butenas et al., 1999). Thus when the APTT assay is used to quantify FVIII products, different clotting values could be produced.</div>
    <div num="p-0139" class="description-paragraph style-scope patent-text">One approach to overcome assay discrepancies is the parallel use of more sensitive and reproducible FVIII activity assays combined with the use of analytical approaches for standardization of FVIII concentration in these assays. As discussed, the monoclonal Abs and immunoassays described herein can be used to precisely determine FVIII concentration in a variety of commercial products. Thus improved assays of FVIII product quality are described herein that utilize a combination of sensitive and reproducible immunoassays to precisely determine the physical mass with activity assays by which the FVIII activity in purified concentrates can be assessed. It is important to emphasize that FVIII activity alone, or FVIII concentration alone (for example, as measured by an immunoassay) are unlikely to be sufficient for accurate determination of FVIII quality in concentrates. For example, activity assays do not reflect the presence of degraded or aggregated FVIII that have lost function. Immunoassay alone is not sufficient because the biological activity of the measured FVIII protein is not determined by this method.</div>
    <div num="p-0140" class="description-paragraph style-scope patent-text">We have determined that the anti-FVIII monoclonal antibodies described herein are not inhibitory in a conventional APTT assay at concentrations as high as 56 nM, as evidenced by the finding that the change in clotting time was minimal in the presence of the anti-FVIII mAbs of the invention, as compared to control mAbs. Therefore the mAbs can be used to in assays to determine the specific activity of FVIII products (activity correlated with measured concentration of FVIII).</div>
    <heading class="style-scope patent-text">Example 8</heading>
    <heading class="style-scope patent-text">Highly Sensitive Fluorescence-Based Immunoassay Suitable for Detection of FVIII in Human Plasma</heading>
    <div num="p-0141" class="description-paragraph style-scope patent-text">This example describes a highly sensitive fluorescence-based immunoassay system that integrates FVIII ELISA with multi-analyte platform technology. The method is useful, for example, to determine FVIII concentration in fluids such as human plasma, and is sufficiently sensitive to detect FVIII in the serum of patients with blood clotting disorders such as hemophilia.</div>
    <div num="p-0142" class="description-paragraph style-scope patent-text">1. Design of Fluorescence-Based Immunoassay (FLI)</div>
    <div num="p-0143" class="description-paragraph style-scope patent-text">The design of an exemplary fluorescence-based FVIII assay of the invention is shown schematically in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref>. Referring to <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref>, a first anti-FVIII mAb is coupled to microsphere beads having a first selected spectral address, for example, fluorescent bead classification #038). Following binding of rFVIII or plasma FVIII to the mAb-bound microspheres, bound FVIII protein is detected using a second anti-FVIII mAb comprising a detectable label, for example biotin. Detection of the biotinylated antibody is achieved for example using fluorescent streptavidin, such as R-Phycoerythrin(PE)-streptavidin). In the example shown, exemplary first and second anti-FVIII mAbs are shown having the respective characteristics: IgG<sub class="style-scope patent-text">2</sub>b, , L-chain specific; and IgG<sub class="style-scope patent-text">1</sub>, , H-chain specific. Those of skill in the art will recognize however that the invention is not so limited and that any suitable combination of antibodies can be used.</div>
    <div num="p-0144" class="description-paragraph style-scope patent-text">Referring to the right-hand side of <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 8</figref>, specificity of the reaction is determined by use of control beads that are included in each assay. Control beads comprise an isotype-matched mAb (in this example, IgG<sub class="style-scope patent-text">2</sub>b, ) with specificity irrelevant to FVIII, coupled to microspheres having a different spectral address than the FVIII-binding beads (for example, fluorescent bead classification #026).</div>
    <div num="p-0145" class="description-paragraph style-scope patent-text">2. Coupling of Anti-FVIII Capture Antibody to Fluorescent Beads</div>
    <div num="p-0146" class="description-paragraph style-scope patent-text">Systems and general protocols for attaching antibodies to fluorescent beads (also termed microspheres) are available from commercial sources such as Luminex Austin, Tex.). To achieve the desired coupling and distribution of the capture antibody on the beads, we found that in order to achieve very high levels of FVIII detection sensitivity, significant experimentation and modification of a typical manufacturer's protocol was required when using a particular combination of a capture antibody and a bead with selected spectral properties.</div>
    <div num="p-0147" class="description-paragraph style-scope patent-text">The following is a general discussion of the various modifications that are necessary to achieve the highest levels of sensitivity, as illustrated in Examples below. Additionally, we provide as an illustration a detailed protocol for the preparation of beads used in a preferred embodiment of the invention, described infra.</div>
    <div num="p-0148" class="description-paragraph style-scope patent-text">Vortexing and sonicating. We have found that the use of vortexes and sonicators, for example as recommended by Luminex, are not appropriate in coupling antibodies to microspheres, due to the fact that significant numbers of beads break down and fall into pieces using these methods. This is determined experimentally by comparing the yields before and after the coupling procedures. Specifically, we obtain much greater yields of coupled beads at the end of the procedure if we did not use either a vortex or a sonicator. Furthermore, the assay sensitivity and detection also improves if the use of vortexing and sonicating is avoided.</div>
    <div num="p-0149" class="description-paragraph style-scope patent-text">Centrifugation time and speed. We determined that centrifugation parameters recommended by Luminex result in significant loss of beads. For best yields, we increase the centrifugation time to 3 min (2 min recommended by Luminex) and the speed to 11000-12000 rpm (Luminex recommends 10,000 rpm or 8000g).</div>
    <div num="p-0150" class="description-paragraph style-scope patent-text">Volumes and pH of activation and coupling buffers. Other changes resulting in increased yield and sensitivity include increasing activation and coupling buffer volumes by 20% over a recommended (Luminex) protocol. This modification results in improved bead activation and enhanced mAb binding to the beads. Another important parameter is the pH of the buffer in which the mAbs are coupled to the beads. A pH of 5.0 is recommended by Luminex. However, we found that a low pH such as 5.0 is not suitable for coupling of our anti-FVIII mAbs to beads. We determined that it is preferable to increase the pH of the coupling buffer to above 6.0.</div>
    <div num="p-0151" class="description-paragraph style-scope patent-text">Antibody concentration. One manufacturer's protocol (Luminex) suggests an antibody concentration of 25 g/ml or higher. In contrast, we have found that best results regarding sensitivity and FVIII detection levels using much lower concentrations of antibody (for example, 5 g/ml of anti-FVIII-68 mAb).</div>
    <div num="p-0152" class="description-paragraph style-scope patent-text">Simultaneous detection of specific and non-specific binding in the same sample. A very important aspect of the invention is a built-in control for non-specific binding that has not been described in any commercial protocol, to our knowledge. This is a particularly important step when biological samples such as plasma are used. Because plasma comprises many proteins besides FVIII and heterophilic antibodies that could bind non-specifically to beads or probes and increase the signal, it is extremely important to be able to distinguish between specific and non-specific signals in the assay, for example to screen out spurious, non-specific binding in a patients' plasma sample. This method ensures that the observed signal is specific for FVIII.</div>
    <div num="p-0153" class="description-paragraph style-scope patent-text">As discussed above, an isotype-matched capture mAb with specificity irrelevant to FVIII is coupled to beads that have a different spectral address from that of the anti-FVIII-mAb-coupled beads. For example, we couple anti-FVIII-68 mAb to <figure-callout id="038" label="beads" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">beads</a></figure-callout> 038, and control mAb to <figure-callout id="026" label="beads" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">beads</a></figure-callout> 026. In the practice of the assay, identical numbers of the anti-FVIII and control mAb-coupled beads (e.g., 5000 particles of each) are added to each well. After capturing plasma FVIII, secondary (probe) antibody labeled with a detectable label (e.g., biotinylated anti-FVIII-24 and fluorophore-streptavidine) are added. Fluorescence is then measured by a detector (such as a Luminex machine), which determines the signals from 038 (specific) and 026 (non-specific) beads.</div>
    <div num="p-0154" class="description-paragraph style-scope patent-text">A particularly preferred protocol for coupling of beads is provided below:</div>
    <div num="p-0155" class="description-paragraph style-scope patent-text">Buffers and Reagents:
</div> <ul class="style-scope patent-text"> <li id="ul0001-0001" num="0155" class="style-scope patent-text">Activation buffer: 0.1M NaH<sub class="style-scope patent-text">2</sub>PO<sub class="style-scope patent-text">4 </sub>pH 6.2, (Sodium Phosphate monobasic anhydrous) (Sigma S-3139), use 5N NaOH to adjust pH, filter sterilize and store at 4 C.</li> <li id="ul0001-0002" num="0156" class="style-scope patent-text">Coupling buffer: 0.1M MES pH 6.0, (2[N-Morpholino]ethanesulfonic acid) (Sigma M-2933), use 5N NaOH to adjust pH, filter sterilize and store at 4 C.</li> <li id="ul0001-0003" num="0157" class="style-scope patent-text">Wash buffer: 1PBS/0.05% Tween-20 pH 7.4, (1 Phosphate Buffered saline/0.05% Tween-20) filter sterilize and store at room temperature (Tween-20:_Sigma P-9416).</li> <li id="ul0001-0004" num="0158" class="style-scope patent-text">Blocking/Storage buffer: 1PBS/1% BSA/0.02% Tween-20/0.05% Azide pH 7.4, (1 Phosphate Buffered Saline/1% Bovine Serum Albumin/0.02% Tween/0.05% Sodium Azide) filter sterilize and store at 4 C. BSA: Sigma A-7888; Tween-20: Sigma P-9416; Sodium Azide: Sigma S-8032</li> <li id="ul0001-0005" num="0159" class="style-scope patent-text">Sulfo-NHS: N-hydroxysulfosuccinimide, store at 4 C. in dessicated container. (Pierce 24510)</li> <li id="ul0001-0006" num="0160" class="style-scope patent-text">EDC: 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride, store at 20 C. in dessicated container. (Sigma E-1769)</li> <li id="ul0001-0007" num="0161" class="style-scope patent-text">Microfuge tubes: 1.5 ml USA Scientific 1415-2500</li> </ul>

    <div num="p-0156" class="description-paragraph style-scope patent-text">Coupling Protocol:</div>
    <div num="p-0157" class="description-paragraph style-scope patent-text">Microspheres should be protected from prolonged exposure to light throughout this procedure. All reagents including buffers and microspheres must be warmed up to room temperature before coupling. No vortexing or sonicating procedures should be used in any of the steps below.</div>
    <div num="p-0158" class="description-paragraph style-scope patent-text">1. Mix stock beads at room temperature by rotating for minimum of 30 minutes before starting.</div>
    <div num="p-0159" class="description-paragraph style-scope patent-text">2. Resuspend the microspheres by pipetting for approximately 20 seconds. Pipette the mixture up and down a few times using a sterile disposable pipette.</div>
    <div num="p-0160" class="description-paragraph style-scope patent-text">3. Transfer 5.010<sup class="style-scope patent-text">6 </sup>(stock 1.2510<sup class="style-scope patent-text">7 </sup>beads in 1 ml) or 400 l to a macrophage tube.</div>
    <div num="p-0161" class="description-paragraph style-scope patent-text">4. If volume to be coupled is less than 400 l adjust the volumes of buffers, activation reagents and protein to be coupled. Do not couple more than 400 l in one microfuge tube.</div>
    <div num="p-0162" class="description-paragraph style-scope patent-text">5. Pellet the microspheres by microcentrifugation at 11,000 rpm for 3 minutes.</div>
    <div num="p-0163" class="description-paragraph style-scope patent-text">6. Remove the supernatant and resuspend the pelleted microspheres in 200 l of activation buffer (0.1M NaH2PO4 pH 6.2)mix well by pipetting using 50-200 l pipette.</div>
    <div num="p-0164" class="description-paragraph style-scope patent-text">7. <figure-callout id="5" label="Repeat step" filenames="US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Repeat step</a></figure-callout> 5, step 6 and again <figure-callout id="5" label="step" filenames="US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">step</a></figure-callout> 5.</div>
    <div num="p-0165" class="description-paragraph style-scope patent-text">8. Remove the supernatant and resuspend the pelleted microspheres in 2000 of activation buffer (0.1M NaH2PO4 pH 6.2)mix well by pipetting.</div>
    <div num="p-0166" class="description-paragraph style-scope patent-text">9. Weigh and prepare 50 mg/ml Sulfo-NHS in activation buffer and 50 mg/ml EDC in activation buffer.</div>
    <div num="p-0167" class="description-paragraph style-scope patent-text">10. Add 25 l of 50 mg/ml Sulfo-NHS (diluted in activation buffer) to the microspheres and mix gently by pipetting. For best results make the stock just before use.</div>
    <div num="p-0168" class="description-paragraph style-scope patent-text">11. Add 25 l of 50 mg/ml EDC (diluted in activation buffer) to the microspheres and mix gently by pipetting. For best results make the stock just before use.</div>
    <div num="p-0169" class="description-paragraph style-scope patent-text">12. Incubate for 20 minutes at room temperature in dark on a shaker.</div>
    <div num="p-0170" class="description-paragraph style-scope patent-text">13. Pellet the activated microspheres by microcentrifugation at 11,000 rpm for 3 minutes.</div>
    <div num="p-0171" class="description-paragraph style-scope patent-text">14. Remove the supernatant and resuspend the pelleted microspheres in 500 l of coupling buffer (0.1M MES pH 6.0)mix well by pipetting.</div>
    <div num="p-0172" class="description-paragraph style-scope patent-text">15. Repeat step 13, step 14 and again step 13 two timestotal of 3 washes.</div>
    <div num="p-0173" class="description-paragraph style-scope patent-text">16. Resuspend beads in 200 l of coupling buffer and mix well. Add 800 l of coupling buffer and spike anti-FVIII-68 mAb to obtain 5 g/ml mixture (7.50 of 0.66 mg/ml stock)mix well by pipetting.</div>
    <div num="p-0174" class="description-paragraph style-scope patent-text">17. Incubate for 2 hours with mixing by rotation at room temperature in dark.</div>
    <div num="p-0175" class="description-paragraph style-scope patent-text">18. Pellet the coupled microspheres by microcentrifugation at 11,000 rpm for 3 minutes.</div>
    <div num="p-0176" class="description-paragraph style-scope patent-text">19. Remove the supernatant and add 6000 of blocking/storage buffer (1PBS/1% BSA/0.05% Tween/0.02% Azide pH 7.4)mix well by pipetting.</div>
    <div num="p-0177" class="description-paragraph style-scope patent-text">20. Repeat step 18.</div>
    <div num="p-0178" class="description-paragraph style-scope patent-text">21. Resuspend the pelleted microspheres in 6000 of blocking/storage buffer (1PBS/1% BSA/0.05% Tween/0.05% Azide pH 7.4)-mix well by pipetting.</div>
    <div num="p-0179" class="description-paragraph style-scope patent-text">22. Rotate the microspheres overnight in dark at 4 C.</div>
    <div num="p-0180" class="description-paragraph style-scope patent-text">23. Next day pellet the coupled microspheres by microcentrifugation at 11,000 rpm for 3 minutes. Remove the supernatant. Add 4000 of fresh blocking/storage buffer, mix well by pipetting and record number of beads/ml on the tube.</div>
    <div num="p-0181" class="description-paragraph style-scope patent-text">Other Procedures:</div>
    <div num="p-0182" class="description-paragraph style-scope patent-text">The following procedures are provided as examples of those suitable for performing various aspects of the FVIII assay fluorescent immunoassay and suitable controls, following coupling of the capture and control antibodies to the microspheres. Those of skill in the art will recognize that many other variations are possible and within the scope of the invention.
</div> <ul class="style-scope patent-text"> <li id="ul0002-0001" num="0000" class="style-scope patent-text"> <ul class="style-scope patent-text"> <li id="ul0003-0001" num="0189" class="style-scope patent-text">i. Bead coupling as per above protocol: anti-FVIII-68 (IgG<sub class="style-scope patent-text">2</sub>b) mAb coupled to <figure-callout id="038" label="bead" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">bead</a></figure-callout> 038 and anti-FXIII 2-4 (IgG<sub class="style-scope patent-text">2</sub>b) mAb coupled to <figure-callout id="026" label="bead region" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">bead region</a></figure-callout> 026 for specificity control.</li> <li id="ul0003-0002" num="0190" class="style-scope patent-text">ii. Individual microcentrifuge tubes containing the desired beads (stored at 4 C. in dark) must be wrapped, e.g. in aluminum foil to prevent exposure to light and warmed to room temperature rotating on a rotor for a minimum of 30 minutes before use.</li> <li id="ul0003-0003" num="0191" class="style-scope patent-text">iii. Mix beads with pipettor for 30 seconds before use.</li> <li id="ul0003-0004" num="0192" class="style-scope patent-text">iv. Make a dilution of beads to be used in the assay (e.g., 100 beads/l as recommended by Luminex). The final number of beads in 100 l reaction mixture (500 sample+50 l beads per well) should be about 5000 beads. Buffer: 1 Phosphate buffered saline 0.1% Bovine Serum Albumin/0.05% Tween20filter sterilized pH 7.4
        <ul class="style-scope patent-text"> <li id="ul0004-0001" num="0193" class="style-scope patent-text">Total number of samples (wells) to be testedthe volume of bead solution per well=total volume of bead solution needed.</li> <li id="ul0004-0002" num="0194" class="style-scope patent-text">Ex. 48 wells50 l/well=2400 l total bead volume needed</li> <li id="ul0004-0003" num="0195" class="style-scope patent-text">Rotate to prevent bead aggregation and precipitation until ready to load the samples onto the plate.
<br class="style-scope patent-text">
Preparation of Intermediates
</li> </ul>
        </li> <li id="ul0003-0005" num="0196" class="style-scope patent-text">i. 1000 mM -mercaptoethanol:
        <ul class="style-scope patent-text"> <li id="ul0005-0001" num="0197" class="style-scope patent-text">a) To a microfuge tube add 276 l of 1PBS/0.1% BSA/0.05% Tween20.</li> <li id="ul0005-0002" num="0198" class="style-scope patent-text">b) From a stock of 12,543 mM -mercaptoethanol add 24 l to 276 l buffer to make a 1000 mM intermediatemix well by vortexing.</li> <li id="ul0005-0003" num="0199" class="style-scope patent-text">c) Keep at room temperature. The intermediate must be made fresh each day neededdiscard unused solution.</li> </ul>
        </li> <li id="ul0003-0006" num="0200" class="style-scope patent-text">ii. 100 nM rFVIII or 28.5 g/ml (MW=285,000):
        <ul class="style-scope patent-text"> <li id="ul0006-0001" num="0201" class="style-scope patent-text">a) To a microfuge tube add 286 l of 1HBS/1% BSA/0.02<figure-callout id="20" label="% Tween" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 20 buffer.</li> <li id="ul0006-0002" num="0202" class="style-scope patent-text">b) Thaw a stock vial of rFVIII (stored in 80 C.), spin down and mix with a pipette. Keep on ice if not used immediately.</li> <li id="ul0006-0003" num="0203" class="style-scope patent-text">c) From a 620 g/ml (2.17 M) rFVIII stock add 14 l to 286 l buffer-mix well. Store on ice if not immediately frozen.</li> <li id="ul0006-0004" num="0204" class="style-scope patent-text">d) This intermediate may be aliquoted and frozen at 80 C. for future use
<br class="style-scope patent-text">
Reduction of rFVIII for Standard:
</li> </ul>
        </li> <li id="ul0003-0007" num="0205" class="style-scope patent-text">i. Thaw FVIII immuno-depleted plasma at 37 C. for 10 minutes in a waterbath.</li> <li id="ul0003-0008" num="0206" class="style-scope patent-text">ii. In a microfuge tube place 475 l of 1PBS/0.1% BSA/0.05% Tween20.</li> <li id="ul0003-0009" num="0207" class="style-scope patent-text">iii. <figure-callout id="5" label="Spike" filenames="US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Spike</a></figure-callout> 5 l of 1000 mM -mercaptoethanol intermediate into the 475 l buffer and mix well by vortexing. Final concentration of -mercaptoethanol will be 10 mM.</li> <li id="ul0003-0010" num="0208" class="style-scope patent-text">iv. Add 20 l of FVIII depleted plasma into the tube containing 10 mM -mercaptoethanol in buffer and mix well by vortexing. Final dilution of FVIII depleted plasma will be 1:25.</li> <li id="ul0003-0011" num="0209" class="style-scope patent-text">v. Prepare a 10 nM rFVIII from 100 nM rFVIII intermediate stored at 80 C. To 45 l of 1PBS/0.1% BSA/0.05% Tween add 50 of 100 nM rFVIII intermediatemix well.</li> <li id="ul0003-0012" num="0210" class="style-scope patent-text">vi. Add 1 l of 10 nM rFVIII intermediate into the 500 l solution containing 10 mM -mercaptoethanol and 1:25 diluted FVIII depleted plasma. Final rFVIII concentration will be 20 pM.</li> <li id="ul0003-0013" num="0211" class="style-scope patent-text">vii. Mix the sample well by vortexing and rotate for two hours at room temperature.</li> <li id="ul0003-0014" num="0212" class="style-scope patent-text">viii. After two hour reduction, sample may be titrated and tested or stored at 80 C.</li> <li id="ul0003-0015" num="0213" class="style-scope patent-text">ix. For control sample of FVIII depleted plasma repeat step i, ii, iii, iv, vi and vii in another microfuge tube omitting the addition of rFVIII in step v.
<br class="style-scope patent-text">
Reduction of FVIII in Plasma Samples:
</li> <li id="ul0003-0016" num="0214" class="style-scope patent-text">i. Thaw plasma samples at 37 C. for 10 minutes in a waterbath.</li> <li id="ul0003-0017" num="0215" class="style-scope patent-text">ii. In a microfuge tube place 475 l of 1PBS/0.1% BSA/0.05% Tween20 buffer.</li> <li id="ul0003-0018" num="0216" class="style-scope patent-text">iii. <figure-callout id="5" label="Spike" filenames="US08715951-20140506-D00029.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Spike</a></figure-callout> 5 l of 1000 mM -mercaptoethanol into the 475 l buffermix well by vortexing. Final concentration of -mercaptoethanol will be 10 mM.</li> <li id="ul0003-0019" num="0217" class="style-scope patent-text">iv. Add 20 l of thawed plasma into the tube containing 10 mM -mercaptoethanol in buffer. Mix well by vortexing. Final plasma dilution will be 1:25.</li> <li id="ul0003-0020" num="0218" class="style-scope patent-text">v. Rotate for two hours at room temperature.</li> <li id="ul0003-0021" num="0219" class="style-scope patent-text">vi. After two hour reduction titrate and test or store at 80 C.
<br class="style-scope patent-text">
Titration of rFVIII Standard and Control FVIII Depleted Plasma (Reduced Samples):
</li> <li id="ul0003-0022" num="0220" class="style-scope patent-text">i. Place multiple (e.g., 9) microfuge tubes in a rack and to each one add 150 l of IX PBS/0.1% BSA/0.05% Tween20.</li> <li id="ul0003-0023" num="0221" class="style-scope patent-text">ii. Take 150 l of the 20 M reduced rFVIII from step IV and add to the first of the nine tubes containing buffer. Mix well by vortexing. Titrate the rFVIII in the remaining tubes in the same manner.</li> <li id="ul0003-0024" num="0222" class="style-scope patent-text">iii. The 20 pM reduced sample and the titrated samples will be diluted a further 2-fold with beads in the well of the assay plate. Therefore the actual concentration of rFVIII in the assay will be 10 pM titrated 2-fold. Make these dilutions immediately before addition to the plate containing MAb-bound beads.
<br class="style-scope patent-text">
Titration of Plasma Samples:
</li> <li id="ul0003-0025" num="0223" class="style-scope patent-text">i. Full titration curve
        <ul class="style-scope patent-text"> <li id="ul0007-0001" num="0224" class="style-scope patent-text">a) Place multiple (e.g., 9) microfuge tubes in a rack.</li> <li id="ul0007-0002" num="0225" class="style-scope patent-text">b) To each tube add 150 l of 1PBS/0.1% BSA/0.05% Tween20.</li> <li id="ul0007-0003" num="0226" class="style-scope patent-text">c) Take 150 l of the reduced 1:25 plasma sample described above and add to the first of the nine tubes containing buffer. Mix well by vortexing. Titrate the plasma sample in the remaining tubes in the same manner.</li> <li id="ul0007-0004" num="0227" class="style-scope patent-text">d) The 1:25 diluted reduced sample and the titrated samples will be diluted further 2-fold with beads in the well of the assay plate. Therefore the actual dilution factor of the plasma sample in the assay will be 1:50 titrated 2-fold.</li> <li id="ul0007-0005" num="0228" class="style-scope patent-text">e) Make these dilutions immediately before addition to the plate containing beads.</li> </ul>
        </li> <li id="ul0003-0026" num="0229" class="style-scope patent-text">ii. 1:1000 and 1:2000 dilution of plasma without the full titration curve:
        <ul class="style-scope patent-text"> <li id="ul0008-0001" num="0230" class="style-scope patent-text">a) Place two microfuge tubes in a rack,</li> <li id="ul0008-0002" num="0231" class="style-scope patent-text">b) To the first tube add 285 l of 1PBS/0.1% BSA/0.05% Tween20.</li> <li id="ul0008-0003" num="0232" class="style-scope patent-text">c) To the second tube add 150 l of 1PBS/0.1% BSA/0.05% Tween20.</li> <li id="ul0008-0004" num="0233" class="style-scope patent-text">d) From the 1:25 reduced plasma sample take 150 and add to the 285 l buffer containing tube. Mix well by vortexing. The final concentration will be 1:500.</li> <li id="ul0008-0005" num="0234" class="style-scope patent-text">e) From the 1:500 dilution, take 150 l and add to the 150 l buffer containing tube. Mix well by vortexing. The final concentration will be 1:1000.</li> <li id="ul0008-0006" num="0235" class="style-scope patent-text">f) The actual dilution factor of the plasma sample in the assay will be 1:1000 and 1:2000 respectively. The 1:500 and 1:1000 dilution from step (d) and (e) will be diluted further 2-fold with beads in the well of the assay plate.</li> <li id="ul0008-0007" num="0236" class="style-scope patent-text">g) Make these dilutions immediately before addition to the plate containing beads.
<br class="style-scope patent-text">
Assay Setup and Procedure:
</li> </ul>
        </li> <li id="ul0003-0027" num="0237" class="style-scope patent-text">i. Pre-wet a multi-well assay plate with 1PBS/0.1% BSA/0.05% Tween buffer for 10 min. Aspirate the liquid before addition of beads using vacuum manifold and in-house vacuum connection.</li> <li id="ul0003-0028" num="0238" class="style-scope patent-text">ii. Add 50 l of 100 bead/l (10<sup class="style-scope patent-text">5 </sup>beads/ml) of the bead dilution to each well.</li> <li id="ul0003-0029" num="0239" class="style-scope patent-text">iii. Add 50 l of FVIII-containing samples to the wells containing bead solution.</li> <li id="ul0003-0030" num="0240" class="style-scope patent-text">iv. Cover the plate with an adhesive tape and place on a shaker.</li> <li id="ul0003-0031" num="0241" class="style-scope patent-text">v. Cover the plate with aluminum foil and set the shaker at 500 rpm for 3 hours.</li> <li id="ul0003-0032" num="0242" class="style-scope patent-text">vi. Wash the <figure-callout id="3" label="plate" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">plate</a></figure-callout> 3 times with 1PBS/0.05% Tween using vacuum manifold and strong in-house vacuum connection.</li> <li id="ul0003-0033" num="0243" class="style-scope patent-text">vii. Prepare a 10 g/ml dilution of biotinylated anti-FVIII-24 mAb in 1PBS/1% BSA/0.05% Tween (must be warmed to room temperature); add 100 l to each well.</li> <li id="ul0003-0034" num="0244" class="style-scope patent-text">viii. Set the plate on a shaker, cover and incubate for 1 hour.</li> <li id="ul0003-0035" num="0245" class="style-scope patent-text">ix. Wash the <figure-callout id="3" label="plate" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">plate</a></figure-callout> 3 times with 1PBS/0.05% Tween.</li> <li id="ul0003-0036" num="0246" class="style-scope patent-text">x. Prepare a 5 g/ml dilution of R-phycoerythrin-streptavidin fluorophore in 1PBS/1% BSA/0.05% Tween; add 100 l to each well.</li> <li id="ul0003-0037" num="0247" class="style-scope patent-text">xi. Set the plate for 10 minute incubation.</li> <li id="ul0003-0038" num="0248" class="style-scope patent-text">xii. Wash the <figure-callout id="3" label="plate" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">plate</a></figure-callout> 3 times with 1PBS/0.05% Tween.</li> <li id="ul0003-0039" num="0249" class="style-scope patent-text">xiii. Add 100 l of 1PBS/0.05% Tween to each well and collect the samples (keep samples in covered boxes to prevent light exposure.)</li> <li id="ul0003-0040" num="0250" class="style-scope patent-text">xiv. Read the samples immediately after collection.</li> </ul> </li> </ul>

    <heading class="style-scope patent-text">Example 9</heading>
    <heading class="style-scope patent-text">Detection of rFVIII in the Picomolar Concentration in Immunodepleted Human Plasma Using Fluorescence-Based Immunoassay</heading>
    <div num="p-0183" class="description-paragraph style-scope patent-text">1. Materials and Methods:</div>
    <div num="p-0184" class="description-paragraph style-scope patent-text">Preparation of FVIII-Immunodepleted Plasma</div>
    <div num="p-0185" class="description-paragraph style-scope patent-text">Plasma (pooled from 5 donors) was spiked with 35 mM (-mercaptoethanol and incubated for 2 hours at room temperature using end-over-end mixing, as described in Methods above. After dialysis in phosphate-buffered saline (pH 7.2), the plasma was immunodepleted on mAb-coupled Sepharose (anti-FVIII-24, 23 and 25 mAbs, H-chain specific). FVIII depletion of the plasma was confirmed using a fluorescence-based immunoassay as described in Example 9.</div>
    <div num="p-0186" class="description-paragraph style-scope patent-text">Generation of Physiologically Relevant Standard Curve for Quantitation of Plasma FVIII</div>
    <div num="p-0187" class="description-paragraph style-scope patent-text">Undiluted FVIII-immunodepleted plasma was spiked with various concentrations of rFVIII as described. A mixture of anti-FVIII-68 mAb beads and isotype matched control mAb beads, prepared as described in Example 9 supra, was incubated with rFVIII-containing plasma in order to simultaneously measure specific and non-specific binding. Binding was probed using biotinylated anti-FVIII-24 mAb and PE-streptavidin.</div>
    <div num="p-0188" class="description-paragraph style-scope patent-text">2. Results:</div>
    <div num="p-0189" class="description-paragraph style-scope patent-text">Detection of FVIII in Standard Curve Using FVIII-Immunodepleted Plasma Spiked with rFVIII</div>
    <div num="p-0190" class="description-paragraph style-scope patent-text">Confirmation of FVIII depletion was confirmed by the fluorescence-based immunoassay (FLI), as shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9</figref>. More specifically, human plasma was immunodepleted as described above, and the depleted plasma was spiked with rFVIII and serially diluted, or tested without addition of rFVIII. Referring to <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 9</figref>, the results show that FVIII is not detectable by the FLI in immunodepleted plasma lacking FVIII, and is detected by increasing levels of fluorescence in samples spiked with increasing amounts of rFVIII.</div>
    <div num="p-0191" class="description-paragraph style-scope patent-text">A typical assay is illustrated in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref>. In this experiment, decreasing concentrations of rFVIII (20-0.04 pM) was spiked in undiluted FVIII immuno-depleted plasma and subjected to FLI. In this assay, anti-FVIII-68 mAb was used for capturing FVIII and biotinylated anti-FVIII-24 mAb and PE-streptavidin was used for detection. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref> shows that an anti-FVIII mAb such as anti-FVIII-68 mAb coupled to a fluorescent bead can capture rFVIII in a concentration-dependent manner, and that the binding can be detected with a biotinylated-anti-FVIII mAb (in this case anti-FVIII-24 mAB) and PE-streptavidin. The detection level in this assay is in the picomolar range (1 pM) assuming a molecular mass of 285 kDa for rFVIII.</div>
    <heading class="style-scope patent-text">Example 10</heading>
    <heading class="style-scope patent-text">Highly Sensitive Quantitation of FVIII in Plasma from Human Subjects Using Fluorescence-Based Immunoassay (FLI)</heading>
    <div num="p-0192" class="description-paragraph style-scope patent-text">This Example demonstrates that the FLI of the invention can be used to quantitate FVIII contained in plasma from human subjects following reduction with a reducing agent such as mercaptoethanol.</div>
    <div num="p-0193" class="description-paragraph style-scope patent-text">In these experiments, plasma from healthy human subjects was reduced using 1 or 10 mM -mercaptoethanol. For generation of concentration curves, the reduced plasma was serially diluted in undiluted FVIII-depleted plasma, prepared as described above for the standard curve using rFVIII, then subjected to FLI. The concentration of FVIII detected in the human plasma was determined by comparison with a standard curve such as that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref>.</div>
    <div num="p-0194" class="description-paragraph style-scope patent-text">Referring to <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 11A</figref>, the concentration of FVIII antigen in plasma that was treated with 10 mM -mercaptoethanol without dialysis was found to be 1.20.17 nM using the standard curve shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 10</figref>. Referring to <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 11B</figref>, FVIII concentration for plasma treated with 1 mM -mercaptoethanol was determined to be 0.4 nM. Thus, addition of 10 mM mercaptoethanol improved assay sensitivity and detection levels. Consistent with this, we have also shown that plasma FVIII depletion on a mAb column is much more successful when plasma is reduced with 35 mM -mercaptoethanol.</div>
    <div num="p-0195" class="description-paragraph style-scope patent-text">It appears that 10 mM -mercaptoethanol is best for use to determine plasma FVIII concentration. The mechanisms by which -mercaptoethanol improves assay sensitivity and detection levels are not known. Without intending to be bound by any particular theory, one explanation is that use of this reducing agent results in irreversible dissociation of FVIII from vWF (Lollar, Fay and Fass, Methods in Enzymology, 1993). Thus the FVIII epitopes recognized by the FVIII mAbs may become more accessible for binding to the antibodies.</div>
    <div num="p-0196" class="description-paragraph style-scope patent-text">We have further determined that there is a significant difference between antibody binding to FVIII both in mercaptoethanol-treated plasma (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 11A</figref>, <b class="style-scope patent-text">11</b>B) and in untreated plasma (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 12</figref>) depending upon whether the plasma is dialyzed before immunoassay. The pattern of antibody binding of untreated normal plasma is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 12</figref> and is compared to dialyzed normal plasma. Without intending to be bound by theory, one explanation is that improved performance of the assay results not from the dialysis itself, but from buffering of the plasma with phosphates. Another explanation is that dialysis removes some inhibitors.</div>
    <div num="p-0197" class="description-paragraph style-scope patent-text">Tests were also conducted to determine whether (-mercaptoethanol treatment can interfere with mAb binding. For these assays, 10 mM -mercaptoethanol was added to undiluted FVIII-depleted plasma containing rFVIII, and incubated for 2 hours at room temperature. The control was untreated FVIII-depleted plasma spiked with rFVIII. As seen in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 13</figref>, the results showed that the addition of -mercaptoethanol does not interfere with the binding of anti-FVIII mAb beads to rFVIII. Thus the binding of FVIII antibodies to FVIII is not compromised by the presence of this reducing agent in the immunoassay. From the foregoing, it appears that assay sensitivity and detectability can be improved by addition of a reducing agent, dialysis of the sample, or both.</div>
    <div num="p-0198" class="description-paragraph style-scope patent-text">Using the highly specific and sensitive double monoclonal antibody (mAb) fluorescence-based immunoassay (FLI) integrated into Luminex Multi-Analyte Platform technology as described herein, free- and von Willebrand factor (vWF)-bound plasma FVIII can be recognized equally well. This is shown for example in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 14</figref>, as determined by spiking rFVIII or Immunate (plasma-derived FVIII containing excess molar concentration of vWF) into FVIII-immunodepleted plasma using methods described above.</div>
    <div num="p-0199" class="description-paragraph style-scope patent-text">Importantly, the fluorescence-based assay of FVIII as described herein can detect FVIII at concentrations significantly lower than 1% mean physiologic concentration. This calculation is based on previous literature reporting that FVIII concentration in normal subjects is about 700 pM. We have determined that concentrations as low as 1-2 pM can be reliably detected using this assay. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 15</figref> shows the results of several independent experiments in which the concentration of FVIII was measured in pooled plasma from healthy individuals using the FLI of the invention, and was found to be detectable in the range of 1.7-2.5 nM.</div>
    <div num="p-0200" class="description-paragraph style-scope patent-text">It has been determined that the FLI can detect FVIII at concentrations at least about 3500-fold below normal physiological concentrations, and is about 300-fold more sensitive than ELISA. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 16</figref> shows a comparison of plasma FVIII antigen levels determined by ELISA and FLI in a healthy human population. More particularly, plasma FVIII concentrations were determined for 44 healthy blood bank donors in two double mAb immunoassays (ELISA and FLI) and compared. Vertical lines in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 16</figref> define the mean of FVIII concentration in the population tested. Pooled plasma was from 6 healthy individuals. Each point is the mean of duplicate determinations.</div>
    <div num="p-0201" class="description-paragraph style-scope patent-text">Detection of FVIII in human plasma at the level of sensitivity now achievable with the immunoassays of the invention should be sufficient to distinguish between the FVIII protein deficiency in hemophilia and non-functional FVIII mutants in which the mutations do not alter the epitope recognized by the mAb.</div>
    <div num="p-0202" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 17</figref> shows results of another high sensitivity FLI study in which the pattern of binding of rFVIII was measured in a double mAb fluorescence-based immunoassay. More particularly, rFVIII was spiked into FVIII-immunodepleted plasma and incubated in the presence of 10 mM -mercaptoethanol for 2 hrs at RT. Binding of 50 ml of various concentrations of rFVIII (0.02-10 pM) diluted in buffer (PBS containing 0.1% BSA and 0.05% Tween 20) to anti-FVIII-68 beads (spectral address 038) and isotype matched control mAb-beads (spectral address 026) was determined simultaneously after probing of beads with biotinylated anti-FVIII-24 mAb and fluorophore-streptavidin. Specific signal was calculated after subtracting non-specific binding. Each point is the mean of 5 independent determinations.</div>
    <heading class="style-scope patent-text">Example 11</heading>
    <heading class="style-scope patent-text">ELISA Assay for Measurement of Plasma Factor VIII and Use Thereof to Determine Factor VIII Concentration in Plasma from Healthy Individuals</heading>
    <div num="p-0203" class="description-paragraph style-scope patent-text">As discussed, the precise measurement of factor (F) VIII concentrations in human plasma is essential for diagnosis and classification of FVIII deficiencies and prothrombotic conditions. Bio-assays measure FVIII concentration indirectly and rely on the generation of activated FVIII (FVIIIa) via complex kinetic reactions in an individual substrate plasma.</div>
    <div num="p-0204" class="description-paragraph style-scope patent-text">In this Example we describe the development and use of an ELISA immunoassay that measures the FVIII antigen concentration in plasma in absolute quantitative terms not relying on other hemostatic components in plasma. The immunoassay is based upon the dissociation of FVIII and von Willebrand factor (vWF) by a reducing agent and the use of a calibrator generated by spiking a well defined, albumin free recombinant factor VIII into FVIII-immunodepleted plasma.</div>
    <div num="p-0205" class="description-paragraph style-scope patent-text">This Example further describes results of the ELISA assay performance evaluated by determining plasma FVIII antigen concentrations for healthy individuals and comparing the results to FVIII concentrations obtained by bioassays (activated partial thromboplastin time, APTT and chromogenic assays). The reliable detection limit of FVIII by our ELISA is 60 pM. The assay gives equivalent results with natural FVIII including those containing vWF and with recombinant full-length FVIII products and concentrates.</div>
    <div num="p-0206" class="description-paragraph style-scope patent-text">Briefly, immunoassay data give a mean plasma concentration of 1.20.6 nM FVIII. This value is significantly higher than that obtained by APTT (0.650.6 nM) or chromogenic (0.50.2 nM) methods. The FVIII ELISA can quantitate FVIII concentrations as low as 5% of the mean physiological concentration. and is suitable for precise determination of FVIII antigen concentration in healthy individuals, mild and moderate hemophilia patients and for FVIII concentrates including those containing vWF. Details of these experiments are presented below.</div>
    <div num="p-0207" class="description-paragraph style-scope patent-text">Introduction</div>
    <div num="p-0208" class="description-paragraph style-scope patent-text">Factor VIII (FVIII) activity assays (bio-assays) are utilized for identification of FVIII deficiency/hemophilia and as monitors of an individual response to FVIII replacement therapy. However, the precision and reproducibility of these assays are a source of controversy [1,2]. Currently, one-stage clotting (APTT) and chromogenic (generation of FXa) assays are used for FVIII activity in plasma. Both assays measure FVIII concentration indirectly [1,3-14]. The significant discrepancies among these activity-based assays [1] arise from the differences in the sensitivity, specificity, standards, source of reagents, variations in the protocols, the nature of FVIII concentrates [12-16] and the instability of activated FVIII (FVIIIa) [17]. More importantly, activity assays involve a complex array of kinetic reactions that rely upon the plasma composition of FVIII congenitally deficient plasma and/or plasma from healthy individuals made chemically deficient for FVIII. Assay expression involves complex kinetic reactions which are influenced by the overall composite and qualitative levels of other plasma factors [18]. Thus, when an APTT assay is used to quantify FVIII products, different clotting values could be produced which results in reduced assay reproducibility and precision.</div>
    <div num="p-0209" class="description-paragraph style-scope patent-text">The FVIII concentration in normal plasma is assigned to be 1 unit mL<sup class="style-scope patent-text">1 </sup>(0.7 nM, 0.2 g mL<sup class="style-scope patent-text">1</sup>) [7]. This concentration of FVIII is sufficient for procoagulant function in healthy individuals [7]. Substantial reduction or absence in circulating FVIII concentration leads to the bleeding disorder, hemophilia A. Hemophilia affects approximately 1 in 5000 males [19-21]. FVIII circulates in the plasma with the binding protein, von Willebrand factor (vWF) [7,8,22,23]. This non-covalent binding enhances FVIII synthesis, protects FVIII from proteolysis and concentrates FVIII at sites of active hemostasis [21]. However, the association of FVIII with vWF has hampered efforts related to immunoassay development for quantitative analysis of FVIII antigen concentration in plasma. Precise determination of FVIII antigen concentration and its relation to specific activity is critical for the diagnosis of individuals with pro-thrombotic conditions, FVIII deficiency, and for predictions of the bleeding episodes and management of hemophilia A.</div>
    <div num="p-0210" class="description-paragraph style-scope patent-text">Current immunoassays of FVIII use polyclonal antibodies (Abs) to bypass steric hindrance of FVIII epitopes by vWF. One major problem with such poly-specific Abs is the lack of specificity. Assays that utilize monoclonal Abs (mAbs) and can quantify plasma FVIII protein directly and in absolute quantitative terms are therefore highly desirable.</div>
    <div num="p-0211" class="description-paragraph style-scope patent-text">As described in Examples above, we have developed a double mAb immunoassay system for the determination of FVIII concentration in absolute quantitative terms. This assay relies on irreversible dissociation of FVIII from vWF using 10 mM -mercaptoethanol (BME) [24]. In studies described in this Example, we evaluated assay performance by determining the concentration ranges of total FVIII for healthy individuals (n=44) using an immunoassay of the invention. The results were compared with those of conventional one-stage clotting (APTT) and chromogenic assays. In all assays, we used a batch of highly pure albumin-free recombinant FVIII (rFVIII) as calibrator. The concentration of this rFVIII had been confirmed by absorbance at 280 nm, by its 1:1 binding stoichiometry with factor IXa (FIXa) and by SDS-gel analysis. Our results define real plasma FVIII protein concentration in absolute quantitative mass.</div>
    <div num="p-0212" class="description-paragraph style-scope patent-text">Materials and Methods.</div>
    <div num="p-0213" class="description-paragraph style-scope patent-text">Proteins</div>
    <div num="p-0214" class="description-paragraph style-scope patent-text">Albumin-free recombinant (r) FVIII (MW 285 kDa, stock concentration 2.2 M, 3143 U mL<sup class="style-scope patent-text">1</sup>, 5000 units mg<sup class="style-scope patent-text">1</sup>, a gift from Dr. R. Lundblad, Hyland Division, Baxter Healthcare Corporation, was used as calibrator in all immunoassays and bio-assays. Immunate (plasma-derived FVIII containing 40-fold molar excess of vWF established by ELISA, stock concentration contained 95 nM FVIII, established by ELISA, or 100 units mL<sup class="style-scope patent-text">1 </sup>reported by the manufacturer) and Refacto (B-domain-deleted rFVIII, MW 170 kDa, stock concentration contained 68 nM protein established by 1:1 functional binding stoichiometry with activated factor IX (FIXa) [25], or 200 units mL<sup class="style-scope patent-text">1 </sup>reported by the manufacturer) were obtained from Baxter Healthcare Corporation (Westlake Village, Calif.). Immunate and ReFacto were used for partial epitope mapping and their concentrations were determined by ELISA using albumin-free full-length rFVIII as calibrator and by their 1:1 binding stoichiometry with FIXa ([25], see below).</div>
    <div num="p-0215" class="description-paragraph style-scope patent-text">Production of FVIII-Specific Monoclonal Antibodies (mAbs)</div>
    <div num="p-0216" class="description-paragraph style-scope patent-text">As described in Examples above, a series of monoclonal antibodies (mAbs) directed against human factor VIII (FVIII) were produced in Balb/c mice. Immunization protocols and mAb production methods were similar to those reported previously [26]. Production and characterization of FVIII light-chain <figure-callout id="68" label="specific mAb clone" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">specific mAb clone</a></figure-callout> 68 was reported previously [27]. All FVIII clones exhibited apparent affinities in the range of 49-160 nM and two <figure-callout id="1" label="clones" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="68" label="clones" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">clones</a></figure-callout> </a></figure-callout> 1 and 68 could be used in immunoblotting for structural analysis of full-length FVIII and FVIII fragments and epitope mapping. Epitope mapping using various forms of FVIII such as full-length rFVIII, activated rFVIII (rFVIIIa), ReFacto (B-domain deleted FVIII), FVIII-von Willebrand factor (vWF) complex (Immunate) in conjunction with immunoblotting indicated that anti-FVIII-1 mAb recognizes an epitope in the FVIII B-domain but anti-FVIII-68 recognizes a region in FVIII light chain. <figure-callout id="24" label="Clone" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Clone</a></figure-callout> 24 binds to full-length FVIII, FVIIIa, ReFacto, and Immunate equally well, but it does not blot with FVIII, thus epitope specificity of this mAb could not be assessed. <figure-callout id="23" label="Clone" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Clone</a></figure-callout> 23 recognizes activated FVIII preferentially as compared to full-length rFVIII. <figure-callout id="20" label="Anti-FVIII mAbs" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"> <figure-callout id="23" label="Anti-FVIII mAbs" filenames="US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Anti-FVIII mAbs</a></figure-callout> </a></figure-callout> 20, 21, 23 and 25 all reacted with ReFacto (B-domain depleted FVIII) thus their epitope specificity was mapped to FVIII heavy or light chain. Because these mAbs do not react with FVIII in immunoblotting, we could not map their epitopes any further.</div>
    <div num="p-0217" class="description-paragraph style-scope patent-text">Plasma FVIII</div>
    <div num="p-0218" class="description-paragraph style-scope patent-text">Freshly frozen citrated plasma from Red Cross blood bank donors at the Fletcher Allen Health Center, University of Vermont was used for immunoassays of FVIII. The donors were Caucasian, reflecting the population in Burlington, Vt. Human studies were approved by the Institutional Review Board at the University of Vermont. For FVIII immunoassays, plasma was diluted 2-fold in PBS buffer (0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2) containing 0.1% BSA (bovine serum albumin) and 0.05% Tween 20 (Sigma, St. Louis, Mo.) and reduced with 10 mM -mercaptoethanol (BME, Sigma) for 2 hrs at room temperature (RT). Various dilutions were made in PBS buffer and added to the wells of microtiter plate pre-coated with capture mAb (described below).</div>
    <div num="p-0219" class="description-paragraph style-scope patent-text">FVIII-Deficient Plasma</div>
    <div num="p-0220" class="description-paragraph style-scope patent-text">FVIII-immunodeficient plasma was prepared in house by reduction of citrated pooled plasma from healthy individuals with 10 mM BME for 2 hrs at room temperature followed by FVIII depletion using anti-FVIII mAb columns. Performance of our in-house immunodepleted plasma was compared to that of commercially available immunodepleted plasma (purchased from PrecisionBiologic, Lot# D8-09, Dartmouth, Canada). Preliminary studies determined that patterns of binding of mAbs to increasing concentrations of rFVIII (0-4 nM) in both plasmas were indistinguishable as determined by ELISA. For FVIII bio-assays (APTT and chromogenic Coatest), congenitally FVIII deficient plasma was purchased (Lot # GK 0884-N8d1, George King Bio-Medical Inc., Overland Park, Kans.).</div>
    <div num="p-0221" class="description-paragraph style-scope patent-text">Validation of Albumin Free rFVIII</div>
    <div num="p-0222" class="description-paragraph style-scope patent-text">The titration behavior of the rFVIII (used as standard in all assays) in an intrinsic FXase assay is described elsewhere [25,28]. This albumin free rFVIII was used as standard in immunoassays and bio-assays. The concentration of rFVIII was ascertained by absorbance at 280 nm (using an extinction coefficient of 1.3) [29,30], by its 1:1 functional stoichiometry with factor IXa (FIXa) (calculated from the Scatchard plot of bound FVIIIa (nM) vs. bound/free) [25,28] and by SDS-gel and immunoblot analyses.</div>
    <div num="p-0223" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 18</figref> shows SDS-gel electrophoresis (<b class="style-scope patent-text">18</b>A) and immunoblot analysis (<b class="style-scope patent-text">18</b>B) of rFVIII. Referring to <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 18A</figref>, twenty g rFVIII was subjected to SDS-PAGE under reducing conditions. rFVIII dissociated into several high molecular weight fragments with apparent molecular masses of 225, 150, 100, 85 and 75 kDa corresponding to heavy and light chain fragments [45]. The absence of the degradation products (&lt;75 kDa) indicates that the protein is pure. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 18B</figref> illustrates the corresponding immunoblot of rFVIII under non-reducing condition. FVIII fragments were detected using mAb clones 1 (B-domain specific) and 68 (light chain specific).</div>
    <div num="p-0224" class="description-paragraph style-scope patent-text">Immunoassays</div>
    <div num="p-0225" class="description-paragraph style-scope patent-text">Enzyme-Linked Immunosorbent Assays (ELISA) of FVIII</div>
    <div num="p-0226" class="description-paragraph style-scope patent-text">Solid-phase direct binding assays were used to evaluate binding of anti-FVIII mAbs to FVIII and to determine the mAb binding region [31]. Purified mAb solutions were added to the wells of microtiter plates (U bottom Falcon plates, Becton Dickinson Labware, NJ, USA) pre-coated with rFVIII, activated FVIII (FVIIIa) and ReFacto. Binding was probed using horseradish-peroxidase (HRP)-anti-mouse IgG (Sigma) and detected by a chromogenic substrate (KPL, Gaithersburg, Md.).</div>
    <div num="p-0227" class="description-paragraph style-scope patent-text">Competition ELISA were performed in the absence or presence of rFVIII (0-200 nM) as previously described [31]. The relative affinity (IC<sub class="style-scope patent-text">50</sub>) is the FVIII concentration that inhibits 50% of the binding of a mAb to immobilized FVIII.</div>
    <div num="p-0228" class="description-paragraph style-scope patent-text">For the double mAb ELISA, anti-FVIII-68 mAb (IgG<sub class="style-scope patent-text">2</sub>b, , IC<sub class="style-scope patent-text">50</sub>=60 nM) was immobilized in the wells of PVC microtiter plate (50 l/well of 5 g mAb mL<sup class="style-scope patent-text">1 </sup>PBS) [31]. Plasma from healthy individuals were spiked in FVIII immunodepleted plasma containing 10 mM BME (final concentration), mixed for 2 hrs at room temperature, diluted in PBS and 50 l of each dilution was added to the pre-coated wells. Binding was probed with biotin-labeled anti-FVIII-24 mAb (IgG1, , IC<sub class="style-scope patent-text">50</sub>=103 nM, 50 l, 5 g mL<sup class="style-scope patent-text">1</sup>) and detected using HRP-streptavidin (Sigma, 0.5 g/ml, 50 l) and a chromogenic substrate.</div>
    <div num="p-0229" class="description-paragraph style-scope patent-text">Plasma FVIII concentrations were determined using a calibration curve of rFVIII. rFVIII (10 nM) was spiked into FVIII immunodepleted plasma in the presence of 10 mM BME, diluted in buffer (0-4000 pM) and subjected to double mAb immunoassay as described above.</div>
    <div num="p-0230" class="description-paragraph style-scope patent-text">Immunoblotting</div>
    <div num="p-0231" class="description-paragraph style-scope patent-text">Immunoblotting was utilized as a complementary approach to assess the blotting capabilities and epitope specificity of each mAb. Various FVIII products were subjected to electrophoresis on a gradient SDS-PAGE (5-15%) and blotted using different anti-FVIII mAbs [31] <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 18</figref> illustrates a selected immunoblot for rFVIII probed with a mixture of two mAbs, <figure-callout id="1" label="clone" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00003.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">clone</a></figure-callout> 1, B-domain specific, and clone 68, light chain specific).</div>
    <div num="p-0232" class="description-paragraph style-scope patent-text">Bioassays</div>
    <div num="p-0233" class="description-paragraph style-scope patent-text">Activated Partial Thromboplastin time (APTT) was performed using a kit from bioMrieux (Durham, N.C.).</div>
    <div num="p-0234" class="description-paragraph style-scope patent-text">Coatest factor VIII (Chromogenix, Lexington, Mass.) was used for the determination of FVIII activity in citrated plasma as described by the manufacturer. Plasma FVIII activity (nM) in both APTT and chromogenic assay was calculated from their corresponding calibrators generated by spiking various molar concentrations of rFVIII into congenitally FVIII deficient plasma (Lot # GK 884-N8d1). In both assays, plasmas were diluted 5- to 40-fold in the same FVIII deficient plasma.</div>
    <div num="p-0235" class="description-paragraph style-scope patent-text">Results.</div>
    <div num="p-0236" class="description-paragraph style-scope patent-text">Evaluation of FVIII ELISA</div>
    <div num="p-0237" class="description-paragraph style-scope patent-text">Addition of 10 mM BME to plasma results in the exposure of FVIII epitopes for mAb binding [24]. This concentration of BME does not interfere with Ab binding to FVIII as assessed by comparing the binding pattern of albumin-free purified rFVIII in the absence or presence of BME which proved to be comparable (data not shown). The optimum concentration of BME was established following extensive analyses of the FVIII ELISA assay performance in the presence of various concentrations of BME (0-35 mM). All immunoassay experiments reported herein were performed in the presence of 10 mM BME during assay.</div>
    <div num="p-0238" class="description-paragraph style-scope patent-text">For the double mAb ELISA, anti-FVIII-68 mAb was immobilized in the wells of microtiter plates. Binding of rFVIII, Immunate or human plasma FVIII was probed using biotinylated anti-FVIII-24 mAb and HRP-streptavidin. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 19</figref> illustrates a calibration curve for rFVIII from seven independent experiments. More particularly, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 19</figref> shows a comparison of binding patterns of equimolar concentrations of rFVIII and Immunate. Four nM rFVIII (), or Immunate () was spiked into FVIII-immunodepleted plasma, diluted 2-fold with PBS buffer containing 0.1% BSA and 0.05<figure-callout id="20" label="% Tween" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 20 and reduced with 10 mM BME for 2 hrs. Proteins were diluted further in the same buffer and subjected to immunoassay as described in Materials and Methods.</div>
    <div num="p-0239" class="description-paragraph style-scope patent-text">The results show that anti-FVIII-68 and 24 mAbs, which bind to spatially and structurally distinct epitopes on FVIII, can capture (anti-FVIII-68 mAb) and detect (anti-FVIII-24 mAb) rFVIII in a concentration-dependent manner. The reliable detectability limit of this assay is in the 60 pM (17 ng mL<sup class="style-scope patent-text">1</sup>) range, assuming an average molecular mass of 285 kDa for rFVIII [9]. The coefficient of variance (CV %) for 7 independent experiments performed over a period of 4 weeks was 125% for FVIII concentrations between 0.06-4 nM.</div>
    <div num="p-0240" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 19</figref> also illustrates that the presence of excess molar concentration of vWF does not interfere with FVIII binding, as the binding patterns of equimolar concentrations of Immunate (contains &gt;40-fold molar excess of vWF) and rFVIII (no vWF) are similar.</div>
    <div num="p-0241" class="description-paragraph style-scope patent-text">Assay reproducibility and precision were further confirmed by a quality control that included repeated measurements of FVIII concentration in plasma that was pooled from five healthy donors (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 20</figref>). More specifically, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 20</figref> shows the additive effect of spiking various molar concentrations of rFVIII in plasma pooled from five donors. Plasma was spiked with 0 (), 1.0 (), 3.0 () or 6.0 () nM rFVIII, diluted 2-fold in buffer and reduced with 10 mM BME and the various dilutions were subjected to immunoassay. FVIII immunodepleted plasma () was used as specificity control. Each point shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 20</figref> is the mean of duplicate determinationsSD. FVIII concentration was determined from a calibration curve of rFVIII similar to that used in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 19</figref>.</div>
    <div num="p-0242" class="description-paragraph style-scope patent-text">The concentration of FVIII in this plasma was determined to be 1.20.1 nM (CV %<sup class="style-scope patent-text">=</sup>8%), calculated from a calibration curve of rFVIII similar to that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 19</figref>. In addition, it was found that the assay was sensitive to variations in FVIII concentration, as spiking various rFVIII concentrations into normal plasma resulted in an additive effect on plasma FVIII concentration proportional to the amount of FVIII added to plasma (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 20</figref>). Plasma FVIII concentration following spiking of 1.0, 3.0 and 6.0 nM rFVIII was 2.0, 4.0 and 7.6 nM, respectively, which approximates the plasma FVIII concentration (1.2 nM) plus the FVIII concentration added.</div>
    <div num="p-0243" class="description-paragraph style-scope patent-text">FVIII Antigen Levels in a Healthy Population</div>
    <div num="p-0244" class="description-paragraph style-scope patent-text">To evaluate the mean FVIII antigen concentrations, and concentration ranges in a healthy population, antigen levels were determined for 44 individual blood donors. The results are shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 21</figref>. Plasma was diluted 2-fold with buffer, reduced with 10 mM BME and subjected to immunoassay as described above. Concentration of FVIII was determined as described for <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 20</figref>. Each point represents the mean of two independent determinations. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 21</figref> illustrates that normal FVIII concentration ranges are between 0.4 and 2.5 nM, with a mean value of 1.20.6 nM. These data indicate that there are significant variations in FVIII concentration among healthy individuals, and that the FVIII immunoassay of the invention is sensitive to these variations (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 21</figref>).</div>
    <div num="p-0245" class="description-paragraph style-scope patent-text">FVIII Concentration in the Healthy Population Determined by APTT and Chromogenic Assay</div>
    <div num="p-0246" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 22</figref> shows determination of the concentration of plasma FVIII as assessed by APTT and chromogenic assay. The calibrators for both APTT and chromogenic assays were generated by spiking rFVIII into FVIII congenitally deficient plasma and used to calculate FVIII concentrations. For each individual, clot time and generation of FXa were determined in duplicates. Calibration curves were generated by spiking various molar concentrations of rFVIII (0-700 nM) into FVIII congenitally deficient plasma and subjected to assay by APTT and Coatest.</div>
    <div num="p-0247" class="description-paragraph style-scope patent-text">Referring to <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 22</figref>, the plasma FVIII concentration for the same healthy individuals using the APTT assay was determined to range from 0.24-1.6 nM, with a mean value 0.650.3 nM. With the assumption that the pooled normal plasma contains 100% FVIII activity, this molar concentration is equivalent to 9744% FVIII activity in the healthy individuals.</div>
    <div num="p-0248" class="description-paragraph style-scope patent-text">With the Coatest chromogenic assay, FVIII concentration range was between 0.16 and 1.0 nM, with a mean value of 0.50.2 nM (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 22</figref>). In the chromogenic assay, this molar concentration of FVIII corresponds to 7230%, based on activity.</div>
    <div num="p-0249" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 23</figref> shows correlation of FVIII antigen concentration by immunoassay with concentration determinations by APTT (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 23A</figref>) and chromogenic assay (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 23B</figref>). <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 23C</figref> illustrates the correlation between APTT and chromogenic assay, and <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 23D</figref> compares the FVIII concentration of each individual determined by immunoassay with that determined by the chromogenic assay. These results show that despite the higher plasma FVIII antigen concentrations obtained by ELISA, comparison of FVIII antigen concentration by ELISA and by APTT demonstrates a linear correlation with Pearson r value of 0.83 and r squared value of 0.69 (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 23A</figref>). A similar linear correlation was observed upon comparison of FVIII antigen concentration determined by ELISA and by the Coatest chromogenic assay (Pearson r value, 0.84 and r squared value of 0.7) (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 23B and 23D</figref>). The Pearson r value of 0.92 was obtained when FVIII concentrations were compared between APTT and Coatest (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 23C</figref>).</div>
    <div num="p-0250" class="description-paragraph style-scope patent-text">Overall FVIII antigen immunoassay data demonstrate that the FVIII antigen molar concentration in plasma is higher than that obtained either by APTT or by the Coatest chromogenic assay, suggesting that some FVIII is circulating in an inactive form.</div>
    <div num="p-0251" class="description-paragraph style-scope patent-text">Advantageous Features of Immunoassay System for FVIII.</div>
    <div num="p-0252" class="description-paragraph style-scope patent-text">We have developed a specific and sensitive double mAb immunoassay format by which plasma FVIII concentrations can be quantified at concentrations as low as 60 pM. One advantageous feature of the immunoassay is the use of 10 mM BME, which results in the irreversible dissociation of vWF from FVIII. This is thought to eliminate the binding interference by vWF (FVIII binding protein) that might otherwise sterically hinder FVIII epitopes involved in mAb binding.</div>
    <div num="p-0253" class="description-paragraph style-scope patent-text">The invention provides for the first time an assay of plasma FVIII concentrations in absolute quantitative terms. This was achieved using a rFVIII calibrator that contained only FVIII protein and exhibited 100% activity based on a 1:1 functional stoichiometry with FIXa [25,28].</div>
    <div num="p-0254" class="description-paragraph style-scope patent-text">The mean values for the concentration of total FVIII and that of active FVIII were determined by immunoassay and two activity-based assays for 44 healthy individuals. The results demonstrated that while FVIII concentration values based upon activity assays are consistent with the commonly accepted mean value for plasma FVIII (0.7 nM or 1 unit mL<sup class="style-scope patent-text">1 </sup>or 0.2 g mL<sup class="style-scope patent-text">1 </sup>or 100%) [7,21,32-34], immunoassay data indicated that the FVIII antigen concentration is significantly higher (1.20.6 nM) than that observed in either APTT or chromogenic assay (0.650.3 and 0.50.2 nM, respectively). These data suggest that a fraction of the FVIII protein in citrated plasma is not detected by either bio-assay. It must be emphasized that FVIII concentrations in all three assays were estimated using a well characterized rFVIII standard [25,28]. This has minimized assay variations that could occur due to the use of different plasma pools as calibration curves and provided an opportunity to determine FVIII concentration in absolute quantitative mass. Variations between APTT and chromogenic assays were further minimized using a single lot of FVIII congenitally deficient plasma.</div>
    <div num="p-0255" class="description-paragraph style-scope patent-text">Comparative analyses between results of the immunoassay and APTT indicated that 38 out of 44 plasmas (86%) had higher FVIII antigen levels than activity. Similarly, when immunoassay results were compared to the results of the chromogenic assay, 43/44 plasmas (97%) showed higher FVIII antigen and only 1/44 plasma had higher FVIII activity than antigen (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 23B and 23D</figref>). The observation that the vast majority of plasmas contain higher levels of FVIII antigen than activity is consistent with the notion that a significant fraction (35-50%, based on comparison of FVIII concentration in immunoassay with that in APTT or chromogenic assay) of FVIII is not quantitatively represented in either activity assay.</div>
    <div num="p-0256" class="description-paragraph style-scope patent-text">Without intending to be bound by theory, one possible explanation is that in activity assays, human FVIIIa heterodimer, which is unstable, rapidly loses activity due to the spontaneous dissociation of the A2 fragment from the A1/A3-C1-C2 dimer [35-37]. While FVIIIa is produced during the initiation phase of thrombin (IIa) generation [38,39], it continuously dissociates from FIXa. Therefore, FVIIIa concentration as determined by APTT will not reach the actual FVIII concentration in plasma, and thus activity-based assays are unable to measure the actual FVIII concentration in plasma of healthy individuals. Alternatively, it is possible that a fraction of FVIII may be inactive in plasma.</div>
    <div num="p-0257" class="description-paragraph style-scope patent-text">A double mAb immunoassay for the quantitation of FVIII in plasma has been reported which requires that the capture mAb be in a form of an (Fab)<sub class="style-scope patent-text">2 </sub>fragment to minimize crossreactivity with rheumatoid factor [32]. The international standard plasma was taken as reference and considered as 1 unit mL<sup class="style-scope patent-text">1 </sup>(0.7 nM) both for FVIII activity and antigen in that study. Plasmas from normal donors compared to this reference plasma contained 1.2 U mL<sup class="style-scope patent-text">1 </sup>by activity assay and 1.01 unit mL<sup class="style-scope patent-text">1 </sup>antigen by immunoassay. Thus, the concentration of FVIII antigen calibration curve was based on the activity, whereas the FVIII antigen concentrations reported herein are based on measurements of FVIII mass and stoichiometry of FIXa binding.</div>
    <div num="p-0258" class="description-paragraph style-scope patent-text">Elevated plasma FVIII concentration is implicated in some prothrombotic states [40-42]; thus it is important to evaluate plasma FVIII concentrations by an immunoassay which bypasses the interferences associated with variations in coagulation profiles of substrate and patients' plasmas, and variations in the levels of FVIII activation. In addition, immunoassays of the invention are an important tool for FVIII concentration determinations in plasma of patients who have prolonged APTTs due to the presence of other anti-coagulant antibodies such as lupus erythematosus [43,44].</div>
    <heading class="style-scope patent-text">Example 12</heading>
    <heading class="style-scope patent-text">Use of Fluorescence-Based Immunoassay (FLI) to Determine Plasma Factor VIII Concentration in Hemophilia Patients</heading>
    <div num="p-0259" class="description-paragraph style-scope patent-text">This Example describes the use of a highly sensitive fluorescence-based assay in accordance with the invention and as described above (see, for instance, Examples 8 and 9) to detect very low levels of Factor VIII present in the plasma of patients with blood clotting disorders such as hemophilia, as well as levels of Factor VIII found in healthy subjects.</div>
    <div num="p-0260" class="description-paragraph style-scope patent-text">Introduction.</div>
    <div num="p-0261" class="description-paragraph style-scope patent-text">Hemophilia A is a clinically heterogeneous disorder due to the large number of different molecular defects in the factor (F) VIII gene. In severe Hemophilia A patients, this heterogeneity is amplified due to variations in FVIII concentration below 1% physiological concentration. This is evident from considerable differences in bleeding tendency among these patients. As discussed, the clinical diagnosis of hemophilia A relies on the bio-assays that are not sensitive at FVIII concentrations&lt;1% physiological concentration. Bio-assay measurements are complicated by many variables including differences in plasma coagulation factor concentrations among individuals, substrate plasmas, presence of inhibitors of coagulation proteins including lupus antibodies, and complications related to the labiality of activated FVIII (FVIIIa). As described above, we have developed a fluorescence-based immunoassay (FLI) that can measure FVIII antigen concentration in plasma in absolute quantitative terms that do not rely on other hemostatic components in plasma. The reliable detection limit of FLI is 2 pM, which is significantly lower than 1% mean physiologic FVIII concentration (1.2 nM).</div>
    <div num="p-0262" class="description-paragraph style-scope patent-text">The human factor VIII (FVIII) glycoprotein plays a key role in conversion of factor X (FX) to activated FX (FXa) in the intrinsic pathway of blood coagulation. In plasma, FVIII circulates at low concentration and is bound to von Willebrand factor (vWF) (Hoyer, 1981; Kane and Davie, 1988; Sadler and Davie, 1987). Concentration of FVIII in plasma of healthy individuals is reported to be in the range of 1 unit/ml (usually translates into 0.7 nM or 0.2 g mL<sup class="style-scope patent-text">1</sup>) (Hoyer, 1981; Hoyer, 1994; Tackaberry et al., 1987). By comparison to FVIII concentration in healthy individuals, FVIII deficiencies are classified as severe (&lt;1%), moderate (1-5%), and mild (&gt;5%). In severe hemophiliacs, FVIII concentration is less than 1% physiological concentration (&gt;0.01% unit mL<sup class="style-scope patent-text">1 </sup>or &lt;7 pM/0.002 g mL<sup class="style-scope patent-text">1</sup>).</div>
    <div num="p-0263" class="description-paragraph style-scope patent-text">Management of severe hemophilia is particularly challenging due to lack of sensitive and reproducible assays that can quantify FVIII concentrations at below 1% normal physiological concentration in plasma. This is increasingly important as new modes of therapy such as continuous FVIII infusion, gene therapy, FVIII mutation correction and other prophylactic approaches are developed (Chuah et al., 2004; Gilchrist et al., 2001; Hawkins et al., 1995; Hurst et al., 1998).</div>
    <div num="p-0264" class="description-paragraph style-scope patent-text">As discussed above, most common quantitative assays of plasma FVIII and FVIII concentrates are based on bio-assays such as one stage clotting (APTT) and chromogenic (generation of FXa) assays that measure FVIII concentration indirectly (Chavin and Fay, 1989; Hoyer, 1981; Kane and Davie, 1988; Kemball-Cook et al., 1993; Langdell et al., 1953; Lenting et al., 1998; Niemetz and Nossel, 1969; Over, 1986). FVIII concentration in bio-assays is estimated from a reference calibration curve generated from normal plasma pools of healthy individuals. This leads to discrepancies and inconsistencies in the assay results, presumably due to variability in plasma FVIII and other components of different plasma pools. In addition, bio-assays are less sensitive with respect to differentiating among severe hemophilia patients (FVIII concentration of &lt;1% physiological concentration). This is important because plasma FVIII concentration in severe hemophilia patients can vary between 0-12 pM, compared with an average of 1.2 nM concentration for a healthy population. It is reported that this variability in FVIII concentration plays an important role in the bleeding tendency and requires a different treatment strategy among hemophiliac patients. Petrini et al reported that prophylactic treatment in patients with severe hemophilia A (concentrations of FVIII below 0.01 IU mL<sup class="style-scope patent-text">1</sup>; &lt;1% physiological concentration) can protect against bleeding (Petrini, 2001). Similarly, recent clinical trials of FVIII and FIX gene therapy have shown clinical efficacies at very low factor levels (Roth et al., 2001).</div>
    <div num="p-0265" class="description-paragraph style-scope patent-text">Accordingly, there is an unmet need for reliable and sensitive assays that can quantify plasma FVIII at concentrations significantly lower than 1% mean physiologic concentration. Such assays are needed in pharmacokinetic studies of FVIII replacement therapy, gene therapy and monitoring of FVIII antigen levels during infusion in order to avoid excess FVIII administration which could elicit neutralizing antibodies (Abs) to FVIII (El Alfy et al., 2000; Klinge et al., 2001; Lindgren et al., 2002; Scandella et al., 1998).</div>
    <div num="p-0266" class="description-paragraph style-scope patent-text">Example 11 above describes development and evaluation of an ELISA FVIII with reliable detection limit in the 60 pM range. This FVIII ELISA is useful for quantitative analysis of plasma FVIII in healthy individuals, as well as in mild and moderate hemophilia and FVIII concentrates. In order to increase assay sensitivity and the reliable detection limit, the FVIII ELISA was converted to a fluorescence immunoassay (FLI) and was integrated into the Luminex Multi-Analyte Platform to develop a sensitive and high throughput fluorescence-based FLI for detection and quantitation of FVIII in human plasma, as described, e.g., in Examples 8 and 9 above. This Example describes additional data from FLI assays regarding sensitivity, specificity, and detection limits both for normal plasma and that of hemophilia patients and patients with various pathological conditions including autoimmune diseases.</div>
    <div num="p-0267" class="description-paragraph style-scope patent-text">Materials and Methods</div>
    <div num="p-0268" class="description-paragraph style-scope patent-text">Proteins</div>
    <div num="p-0269" class="description-paragraph style-scope patent-text">Albumin-free recombinant (r) FVIII (MW 285 kDa, stock concentration 2.2 M, 3143 U mL<sup class="style-scope patent-text">1</sup>, 5000 U mg<sup class="style-scope patent-text">1</sup>, a gift from Dr. R. Lundblad, Hyland Division, Baxter Healthcare Corporation), was used as calibrator in all immunoassays and bio-assays. Immunate (plasma-derived FVIII containing 40-fold molar excess vWF established by ELISA, stock concentration contained 95 nM FVIII, established by ELISA or 100 units mL<sup class="style-scope patent-text">1 </sup>reported by the manufacturer, Baxter Healthcare Corporation, Westlake Village, Calif.).</div>
    <div num="p-0270" class="description-paragraph style-scope patent-text">Production of FVIII-Specific Monoclonal Antibodies (mAbs)</div>
    <div num="p-0271" class="description-paragraph style-scope patent-text">A series of monoclonal antibodies (mAbs) directed against human FVIII were produced in Balb/C mice. Immunization protocols and mAb production methods were similar to those reported previously (Foster et al., 1983). FVIII light-chain <figure-callout id="68" label="specific mAb clone" filenames="US08715951-20140506-D00000.png,US08715951-20140506-D00013.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">specific mAb clone</a></figure-callout> 68 has been described previously (Precup et al., 1991). Other mouse monoclonal antibodies were generated and immunochemically characterized as described, e.g., in Examples 1-4, supra.</div>
    <div num="p-0272" class="description-paragraph style-scope patent-text">FVIII-Deficient Plasma</div>
    <div num="p-0273" class="description-paragraph style-scope patent-text">FVIII-immunodeficient plasma was either purchased from PrecisionBiologic (Lot # D8-09, Darmouth, Nova Scotia, Canada) or prepared in house by reducing citrated pooled plasma from 5-6 healthy individuals with 10 mM -mercaptoethanol for 2 hrs. FVIII was depleted using anti-FVIII mAb columns.</div>
    <div num="p-0274" class="description-paragraph style-scope patent-text">Validation of Albumin Free rFVIII and Generation of Calibration Curve</div>
    <div num="p-0275" class="description-paragraph style-scope patent-text">Albumin free recombinant (r) FVIII (stock solution of 2.2 M in HBS buffer (<figure-callout id="20" label="HEPES" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">HEPES</a></figure-callout> 20 mM, <figure-callout id="150" label="NaCl" filenames="US08715951-20140506-D00015.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">NaCl</a></figure-callout> 150 mM, pH 7.3) was used as calibrator in all immuno- and bio-assay experiments. Concentration of rFVIII was ascertained by absorbance at 280 nm (using an extinction coefficient of 1.3) (Kumar et al., 2003; Pace et al., 1995), 1:1 functional stoichiometry with activated factor IX (FIXa, calculated from the Scachard plot of bound FVIIIa (nM) vs. bound/free) (Butenas et al., 2005; Parhami-Seren et al., 2004) and by SDS-gel and immunoblot analyses.</div>
    <div num="p-0276" class="description-paragraph style-scope patent-text">For preparation of the FVIII calibration curve, rFVIII (1 nM) was spiked into FVIII-immunodepleted plasma and diluted 2-fold in PBS buffer (0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2) containing 0.1% BSA and 0.05<figure-callout id="20" label="% Tween" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 20. Following addition of 10 mM -mercaptoethanol (BME) for 2 hrs, the sample was diluted further in FVIII-immunodepleted plasma (containing 10 mM BME). FVIII containing plasma samples were subjected to FLI (see below).</div>
    <div num="p-0277" class="description-paragraph style-scope patent-text">Plasma FVIII</div>
    <div num="p-0278" class="description-paragraph style-scope patent-text">For FVIII FLI, freshly frozen citrated plasma from Red Cross blood bank donors at the Fletcher Allen Health Center, University of Vermont, was used. The donors were Caucasian, reflecting the population in Burlington, Vt. Plasma from hemophilia patients were obtained from Dr. George E. Rivard (The Hopital Saint-Justine, Montreal, Canada) and Dr. Edward Gomperts (The Childrens Hospital, Los Angeles). Human studies were approved by the Institutional Review Board at the University of Vermont, Saint-Justine hospital and Childrens Hospital.</div>
    <div num="p-0279" class="description-paragraph style-scope patent-text">For FLI, plasma was diluted 2-fold in PBS buffer containing 0.1% bovine serum albumin (BSA) and 0.05<figure-callout id="20" label="% Tween" filenames="US08715951-20140506-D00029.png,US08715951-20140506-D00031.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">% Tween</a></figure-callout> 20 and reduced with 10 mM BME for 2 hrs at room temperature. Various dilutions were made in FVIII-immunodepleted plasma (also reduced with 10 mM BME to prevent vWF binding to FVIII), and added to the wells of microtiter plate containing mAb-beads as described below.</div>
    <div num="p-0280" class="description-paragraph style-scope patent-text">Fluorescence Immunoassay (FLI)</div>
    <div num="p-0281" class="description-paragraph style-scope patent-text">FLI FVIII ELISA was integrated into the Luminex Multi-Analyte Platform (LMAP) as described above. Briefly, microsphere beads with predefined 658:712 nm emission ratios (Luminex classification #038) were coupled to anti-FVIII-68 mAb (IgG2b, ) according to the manufacturer's instructions (Luminex Corporation, Austin, Tex., USA). The binding of FVIII to mAb-beads was probed with biotinylated anti-FVIII-24 mAb (IgG1, ) and detected using R-Phycoerythrin (PE) coupled-streptavidin as described above. Briefly, fifty l of anti-FVIII-68 mAb-beads (510<sup class="style-scope patent-text">3 </sup>beads, 50 l) were added to the wells of a microtiter plate (wells were covered with 1.2 m PVDF membrane, Multi-Screen filter plates, part # MABV-N1250, Millipore Corporation, Billerica, Mass.). Fifty l of various concentrations of rFVIII or plasma dilutions in FVIII-immunodepleted plasma were added to the beads. Following a 3-hr incubation at room temperature, excess antigen was removed. One hundred l of biotinylated anti-FVIII-24 mAb (10 g mL<sup class="style-scope patent-text">1 </sup>PBS-1% BSA-0.05% Tween 20) was added for an additional 1 hr. Following three more washes, the beads were reacted for 30 min with PE-streptavidin (100 l of 5 g mL<sup class="style-scope patent-text">1 </sup>probe in PBS-1% BSA-0.05% Tween 20).</div>
    <div num="p-0282" class="description-paragraph style-scope patent-text">Non-specific binding controls were performed by using an isotype-matched mAb with a specificity irrelevant to FVIII, coupled to microsphere beads with a different 658/712 nm emission ratios (Luminex classification #027) than those used for anti-FVIII-68. The Luminex technology permits the specific and non-specific binding signal to be determined simultaneously in real time. Data are reported as  mean fluorescence intensity units, representing intensity for anti-FVIII mAb-beads minus that measured for control mAb-beads.</div>
    <div num="p-0283" class="description-paragraph style-scope patent-text">Bioassay</div>
    <div num="p-0284" class="description-paragraph style-scope patent-text">Activated Partial Thromboplastin time, APTT (bioMrieux, Durham, N.C.) was performed as described by the manufacturer. APTT calibrator was generated by spiking increasing concentrations of rFVIII into FVIII-immunodepleted plasma (PrecisionBiologic, Lot# D8-09) followed by clot time determination. In all immunoassays and bioassays, a single lot of FVIII-deficient plasma was used and plasmas were diluted 1 to 40-fold in the same FVIII-deficient plasma.</div>
    <div num="p-0285" class="description-paragraph style-scope patent-text">Results</div>
    <div num="p-0286" class="description-paragraph style-scope patent-text">Evaluation of FLI</div>
    <div num="p-0287" class="description-paragraph style-scope patent-text">The success of this FLI relies in part on the addition of 10 mM BME to plasma to expose FVIII epitopes for mAb binding (Lollar et al., 1993). We have determined that this concentration of BME does not interfere with antibody binding. All immunoassay experiments described in this Example were performed in the presence of 10 mM BME during assay.</div>
    <div num="p-0288" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24A</figref> shows a high range and <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24B</figref> shows a low range calibration curve of rFVIII in immunodepleted plasma. rFVIII (0-500 pM) or (0.25-20 pM) was spiked into our in house () or commercial source (, Pricision Biologic) FVIII-immunodepleted plasma. Plasma was reduced with 10 mM BME and subjected to FLI. Each point is the mean of 2-4 independent determinationsSD.</div>
    <div num="p-0289" class="description-paragraph style-scope patent-text">There is no significant difference between the calibration curve generated in our in house FVIII immunodepleted plasma and that generated in the FVIII-immunodepleted plasma from the commercial source (PrecisionBiologic). The difference between these two FVIII deficient plasmas is that our in house immunodepleted plasma is reduced with 10 mM BME before depleting FVIII with anti-FVIII mAbs and it also contains physiological concentrations of vWF. The Commercial plasma is depleted of FVIII using anti-vWF Abs; thus there is no detectable FVIII (established by ELISA and FLI) or vWF (established by ELISA).</div>
    <div num="p-0290" class="description-paragraph style-scope patent-text">We next tested the assay reliable detection limits in plasma. rFVIII concentrations ranging from 0.25-20 pM were spiked into FVIII-immunodepleted plasma and subjected to FLI. The reliable detection limit in whole plasma was in the 2 pM range. Overall assay coefficient of variation at concentrations between 2-20 pM was between 12-16%. Thus this FLI can measure FVIII concentrations significantly below 1% physiological concentration in plasma (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24B</figref>).</div>
    <div num="p-0291" class="description-paragraph style-scope patent-text">The binding pattern of plasma FVIII pooled from 6 healthy individuals was evaluated to determine the physiological concentration of FVIII in plasma by FLI (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 25A</figref>). Referring to <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 25A</figref>, pooled plasma from 6-donors () was diluted in immunodepleted plasma (1:1) and then in PBS buffer (2-fold), was reduced with 10 mM BME. Several dilutions were made in FVIII-immunodepleted plasma and subjected to FLI. Immunodepleted plasma () similarly treated was used as negative control. FVIII antigen concentration was determined from a calibration graph of rFVIII similar to that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24A</figref>. Each point is the mean of duplicate determinationsSD.</div>
    <div num="p-0292" class="description-paragraph style-scope patent-text">A mean concentration of 1.30.2 (CV %=15%) was obtained from 4 independent experiments using a standard curve similar to that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24B</figref>. This value is generally consistent with FVIII concentration obtained by ELISA (1.20.1 nM).</div>
    <div num="p-0293" class="description-paragraph style-scope patent-text">We further evaluated FLI by measuring plasma FVIII concentration and ranges in the same 44 healthy individuals for which FVIII concentrations had been determined by ELISA, as described above. Data are illustrated in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 25B</figref>. Plasma from red-cross donors () were diluted 2-fold in immunodepleted plasma and an additional 2-fold in PBS buffer, reduced with 10 mM BME and various final dilutions (500- and 1000-fold) were made in immunodepleted plasma and subjected to FLI. Mean FVIII concentration for healthy population was 10.4 nM. FVIII concentrations were determined from a calibration graph of rFVIII similar to that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24A</figref>. Each point in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 25B</figref> is the mean of concentrations obtained for 4-8 independent determinationsSD. The data indicate that there are significant variations in FVIII concentration among healthy individuals ranging from 0.3-2.1 nM, with a mean value of 1.00.4 nM. These data are generally consistent with FVIII concentration obtained by ELISA (FVIII concentration range 0.4-2.5 nM, with mean concentration of 1.20.6 nM). Overall, the results of FVIII FLI confirms our previous finding that the mean FVIII antigen concentration in plasma is significantly higher (30%) than that reported by the activity-based assay (0.7 nM) (Girma et al., 1998; Hoyer, 1981; Hoyer, 1994; Hubbard and Heath, 2004; Ingerslev et al., 2004).</div>
    <div num="p-0294" class="description-paragraph style-scope patent-text">To determine the assay dynamics and sensitivity to variations in FVIII concentration, plasma FVIII concentrations were determined for plasmas from severe, moderate and mild hemophilia patients (n=19) with wide ranges of FVIII concentration. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 26A</figref> illustrates the results of FVIII antigen concentration in hemophilia in comparison to that obtained by our in house APTT assay. Comparison of plasma FVIII concentrations of hemophilia patients is indicated by FLI () and APTT (). For FLI, plasmas were diluted 2-fold in immunodepleted plasma, reduced with 10 mM BME and subjected to FLI. FVIII antigen concentrations were determined from a calibration graph of rFVIII similar to that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24B</figref>. For APTT, plasmas were used undiluted. APTT calibrator was generated by spiking rFVIII into FVIII-immunodepleted plasma (Precision Biologics). <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 26B</figref> illustrates relationships between FVIII antigen concentration as determined by FLI and APTT (4 patients whose APTT and FLI did not correlate were excluded).</div>
    <div num="p-0295" class="description-paragraph style-scope patent-text">In both assays calibration curves were generated by spiking rFVIII into a single lot of FVIII-immunodepleted plasma from the commercial source (Precision Biologic). Comparison of FLI results with the results of APTT indicated that in general there is a good correlation between FVIII concentration determined by FLI and that determined by APTT in hemophilia patients. However, in two patients (10%), antigen concentration appeared to be significantly higher (&gt;2-fold) than FVIII concentration by APTT and in two patients (10%), FVIII concentration by APTT was significantly higher (&gt;2-fold) than FVIII antigen (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 26A</figref>). With the exception of these four patients, there was a linear correlation between FVIII antigen concentration (FLI) and FVIII activity (APTT) (Pearson r&gt;0.97, R squared 0.94) (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 26B</figref>).</div>
    <div num="p-0296" class="description-paragraph style-scope patent-text"> <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 27</figref> illustrates FVIII antigen concentration ranges (FLI) in comparison to FVIII concentration by APTT in severe hemophilia (n=8). A large scope of FVIII concentrations ranging from 5 pM to 76 pM could be readily detected, emphasizing the sensitivity of the FLI to variations in FVIII concentration (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 27</figref>).</div>
    <div num="p-0297" class="description-paragraph style-scope patent-text">Additional studies were performed on plasmas from children (n<sup class="style-scope patent-text">=</sup>100) with various pathological conditions including hemophilia patients and patients with autoimmune disorders (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 28</figref>). More particularly, comparison of FVIII concentrations and ranges in patients (n=100) with various diseases (including autoimmune and FVIII deficiency) determined by FLI and APTT is shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 28A</figref>. For FLI (), plasmas were diluted 2-fold in FVIII-depleted plasma and an additional 2-fold with PBS buffer, reduced with 10 mM BME, diluted further 4-, 10 and 20-fold and subjected to FLI. FVIII concentrations were determined from high range calibrator similar to that shown in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 24A</figref>. For APTT (), plasmas were diluted 5- and 10-fold in FVIII-immunodepleted plasma (Precision Biologic) and subjected to APTT. APTT calibrator was generated by spiking rFVIII (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 28A and 28B</figref>) or Immunate into FVIII-depleted plasma (Precision Biologic). <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 28B</figref> shows correlation between plasma FVIII concentration by FLI and APTT.</div>
    <div num="p-0298" class="description-paragraph style-scope patent-text">The patient populations included those with a significant amount of auto- and anti-coagulant antibodies. Results illustrated in <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 28</figref> indicate that there are significant variations in FVIII concentration among these patients and that FLI is sensitive to low as well as high FVIII concentrations over a range of &gt;3 orders of magnitude (2-4000 pM, <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 28A</figref>). When the results of FVIII antigen concentration were compared to our in house APTT, mean FVIII concentration by FLI was 2.6-fold higher (14241024 pM) than the FVIII concentration by APTT (556375). These data show that plasma FVIII concentration is 39% higher by FLI as compared to APTT, consistent with our FVIII results for 44 healthy individuals, showing that the concentration of plasma FVIII by FLI is 30% higher than that obtained by APTT. Despite significant variations in FVIII concentration among patients, there is a linear correlation between the results of FLI and APTT with Pearson r of 0.8 (R squared 0.64).</div>
    <div num="p-0299" class="description-paragraph style-scope patent-text">Our APTT assay was performed with a FVIII immunodepleted plasma substrate that was also depleted of vWF. In order to determine whether absence of vWF could result in significant differences between FVIII antigen results (FLI) and those obtained by APTT (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 28B</figref>), we used Immunate as FVIII calibrator. The concentration of Immunate was verified by ELISA, FLI and 1:1 functional stoichiometry (Butenas et al., 2004; Parhami-Seren et al., 2004). Immunate contained 40-fold molar excess molar of vWF, as established by ELISA. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 29A</figref> illustrates the results of plasma FVIII concentration determination using either rFVIII or Immunate as calibrator. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 29A</figref> shows a comparison of plasma FVIII concentrations calculated from rFVIII () and Immunate () calibrators. <figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 29B</figref> is a comparison between FVIII concentrations calculated from rFVIII () or Immunate () calibrators showing that at concentrations below 1000 pM, there is no significant difference between the results of these two calibrators. At concentrations above 1000 pM, the Immunate calibrator gives 25% higher FVIII concentrations by APTT as compared to rFVIII calibrator.</div>
    <div num="p-0300" class="description-paragraph style-scope patent-text">As discussed, there was no significant difference between FVIII concentrations of up to 1000 pM when either calibrator was used. However, at FVIII concentrations&gt;1000 pM Immunate calibrator, FVIII concentrations were slightly (25%) higher in comparison to the FVIII results obtained from the rFVIII calibrator (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIGS. 29A and 29B</figref>). This indicates that at high FVIII concentrations, absence or presence of vWF results in slight differences in the results of FVIII concentration determination.</div>
    <div num="p-0301" class="description-paragraph style-scope patent-text">These data indicate that FLI can detect FVIII concentrations significantly below 1% physiological concentration (detection limit 2 pM, 0.16-0.2% FVIII based on 1-1.2 nM FVIII mean physiological concentration obtained by FLI and by ELISA. FLI also quantifies FVIII at concentrations between 2-4000 pM (3 orders of magnitude); thus FLI should facilitate quantitative measurements of FVIII in healthy individuals, in individuals with prothrombotic conditions due to high concentration of FVIII, and severe hemophilia patients and patients receiving FVIII replacement.</div>
    <div num="p-0302" class="description-paragraph style-scope patent-text">FVIII concentrations obtained by FLI were compared with those obtained by activated partial thromboplastin time (APTT). FLI exhibited large dynamics by detecting FVIII concentrations in severe, moderate and mild hemophilia ranging between 0-4.5 nM. This assay will not only permit FVIII antigen quantitation and further classification of severe hemophilia patients, but it can also be useful in pharmacokinetic studies involving FVIII replacement.</div>
    <div num="p-0303" class="description-paragraph style-scope patent-text">In summary, we have developed a specific and sensitive assay format by which plasma FVIII can be quantified at concentrations as low as 2 pM. Integration of FVIII ELISA with LMAP technology allows quantitation of plasma at concentrations significantly below 1% physiological concentration. Such sensitivity could not be achieved by conventional ELISA.</div>
    <div num="p-0304" class="description-paragraph style-scope patent-text">Our data using this highly sensitive assay show that the mean value for plasma FVIII antigen in healthy population is about 30% higher (1.0 nM) than that reported by activity assay (0.7 nM) (Girma et al., 1998; Hoyer, 1981; Hoyer, 1994; Hubbard and Heath, 2004; Ingerslev et al., 2004) although significant variations in FVIII levels were observed among healthy individuals. The sensitivity and large dynamics of the assay is evident by its ability to quantify a low range of plasma FVIII from patients with severe hemophilia patients (<figref idrefs="DRAWINGS" class="style-scope patent-text">FIG. 27</figref>). FVIII concentrations in all experiments were determined from the standard curve of rFVIII; thus plasma FVIII concentrations reported here are fundamental measurements of mass of FVIII across healthy and hemophilia populations as well as population with diverse diseases.</div>
    <div num="p-0305" class="description-paragraph style-scope patent-text">The FLI described herein provides an important tool for precise determination of FVIII concentration for the diagnosis of FVIII deficiencies (genetic vs. production of non-functional FVIII protein) and management of hemophilia A.</div>
    <heading class="style-scope patent-text">REFERENCES</heading>
    <div num="p-0306" class="description-paragraph style-scope patent-text">It is believed that a review of the references will increase appreciation of the present invention. In some instances, the references are prefaced by a number in parentheses referred to in the specification.
</div> <ul class="style-scope patent-text"> <li id="ul0009-0001" num="0375" class="style-scope patent-text">Barrowcliffe, T. W., Raut, S., Sands, D. and Hubbard, A. R. (2002) Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin. Thromb. Haemost. 28, 247-255.</li> <li id="ul0009-0002" num="0376" class="style-scope patent-text">Bihoreau, N., Paolantonacci, P., Bardelle, C., Fontaine-Aupart, M.-P., Krishnan, S., Yon, J. and Romet-Lemonne, J.-L. (1991) Structural and functional characterization of Factor VIII-dII, a new recombinant Factor VIII lacking most of the B-domain. Biochem. J. 277, 23-31.</li> <li id="ul0009-0003" num="0377" class="style-scope patent-text">Brackmann, H. H., Aygoren, E., Scharrer, I., Schwaab, R., Hammerstein, U. and Oldenburg, J. (1993) Two years' experience with two recombinant factor VIII concentrate. Blood Coagul. <figure-callout id="4" label="Fibrinolysis" filenames="US08715951-20140506-D00022.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Fibrinolysis</a></figure-callout> 4, 421-424.</li> <li id="ul0009-0004" num="0378" class="style-scope patent-text">Butenas, S., van't Veer, C. and Mann, K. G. (1999) Normal thrombin generation. Blood 94, 2169-2178.</li> </ul>

    <div num="p-0307" class="description-paragraph style-scope patent-text">Chavin, S. T. and Fay, P. J. (1989) The purification, Structure and Function of Factor VIII. CRC Press, Boca Raton, Fla.
</div> <ul class="style-scope patent-text"> <li id="ul0010-0001" num="0380" class="style-scope patent-text">El Alfy, M. S., Tantawy, A. A., Ahmed, M. H. and Abdin, I. A. (2000) Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction. Haemophilia 6, 635-638.</li> <li id="ul0010-0002" num="0381" class="style-scope patent-text">Fay, P. J. (1993) Factor VIII Structure and Function. Thromb. Haemost. 70, 63-67.</li> <li id="ul0010-0003" num="0382" class="style-scope patent-text">Foster, P. A. and Zimmerman, T. S. (1989) Factor VIII structure and function. <figure-callout id="3" label="Blood Reviews" filenames="US08715951-20140506-D00001.png,US08715951-20140506-D00002.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Blood Reviews</a></figure-callout> 3, 180-191.</li> <li id="ul0010-0004" num="0383" class="style-scope patent-text">Foster, W. B., Katzmann, J. A., Miller, R. S., Nesheim, M. E. and Mann, K. G. (1982) Monoclonal antibodies selective for the functional states of bovine factor V and factor Va. Thromb. Res. 28, 649-661.</li> <li id="ul0010-0005" num="0384" class="style-scope patent-text">Foster, W. B., Tucker, M. M., Katzmann, J. A., Miller, R. S., Nesheim, M. E. and Mann, K. G. (Blood) Monoclonal antibodies to human coagulation factor V and factor Va. Blood 61, 1060-1067.</li> <li id="ul0010-0006" num="0385" class="style-scope patent-text">Hoyer, L. W. (1981) The factor VIII complex: structure and function. Blood 58, 1-13. Kane, W. H. and Davie, E. W. (1988) Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 71, 539-555.</li> <li id="ul0010-0007" num="0386" class="style-scope patent-text">Kemball-Cook, G., Tubbs, J. E., Dawson, N. J. and Barrowcliffe, T. W. (1993) The behavior of different factor VIII concentrates in a chromogenic factor X-activating system. Brit. J. Haematol. 84, 273-278.</li> <li id="ul0010-0008" num="0387" class="style-scope patent-text">Kleinveld, H. A., Anderson, N. E., van Voorthuiozen, H., den Hartog, J. and de Groot, P. G. (1999) Determination of coagulation FVIII activity by chromogenic substrate method on STA, an automated coagulation analyzer. Scans. J. Clin. Invest. 59, 335-341.</li> <li id="ul0010-0009" num="0388" class="style-scope patent-text">Klinge, J., Auerswald, G., Budde, U., Klose, H., Kreuz, W., Lenk, H. and Scandella, D. (2001) Paediatric Inhibitor Study Group of the German Society on Thrombosis and Haemostasis. Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. Haemophilia 7, 26-32.</li> <li id="ul0010-0010" num="0389" class="style-scope patent-text">Langdell, R. D., Wagner, R. H. and Brinkhous, K. M. (1953) Effect of antihemophilic factor on one-stage clotting tests. A presumptive assay for hemophilia and a simple one-stage antihemophilic factor assay procedure. J. Lab. Clin. Med. 41, 637-647.</li> <li id="ul0010-0011" num="0390" class="style-scope patent-text">Lenting, P. J., van Mourik, J. A. and Mertens, K. (1998) The life cycle of factor VIII in view of its structure and function. Blood 92, 3983-3996.</li> <li id="ul0010-0012" num="0391" class="style-scope patent-text">Lindgren, A., Wadenvik, H. and Tengborn, L. (2002) Characterization of inhibitors to FVIII with an ELISA in congenital and aquired haemophilia A. Haemophilia 8, 644-648. Lollar, P., Fay, P. J., and Fass, D. N. (1993) Factor VIII and Factor VIIIa. Methods in Enzymology:128-143.</li> <li id="ul0010-0013" num="0392" class="style-scope patent-text">Lundblad, R. L., Kingdon, H. S., Mann, K. G. and White, G. C. (2000) Issues with the assay of FVIII activity in plasma and factor VIII concentrates. Thromb. Haemost. 84, 942-948. Lusher, J. M., Arkin, S., Abildgaard, C. F. and Schwartz, R. S. (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 328, 453-459.</li> <li id="ul0010-0014" num="0393" class="style-scope patent-text">Lusher, J. M., Hillman-Wiseman, C. and Hurst, D. (1998) In vivo recovery with products of very high purity-assay discrepancies. <figure-callout id="4" label="Haemophilia" filenames="US08715951-20140506-D00022.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Haemophilia</a></figure-callout> 4, 641-645.</li> <li id="ul0010-0015" num="0394" class="style-scope patent-text">Mikaelsson, M., Oswaldson, U. and Jankowski, M. A. (2001) Measurement of FVIII activity of B-domain deleted recombinant factor VIII. Semin. Hematol. 38 (Suppl. 4), 13-23.</li> <li id="ul0010-0016" num="0395" class="style-scope patent-text">Mikaelsson, M. and Oswaldsson, U. (2002) Assaying the cirulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin. Thromb. Haemost. 28, 257-264.</li> <li id="ul0010-0017" num="0396" class="style-scope patent-text">Mikaelsson, M., Oswaldsson, U. and Sandberg, H. (1998) Influence of phospholipids on the assessment of factor VIII activity. Haemophilia. 4, 646-650.</li> <li id="ul0010-0018" num="0397" class="style-scope patent-text">Niemetz, J. and Nossel, H. L. (1969) Activated coagulation factors: In vivo and in vitro studies. Brit. J. Haematol. 16, 337-351.</li> <li id="ul0010-0019" num="0398" class="style-scope patent-text">Over, J. (1986) Methodology of the one-stage assay of factor VIII (VIII:C). Scand. J. Haematol. 33 (Suool. 41), 13-24.</li> <li id="ul0010-0020" num="0399" class="style-scope patent-text">Pipe, S. W. and Kaufman, R. J. (1997) Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc. Natl. Acad. Sci. USA 94, 11851-11856. Rick, M. E., Walsh, C. E. and Key, N. S. (2003) Congenital bleeding disorders. Hematology (Am Soc Hematol Educ Program)., 559-574.</li> <li id="ul0010-0021" num="0400" class="style-scope patent-text">Sandberg, H., Almstedt, A., Brandt, J., Gray, E., Holmquist, L., Oswaldsson, U., Sebring, S. and Mikaelsson, M. (2001) Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, rFVIII SQ. Thromb. Haemost. 85, 93-100.</li> <li id="ul0010-0022" num="0401" class="style-scope patent-text">Scandella, D., Mondorf, W. and Klinge, J. (1998) The natural history of the immune response to exogenous factor VIII in severe <figure-callout id="4" label="haemophilia A. Haemophilia" filenames="US08715951-20140506-D00022.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">haemophilia A. Haemophilia</a></figure-callout> 4, 546-551.</li> <li id="ul0010-0023" num="0402" class="style-scope patent-text">1. Lundblad R L, Kingdon H S, Mann K G, White G C. Issues with the assay of FVIII activity in plasma and factor VIII concentrates. <figure-callout id="2000" label="Thromb Haemost" filenames="US08715951-20140506-D00033.png,US08715951-20140506-D00034.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Thromb Haemost</a></figure-callout> 2000; 84:942-948.</li> <li id="ul0010-0024" num="0403" class="style-scope patent-text">2. Hubbard A R, Bevan S A, Weller L J. Potency estimation of recombinant factor VIII: effect of assay method and standard. Br J Haematol 2001; 113:533-536.</li> <li id="ul0010-0025" num="0404" class="style-scope patent-text">3. Over J. Methodology of the one-stage assay of factor VIII (VIII:C). Scand J Haematol. 1986; 33 (Suool. 41):13-24.</li> <li id="ul0010-0026" num="0405" class="style-scope patent-text">4. Langdell R D, Wagner R H, Brinkhous K M. Effect of antihemophilic factor on one-stage clotting tests. A presumptive assay for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41:637-647.</li> <li id="ul0010-0027" num="0406" class="style-scope patent-text">5. Niemetz J, Nossel H L: Activated coagulation factors. In vivo and in vitro studies. Brit J Haematol 1969; 16:337-351.</li> <li id="ul0010-0028" num="0407" class="style-scope patent-text">6. Kemball-Cook G, Tubbs J E, Dawson N J, Barrowcliffe T W. The behavior of different factor VIII concentrates in a chromogenic factor X-activating system. Brit J Haematol 1993; 84:273-278.</li> <li id="ul0010-0029" num="0408" class="style-scope patent-text">7. Hoyer L W. The factor VIII complex: structure and function. Blood 1981; 58:1-13.</li> <li id="ul0010-0030" num="0409" class="style-scope patent-text">8. Kane W H, Davie E W. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71:539-555.</li> <li id="ul0010-0031" num="0410" class="style-scope patent-text">9. Chavin S T, Fay P J. The purification, Structure and Function of Factor VIII. Boca Raton, Fla., CRC Press, 1989.</li> <li id="ul0010-0032" num="0411" class="style-scope patent-text">10. Lenting P J, van Mourik J A, Mertens K. The life cycle of factor VIII in view of its structure and function. Blood 1998; 92:3983-3996.</li> <li id="ul0010-0033" num="0412" class="style-scope patent-text">11. Kleinveld H A, Anderson N E, van Voorthuiozen H, den Hartog J, de Groot P G. Determination of coagulation FVIII activity by chromogenic substrate method on STA, an automated coagulation analyzer. Scans J Clin Invest 1999; 59:335-341.</li> <li id="ul0010-0034" num="0413" class="style-scope patent-text">12. Mikaelsson M, Oswaldson U, Jankowski M A. Measurement of FVIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38 (Suppl. 4):13-23.</li> <li id="ul0010-0035" num="0414" class="style-scope patent-text">13. Barrowcliffe T W, Raut S, Sands D, Hubbard A R. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Haemost 2002; 28:247-255.</li> <li id="ul0010-0036" num="0415" class="style-scope patent-text">14. Mikaelsson M, Oswaldsson U. Assaying the cirulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Haemost 2002; 28:257-264.</li> <li id="ul0010-0037" num="0416" class="style-scope patent-text">15. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4:646-650.</li> <li id="ul0010-0038" num="0417" class="style-scope patent-text">16. Lusher J M, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia 1998; 4:641-645.</li> <li id="ul0010-0039" num="0418" class="style-scope patent-text">17. Lu D, Kalafatis M, Mann K G, Long G L. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87:4708-4717.</li> <li id="ul0010-0040" num="0419" class="style-scope patent-text">18. Butenas S, van't Veer C, Mann K G. Normal thrombin generation. Blood 1999; 94:2169-2178.</li> <li id="ul0010-0041" num="0420" class="style-scope patent-text">19. Scandella D, Mondorf W, Klinge J. The natural history of the immune response to exogenous factor VIII in severe haemophilia A. Haemophilia 1998; 4:546-551.</li> <li id="ul0010-0042" num="0421" class="style-scope patent-text">20. Rick M E, Walsh C E, Key N S. Congenital bleeding disorders. Hematology (Am Soc Hematol Educ Program). 2003:559-574.</li> <li id="ul0010-0043" num="0422" class="style-scope patent-text">21. Hoyer L W. Medical progress-Hemophilia A. N Engl J Med 1994; 330:38-47.</li> <li id="ul0010-0044" num="0423" class="style-scope patent-text">22. Olson J D, Brockway W J, Fass D N, Bowie E J, Mann K G. Purification of porcine and human ristocetin-Willebrand factor. J Lab Clin Med 1977; 89:1278-1294.</li> <li id="ul0010-0045" num="0424" class="style-scope patent-text">23. Sadler J E, Davie E W. The molecular basis of blood diseases. Philadelphia, W. B. Saunders, 1987.</li> <li id="ul0010-0046" num="0425" class="style-scope patent-text">24. Lollar P, Fay P J, Fass D N. Factor VIII and factor VIIIa. Methods Enzymol 1993; 222:128-143.</li> <li id="ul0010-0047" num="0426" class="style-scope patent-text">25. Butenas S, Parhami-Seren B, Gissel M T, Gomperts E D, Mann K G. Activity and content of factor VIII in various FVIII products. J Thromb Haemost 2005; 3:Supplement 1 (Abstract#2028).</li> <li id="ul0010-0048" num="0427" class="style-scope patent-text">26. Foster W B, Tucker M M, Katzmann J A, Miller R S, Nesheim M E, Mann K G. Monoclonal antibodies to human coagulation factor V and factor Va. Blood 1983; 61:1060-1067.</li> <li id="ul0010-0049" num="0428" class="style-scope patent-text">27. Precup J W, Kline B C, Fass D N. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage. Blood 1991; 77:1929-1936.</li> <li id="ul0010-0050" num="0429" class="style-scope patent-text">28. Parhami-Seren B, Butenas S, Amblo J, Fass D N, Mann K G. Quantitation of FVIII antigen in human plasma. J Thromb Haemost 2005; 3: Supplement 1 (Abstract#650).</li> <li id="ul0010-0051" num="0430" class="style-scope patent-text">29. Pace C N, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 1995; 4:2411-2423.</li> <li id="ul0010-0052" num="0431" class="style-scope patent-text">30. Kumar H, Healey J F, Lollar P, Durrani M J. Determination of free sulfhydryls in human factor VIII. J Thromb Haemost 2003; 1 (Supplement 1):P1067.</li> <li id="ul0010-0053" num="0432" class="style-scope patent-text">31. Parhami-Seren B, Butenas S, Amblo J, Mann K G. Immunologic quantitation of tissue factors. J Thromb Haemost 2006; 4:1-6.</li> <li id="ul0010-0054" num="0433" class="style-scope patent-text">32. Girma J P, Fressinaud E, Houllier A, Laurian Y, Amiral J, Meyer D. Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies. Haemophilia 1998; 4:98-103.</li> <li id="ul0010-0055" num="0434" class="style-scope patent-text">33. Ingerslev J, Jankowski M A, Weston S B, Charles L A. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2:623-628.</li> <li id="ul0010-0056" num="0435" class="style-scope patent-text">34. Hubbard A R, Heath A B. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J Thromb Haemost 2004; 2:1380-1384.</li> <li id="ul0010-0057" num="0436" class="style-scope patent-text">35. Nogami K, Wakabayashi H, Fay P J. Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation. J Biol Chem 2003; 278:16502-16509.</li> <li id="ul0010-0058" num="0437" class="style-scope patent-text">36. Fay P J, Beattie T L, Regan L M, O'Brien L M, Kaufman R J. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem 1996; 271:6027-6032.</li> <li id="ul0010-0059" num="0438" class="style-scope patent-text">37. Parker E T, Doering C B, Lollar P. A1 Subunit-mediated Regulation of Thrombin-activated Factor VIII A2 Subunit Dissociation. J Biol Chem 2006; 281:13922-13930.</li> <li id="ul0010-0060" num="0439" class="style-scope patent-text">38. Hockin M F, Jones K C, Everse S J, Mann K G. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277:18322-18333.</li> <li id="ul0010-0061" num="0440" class="style-scope patent-text">39. Lawson J H, Kalafatis M, Stram S, Mann K G. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269:23357-23366.</li> <li id="ul0010-0062" num="0441" class="style-scope patent-text">40. Kalashnikova L A, Berkovskii A L, Dobrynina L A, Sergeeva E V, Kozlov A A, Aleksandrova E N, Nasonov E L. [Clotting factor VIII in Sneddon syndrome]. Klin Med (Mosk) 2003; 81:42-45.</li> <li id="ul0010-0063" num="0442" class="style-scope patent-text">41. Hoppener M R, Kraaijenhagen R A, Hutten B A, Buller H R, Peters R J, Levi M. Beta-receptor blockade decreases elevated plasma levels of factor VIII:C in patients with deep vein thrombosis. J Thromb Haemost 2004; 2:1316-1320.</li> <li id="ul0010-0064" num="0443" class="style-scope patent-text">42. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci P M. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004; 104:3631-3634.</li> <li id="ul0010-0065" num="0444" class="style-scope patent-text">43. Conley C L. Disorders of the blood in disseminated lupus erythematosus. Am J Med 1952; 13:1-2.</li> <li id="ul0010-0066" num="0445" class="style-scope patent-text">44. Conley C L, Hartmann R C. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31:621-622.</li> <li id="ul0010-0067" num="0446" class="style-scope patent-text">45. Andersson L O, Forsman N, Huang K, Larsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Nall Acad Sci USA 1986; 83:2979-2983.</li> <li id="ul0010-0068" num="0447" class="style-scope patent-text">Butenas S., Parhami-Seren B., Gissel M. T., Gomperts E. D. and Mann K. G. (2004) Quantitative evaluation of factor VIII in factor VIII products. <figure-callout id="104" label="Blood" filenames="US08715951-20140506-D00011.png,US08715951-20140506-D00012.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Blood</a></figure-callout> 104, 89b (Abstract#4012).</li> <li id="ul0010-0069" num="0448" class="style-scope patent-text">Butenas S., Parhami-Seren B., Gissel M. T., Gomperts E. D. and Mann K. G. (2005) Activity and content of factor VIII in various FVIII products. J. Thromb. Haemost. 3, Supplement 1 (Abstract#2028).</li> <li id="ul0010-0070" num="0449" class="style-scope patent-text">Chuah M. K., Collen D. and Vandendiressche T. (2004) Preclinical and clinical gene therapy for haemophilia. <figure-callout id="4" label="Haemophilia" filenames="US08715951-20140506-D00022.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Haemophilia</a></figure-callout> 4, 119-125.</li> <li id="ul0010-0071" num="0450" class="style-scope patent-text">Fay P. J., Beattie T. L., Regan L. M., O'Brien L. M. and Kaufman R. J. (1996) Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J. Biol. Chem. 271, 6027-6032.</li> <li id="ul0010-0072" num="0451" class="style-scope patent-text">Gilchrist G. S., Wilke J. L., Muehlenbein L. R. and Danilenko-Dixon D. (2001) Intrauterine correction of factor VIII (FVIII) deficiency. Haemophilia 7, 497-499.</li> <li id="ul0010-0073" num="0452" class="style-scope patent-text">Girma J. P., Fressinaud E., Houllier A., Laurian Y., Amiral J. and Meyer D. (1998) Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies. <figure-callout id="4" label="Haemophilia" filenames="US08715951-20140506-D00022.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Haemophilia</a></figure-callout> 4, 98-103.</li> <li id="ul0010-0074" num="0453" class="style-scope patent-text">Hawkins T. E., Green G. J., Romeril K., Milicih G. S, and Carter J. M. (1995) Treatment of Haemophilia A by continuous factor VIII infusion. Aus. NZ J. Med. 25, 37-39.</li> <li id="ul0010-0075" num="0454" class="style-scope patent-text">Hockin M. F., Jones K. C., Everse S. J. and Mann K. G. (2002) A model for the stoichiometric regulation of blood coagulation. J Biol Chem 277, 18322-33.</li> <li id="ul0010-0076" num="0455" class="style-scope patent-text">Hoyer L. W. (1994) Medical progress-Hemophilia A. N. Engl. J. Med. 330, 38-47.</li> <li id="ul0010-0077" num="0456" class="style-scope patent-text">Hubbard A. R. and Heath A. B. (2004) Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J. Thromb. Haemost. 2, 1380-1384.</li> <li id="ul0010-0078" num="0457" class="style-scope patent-text">Hurst D., Zabor S., Malianni D. and Miller D. (1998) Evaluation of recombinant factor VIII (KogenateR) stability for continuous infusion using a minipump infusion device. <figure-callout id="4" label="Haemophilia" filenames="US08715951-20140506-D00022.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Haemophilia</a></figure-callout> 4, 785-789.</li> <li id="ul0010-0079" num="0458" class="style-scope patent-text">Ingerslev J., Jankowski M. A., Weston S. B. and Charles L. A. (2004) Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J. Thromb. Haemost. 2, 623-628.</li> <li id="ul0010-0080" num="0459" class="style-scope patent-text">Kane W. H. and Davie E. W. (1988) Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 71, 539-555.</li> <li id="ul0010-0081" num="0460" class="style-scope patent-text">Kumar H., Healey J. F., Lollar P. and Durrani M. J. (2003) Determination of free sulfhydryls in human factor VIII. J. Thromb. Haemost. 1 (Supplement 1), P1067.</li> <li id="ul0010-0082" num="0461" class="style-scope patent-text">Lawson J. H., Kalafatis M., Stram S, and Mann K. G. (1994) A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 269, 23357-66.</li> <li id="ul0010-0083" num="0462" class="style-scope patent-text">Lindgren A., Wadenvik H. and Tengborn L. (2002) Characterization of inhibitors to FVIII with an ELISA in congenital and aquired haemophilia A. Haemophilia 8, 644-648.</li> <li id="ul0010-0084" num="0463" class="style-scope patent-text">Nogami K., Wakabayashi H. and Fay P. J. (2003) Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation. J. Biol. Chem. 278, 16502-16509.</li> <li id="ul0010-0085" num="0464" class="style-scope patent-text">Pace C. N., Vajdos F., Fee L., Grimsley G. and Gray T. (1995) How to measure and predict the molar absorption coefficient of a protein. <figure-callout id="4" label="Protein Sci" filenames="US08715951-20140506-D00022.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Protein Sci</a></figure-callout> 4, 2411-23.</li> <li id="ul0010-0086" num="0465" class="style-scope patent-text">Parhami-Seren B., Butenas S., Amblo J. and Mann K. G. (2006) Immunologic quantitation of tissue factors. J. Thromb. Haemost. 4, 1-6.</li> <li id="ul0010-0087" num="0466" class="style-scope patent-text">Parhami-Seren B., Butenas S., Bouchard B., Amblo J. and Mann K. G. (2004) Quantitation of natural, recombinant, cell-surface and plasma tissue factor. <figure-callout id="104" label="Blood" filenames="US08715951-20140506-D00011.png,US08715951-20140506-D00012.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Blood</a></figure-callout> 104, 533a (Abstract#1929).</li> <li id="ul0010-0088" num="0467" class="style-scope patent-text">Petrini P. (2001) What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 7, 99-102.</li> <li id="ul0010-0089" num="0468" class="style-scope patent-text">Precup J. W., Kline B. C. and Fass D. N. (1991) A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage. Blood 77, 1929-36.</li> <li id="ul0010-0090" num="0469" class="style-scope patent-text">Roth D. A., Tawa N. E., Jr., O'Brien J. M., Treco D. A. and Selden R. F. (2001) Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 344, 1735-42.</li> <li id="ul0010-0091" num="0470" class="style-scope patent-text">Sadler J. E. and Davie E. W. (1987) The molecular basis of blood diseases. W. B. Saunders, Philadelphia.</li> <li id="ul0010-0092" num="0471" class="style-scope patent-text">Tackaberry E. S., Ganz P. R. and Rock G. (1987) Measurement of human factor VIII by avidin-biotin dot immunobinding ELISAs. J. Immunol. Methods 99, 59-66.</li> </ul>

    <div num="p-0308" class="description-paragraph style-scope patent-text">The disclosures of all references cited herein are incorporated herein by reference. The invention has been described in detail with reference to preferred embodiments thereof.</div>
    <div num="p-0309" class="description-paragraph style-scope patent-text">However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention.</div>
    
  </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(14)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result" hidden="">translated from </div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><div mxw-id="PCLM60537303" lang="EN" load-source="patent-office" class="claims style-scope patent-text">
    <claim-statement class="style-scope patent-text">What is claimed is:</claim-statement>
    <div class="claim style-scope patent-text"> <div id="CLM-00001" num="00001" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">1. A method for determining the level of a FVIII protein or a fragment thereof in a sample, comprising:
<div class="claim-text style-scope patent-text">(a) contacting the sample with a first antibody directed to a FVIII antigen, said first antibody being attached to a first bead having at least one first characteristic, wherein the FVIII protein or fragment thereof comprising said FVIII antigen binds to said first antibody being attached to the first bead, thereby forming a capture antibody, and forms a complex therewith;</div>
<div class="claim-text style-scope patent-text">(b) contacting the sample with a control antibody not directed to a FVIII antigen, said control antibody being attached to a second bead having at least one second characteristic distinguishable from the first characteristic of the first bead, wherein one or more proteins in the sample may form non-specific complexes with the control antibody;</div>
<div class="claim-text style-scope patent-text">(c) contacting the complexes formed in steps (a) and (b) with a second antibody directed to the FVIII antigen, said second antibody being labeled with a marker, to form a complex which includes the antibody of step (a) or (b), the FVIII protein or fragment thereof comprising said FVIII antigen, and the second antibody; and</div>
<div class="claim-text style-scope patent-text">(d) subtracting the quantity of the second labeled antibody in complexed associated with the second beads attached to the control antibody from the quantity of the second labeled antibody in complexes associated with the first beads attached to the first antibody directed against the FVIII antigen, thereby removing spurious non-specific binding and more accurately determining the level of the FVIII protein or fragment thereof comprising said antigen in the sample.</div>
</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00002" num="00002" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">2. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the sample comprises plasma.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00003" num="00003" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">3. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the sample comprises plasma obtained from a human having or at risk of developing a blood clotting disorder.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00004" num="00004" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">4. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the sample is a pharmaceutical product comprising FVIII protein obtained from human blood.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00005" num="00005" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">5. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the sample comprises recombinant FVIII protein.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00006" num="00006" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">6. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the first antibody can bind to FVIII under conditions wherein FVIII is dissociated from von Willebrand factor.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00007" num="00007" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">7. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein an epitope recognized by the first antibody resides in the L-chain of FVIII.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00008" num="00008" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">8. The method of <claim-ref idref="CLM-00007" class="style-scope patent-text">claim 7</claim-ref>, wherein the first antibody is anti-FVIII-68 mAb, deposited under ATCC Accession No. PTA-6891.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00009" num="00009" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">9. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein an epitope recognized by the second antibody resides in the H/L-chain of FVIII.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00010" num="00010" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">10. The method of <claim-ref idref="CLM-00009" class="style-scope patent-text">claim 9</claim-ref>, wherein the second antibody is anti-FVIII-24 mAb, deposited under ATCC Accession No. PTA-6890.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00011" num="00011" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">11. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the determined level of FVIII protein in the sample is between about 0.001 nM and 1000 nM.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00012" num="00012" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">12. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, wherein the first antibody is anti-FVIII-68 mAb and the second antibody is anti-FVIII-24 mAb.</div>
    </div>
    </div> <div class="claim-dependent style-scope patent-text"> <div id="CLM-00013" num="00013" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">13. The method of <claim-ref idref="CLM-00001" class="style-scope patent-text">claim 1</claim-ref>, further comprising prior to step (a) contacting the sample with a reducing agent that releases FVIII from a FVIII-binding molecule, wherein the reducing agent is selected from the group consisting of -mercaptoethanol, sodium borohydride, dithiothreitol, erytritol, and ethane thiol.</div>
    </div>
    </div> <div class="claim style-scope patent-text"> <div id="CLM-00014" num="00014" class="claim style-scope patent-text">
      <div class="claim-text style-scope patent-text">14. An isolated antibody directed to FVIII protein, wherein the epitope recognized by said antibody resides in the H/L-chain of FVIII antigen, said antibody having a binding affinity (IC<sub class="style-scope patent-text">50</sub>) in the range of about 50-100 nM. </div>
    </div>
  </div> </div>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (6)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4795806A/en"><a id="link" href="#" class="style-scope state-modifier">US4795806A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1987-07-16</span>
                    <span class="td style-scope patent-result">1989-01-03</span>
                    <span class="td style-scope patent-result">Miles Laboratories, Inc.</span>
                    <span class="td style-scope patent-result">Phospholipid affinity purification of Factor VIII:C 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030170613A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030170613A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-09-06</span>
                    <span class="td style-scope patent-result">2003-09-11</span>
                    <span class="td style-scope patent-result">Don Straus</span>
                    <span class="td style-scope patent-result">Rapid and sensitive detection of cells and viruses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030224477A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030224477A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-05-31</span>
                    <span class="td style-scope patent-result">2003-12-04</span>
                    <span class="td style-scope patent-result">Heartlein Michael W.</span>
                    <span class="td style-scope patent-result">Optimized promoter constructs 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7855274B2/en"><a id="link" href="#" class="style-scope state-modifier">US7855274B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-12-03</span>
                    <span class="td style-scope patent-result">2010-12-21</span>
                    <span class="td style-scope patent-result">University Of Rochester</span>
                    <span class="td style-scope patent-result">Recombinant factor VIII having increased specific activity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8236518B2/en"><a id="link" href="#" class="style-scope state-modifier">US8236518B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-15</span>
                    <span class="td style-scope patent-result">2012-08-07</span>
                    <span class="td style-scope patent-result">The University Of Vermont And State Agriculture College</span>
                    <span class="td style-scope patent-result">Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR100311971B1/en"><a id="link" href="#" class="style-scope state-modifier">KR100311971B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-23</span>
                    <span class="td style-scope patent-result">2001-12-28</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Non-volatile Memory Semiconductor Device Manufacturing Method
 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="nplCitations" class="scroll-target style-scope patent-result">
              Non-Patent Citations (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      International Search Report for PCT/US06/27409 issued Jan. 15, 2007 and mailed Apr. 23, 2007.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Precup et al. A Monoclonal Antibody to Factor VIII Inhibits von Willebrand Factor Binding and Thrombin Cleavage, Blood (1991), 77 (9): pp. 1929-1936.
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      Precup, et al., "A Monoclonal Antibody to Factor VIII Inhibits von Willebrand Factor Binding and Thrombin Cleavage," Blood. 1991, 77(9): pp. 1929-1936.
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (13)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9788776B1/en"><a id="link" href="#" class="style-scope state-modifier">US9788776B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-22</span>
                    <span class="td style-scope patent-result">2017-10-17</span>
                    <span class="td style-scope patent-result">Verily Life Sciences Llc</span>
                    <span class="td style-scope patent-result">Protein M-based in vivo diagnostic system and detection method 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018042251A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2018042251A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-08-29</span>
                    <span class="td style-scope patent-result">2018-03-08</span>
                    <span class="td style-scope patent-result">Oslo Universitetssykehus Hf</span>
                    <span class="td style-scope patent-result">Chip-seq assays 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9927442B1/en"><a id="link" href="#" class="style-scope state-modifier">US9927442B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-31</span>
                    <span class="td style-scope patent-result">2018-03-27</span>
                    <span class="td style-scope patent-result">Verily Life Sciences Llc</span>
                    <span class="td style-scope patent-result">Biosensor for in vitro detection system and method of use 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007011746A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2007011746A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-15</span>
                    <span class="td style-scope patent-result">2007-01-25</span>
                    <span class="td style-scope patent-result">The University Of Vermont And State Agriculture College</span>
                    <span class="td style-scope patent-result">Highly sensitive immunoassays and antibodies for detection of blood factor viii 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010088547A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010088547A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-01-29</span>
                    <span class="td style-scope patent-result">2010-08-05</span>
                    <span class="td style-scope patent-result">Bayer Healthcare Llc</span>
                    <span class="td style-scope patent-result">Assays for detecting pegylated blood coagulation factors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9334331B2/en"><a id="link" href="#" class="style-scope state-modifier">US9334331B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-11-17</span>
                    <span class="td style-scope patent-result">2016-05-10</span>
                    <span class="td style-scope patent-result">Chugai Seiyaku Kabushiki Kaisha</span>
                    <span class="td style-scope patent-result">Bispecific antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11181534B2/en"><a id="link" href="#" class="style-scope state-modifier">US11181534B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-04-04</span>
                    <span class="td style-scope patent-result">2021-11-23</span>
                    <span class="td style-scope patent-result">Bloodworks</span>
                    <span class="td style-scope patent-result">Routine laboratory and point-of-care (POC) testing for hemostasis 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI700300B/en"><a id="link" href="#" class="style-scope state-modifier">TWI700300B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-26</span>
                    <span class="td style-scope patent-result">2020-08-01</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII)
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI701435B/en"><a id="link" href="#" class="style-scope state-modifier">TWI701435B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-09-26</span>
                    <span class="td style-scope patent-result">2020-08-11</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Method to determine the reactivity of FVIII
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018133039A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2018133039A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-01-20</span>
                    <span class="td style-scope patent-result">2018-07-26</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Method and kit for preparing antibody pair and use of kit, and system for preparing antibody pair 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN113474657A/en"><a id="link" href="#" class="style-scope state-modifier">CN113474657A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-02-21</span>
                    <span class="td style-scope patent-result">2021-10-01</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Method for removing non-specific binding signals using microparticles 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20220163520A1/en"><a id="link" href="#" class="style-scope state-modifier">US20220163520A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-03-19</span>
                    <span class="td style-scope patent-result">2022-05-26</span>
                    <span class="td style-scope patent-result">Indian Council Of Medical Research</span>
                    <span class="td style-scope patent-result">Apparatus, method and kit for detection of von willebrand factor and factor viii 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN114397464B/en"><a id="link" href="#" class="style-scope state-modifier">CN114397464B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-03-24</span>
                    <span class="td style-scope patent-result">2022-06-10</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Coupling compound of erythrocyte membrane fragments and carrier, coupling method and application thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8715951B2/en"><a id="link" href="#" class="style-scope state-modifier">US8715951B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-05-06</span>
                    <span class="td style-scope patent-result">Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/262532959212830043"><a id="link" href="#" class="style-scope state-modifier">Ingerslev</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1987</span>
                    <span class="td style-scope patent-result">A sensitive ELISA for von Willebrand factor (vWf: Ag)</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/793272791744370598"><a id="link" href="#" class="style-scope state-modifier">Peerlinck et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999</span>
                    <span class="td style-scope patent-result">Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/3056530751046240487"><a id="link" href="#" class="style-scope state-modifier">Baronciani et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020</span>
                    <span class="td style-scope patent-result">How we make an accurate diagnosis of von Willebrand disease</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/17512690005129670985"><a id="link" href="#" class="style-scope state-modifier">Favaloro</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014</span>
                    <span class="td style-scope patent-result">Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/11919233044866623364"><a id="link" href="#" class="style-scope state-modifier">Lebreton et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011</span>
                    <span class="td style-scope patent-result">Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2533788B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2533788B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-12-16</span>
                    <span class="td style-scope patent-result">Stable solution 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2001503861A/en"><a id="link" href="#" class="style-scope state-modifier">JP2001503861A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-21</span>
                    <span class="td style-scope patent-result">
  Solid-phase immunoassay
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/17759524466140528869"><a id="link" href="#" class="style-scope state-modifier">Pruthi et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999</span>
                    <span class="td style-scope patent-result">Autoimmune factor VIII inhibitors</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPWO2002079782A1/en"><a id="link" href="#" class="style-scope state-modifier">JPWO2002079782A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-07-22</span>
                    <span class="td style-scope patent-result">
  Reagent for immunoassay for elastase 1, immunoassay method and method for detecting pancreatic disease
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/8168056839394626389"><a id="link" href="#" class="style-scope state-modifier">Batlle et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996</span>
                    <span class="td style-scope patent-result">Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/7074707517499999509"><a id="link" href="#" class="style-scope state-modifier">Benson et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991</span>
                    <span class="td style-scope patent-result">A sensitive immunoassay for von Willebrand factor</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0944837B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0944837B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-12-01</span>
                    <span class="td style-scope patent-result">Method for determining protein s 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/14051903285083149059"><a id="link" href="#" class="style-scope state-modifier">Lindgren et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002</span>
                    <span class="td style-scope patent-result">Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/9654711547258120081"><a id="link" href="#" class="style-scope state-modifier">Benson et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992</span>
                    <span class="td style-scope patent-result">A multispecies enzyme-linked immunosorbent assay for von Willebrand's factor</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/14285514185690887707"><a id="link" href="#" class="style-scope state-modifier">Timm et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015</span>
                    <span class="td style-scope patent-result">Comparison of automated von Willebrand factor activity assays</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/4244950851040008484"><a id="link" href="#" class="style-scope state-modifier">Lavigne-Lissalde et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008</span>
                    <span class="td style-scope patent-result">Simultaneous detection and epitope mapping of anti-factor VIII antibodies</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0437547B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0437547B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-12-29</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies against receptor-induced binding sites on ligands binding to proteins of the cytoadhesin super family 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7041458B2/en"><a id="link" href="#" class="style-scope state-modifier">US7041458B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-05-09</span>
                    <span class="td style-scope patent-result">Methods and reagents for determining protein S 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/10326130190996695396"><a id="link" href="#" class="style-scope state-modifier">Lindahl et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003</span>
                    <span class="td style-scope patent-result">A new flow cytometric method for measurement of von Willebrand factor activity</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010088547A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2010088547A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-08-05</span>
                    <span class="td style-scope patent-result">Assays for detecting pegylated blood coagulation factors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/5531571866227107633"><a id="link" href="#" class="style-scope state-modifier">Sultan et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1984</span>
                    <span class="td style-scope patent-result">An Immunoradiometric Assay for Factor VIII Related Antigen (VIIIRAg) Using Two Monoclonal Antibodies-Comparison with Polyclonal Rabbit Antibodies for Use in von Willebrands Disease Diagnosis</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/8891419856191125149"><a id="link" href="#" class="style-scope state-modifier">Takase et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies to human factor VII: a one step immunoradiometric assay for VII: Ag.</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/10630905555017267349"><a id="link" href="#" class="style-scope state-modifier">Awasthi et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022</span>
                    <span class="td style-scope patent-result">Revealing and IgG4 analysis to factor VIII in haemophilia-A patients with and without inhibitors</span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="scholar/7955776101641952131"><a id="link" href="#" class="style-scope state-modifier">Karlman et al.</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011</span>
                    <span class="td style-scope patent-result">A new method measuring the interaction between von Willebrand factor and coagulation factor VIII</span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            
            <h3 id="parentApplications" class="scroll-target style-scope patent-result">
              Parent Applications (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Relation</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8236518B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/988,518</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2005-07-15</span>
                    <span class="td nowrap style-scope patent-result">2006-07-13</span>
                    <span class="td nowrap style-scope patent-result">
                        Continuation<template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007011746A2/en"><a id="link" href="#" class="style-scope state-modifier">PCT/US2006/027409</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2005-07-15</span>
                    <span class="td nowrap style-scope patent-result">2006-07-13</span>
                    <span class="td nowrap style-scope patent-result">
                        Continuation<template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">Highly sensitive immunoassays and antibodies for detection of blood factor viii 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9553315B2/en"><a id="link" href="#" class="style-scope state-modifier">US12/988,518</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2008-11-12</span>
                    <span class="td nowrap style-scope patent-result">2009-11-12</span>
                    <span class="td nowrap style-scope patent-result">
                        Continuation<template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">Direct liquid fuel cell having ammonia borane or derivatives thereof as fuel 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="applicationPriorityApps" class="scroll-target style-scope patent-result">
              Priority Applications (1)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8715951B2/en"><a id="link" href="#" class="style-scope state-modifier">US13/552,246</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2005-07-15</span>
                    <span class="td nowrap style-scope patent-result">2012-07-18</span>
                    <span class="td style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
       <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (5)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US69958405P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2005-07-15</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US71597805P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2005-09-09</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2007011746A2/en"><a id="link" href="#" class="style-scope state-modifier">PCT/US2006/027409</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-07-13</span>
                    <span class="td style-scope patent-result">Highly sensitive immunoassays and antibodies for detection of blood factor viii 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8236518B2/en"><a id="link" href="#" class="style-scope state-modifier">US11/988,518</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2006-07-13</span>
                    <span class="td style-scope patent-result">Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8715951B2/en"><a id="link" href="#" class="style-scope state-modifier">US13/552,246</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2012-07-18</span>
                    <span class="td style-scope patent-result">Highly sensitive immunoassays and antibodies for detection of blood factor VIII 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2014-04-16</span>
                    <span class="td nowrap style-scope patent-result">STCF</span>
                    <span class="td nowrap style-scope patent-result">Information on status: patent grant</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PATENTED CASE</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2017-11-06</span>
                    <span class="td nowrap style-scope patent-result">MAFP</span>
                    <span class="td nowrap style-scope patent-result">Maintenance fee payment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551)</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Year of fee payment</strong>: 4</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-11-08</span>
                    <span class="td nowrap style-scope patent-result">MAFP</span>
                    <span class="td nowrap style-scope patent-result">Maintenance fee payment</span>
                    <span class="td style-scope patent-result">
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Free format text</strong>: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY</p>
                      
                      <p class="style-scope patent-result"><strong class="style-scope patent-result">Year of fee payment</strong>: 8</p>
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.3876990999" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.3876990999" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=630914004" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>